LOWERING CHOLESTEROL THRU FASTING, DIET & MEDICINAL PLANTS

  1. A boost in mitochondrial activity underpins the cholesterollowering effect of annurca apple polyphenols on hepatic cells
  2. A Case of Acquired Ichthyosis Developed During cholesterollowering Treatment
  3. A chalcone derivative, 1m‐6, exhibits atheroprotective effects by increasing cholesterol efflux and reducing inflammation‐induced endothelial dysfunction
  4. A chicken protein hydrolysate exerts anti‐atherosclerotic effect beyond plasma cholesterollowering activity in Apoe−/− mice
  5. A cholesterollowering diet does not produce adverse psychological effects in children: three-year results from the dietary intervention study in children.
  6. A cholesterollowering gene maps to chromosome 13q
  7. A cholesterollowering VLP vaccine that targets PCSK9
  8. A combination of chenodeoxycholic acid and ursodeoxycholic acid is more effective than either alone in reducing biliary cholesterol saturation
  9. A comparison of clinical outcome studies among cholesterollowering agents
  10. A comparison of the LDL-cholesterol lowering efficacy of plant stanols and plant sterols over a continuous dose range: results of a meta-analysis of randomized …
  11. A Contemporary Assessment of Lipid lowering Therapies and Low-density Lipoprotein cholesterol in Peripheral Artery Disease
  12. A High cholesterol-reducing Lactic Acid Bacterial Strain: Screening, Identification and Probiotic Potential Evaluation
  13. A Intervention Study on cholesterollowering Effect of Phytosterol Ester
  14. A koleszterincsökkentés nem a Szent Grál, de nem is az ördög műve= cholesterollowering is not the Holy Grail, but neither is the work of the devil
  15. A laboratory based intervention to improve appropriateness of lipid tests and audit cholesterol lowering in primary care
  16. A Lipid-lowering diet Combined with Exercise is Effective for Achieving Healthy Serum cholesterol in a Male with a Predisposition for Developing Hyperlipidemia …
  17. A lipidomic analysis approach to evaluate the response to cholesterollowering food intake
  18. A long-term population study of cholesterol lowering by sitostanol ester margarine
  19. A mechanism for the action of unsaturated fat in reducing the serum cholesterol.
  20. A mechanistic systems pharmacology model for prediction of LDL cholesterol lowering by PCSK9 antagonism in human dyslipidemic populations
  21. A Mendelian Randomization Analysis Of Lipoprotein (A) lowering And Cardiovascular Risk Stratified By Ldl cholesterol, Gender, And Antiplatelet Therapy …
  22. A mini-review of human studies on cholesterollowering properties of probiotics
  23. A model for evaluating the cost-effectiveness of cholesterollowering treatment
  24. A Model of Life Extension from Reducing Serum cholesterol
  25. A multicenter, randomized, double-blind clinical trial comparing the low-density lipoprotein cholesterollowering ability of lovastatin 10, 20, and 40 mg/d with fluvastatin …
  26. A multidisciplinary study of the bioavilability and cholesterollowering property of peptides from lupin protein
  27. A nano‐emulsion of lutein is more effective than regular lutein in reducing cholesterol‐induced liver injury in guinea pigs
  28. A national program for lowering high blood cholesterol
  29. A new feature on the cholesterollowering landscape
  30. A New Perspective on the Development of cholesterollowering Products
  31. A new reality: achieving cholesterollowering goals in clinical practice
  32. A pediatrician attends the National Institutes of Health Consensus Conference on lowering blood cholesterol
  33. A pharmacoeconomic evaluation of aggressive cholesterol lowering in Sweden
  34. A pharmacoeconomic evaluation of the Myocardial Ischaemia Reduction with Aggressive cholesterol lowering (MIRACL) study in the United Kingdom
  35. A pharmacoeconomic evaluation of the myocardial ischemia reduction with aggressive cholesterol lowering (MIRACL) study in Canada
  36. A PHARMACOECONOMIC REVIEW OF cholesterollowering THERAPY INTERVENTIONS.
  37. A phase 1 study to evaluate the safety and LDL cholesterollowering effects of RG7652, a fully human monoclonal antibody against proprotein convertase subtilisin …
  38. A pilot randomized controlled clinical trial to assess tolerance and efficacy of navy bean and rice bran supplementation for lowering cholesterol in children
  39. A pilot study to assess food safety and potential cholesterollowering efficacy of Antrodia cinnamomea solid-state cultivated mycelium in healthy adults
  40. A promoter polymorphism in cholesterol 7α-hydroxylase interacts with apolipoprotein E genotype in the LDL-lowering response to atorvastatin
  41. A pulse-based diet is effective for reducing total and LDL-cholesterol in older adults
  42. A Quantitative Systems Pharmacology PhysioPDTM Platform to Investigate the Impact of cholesterollowering Therapies on Lipid Profiles and Plaque …
  43. A quantitative systems pharmacology platform to investigate the impact of alirocumab and cholesterollowering therapies on lipid profiles and plaque characteristics
  44. A randomized clinical trial evaluating a proprietary mixture of Lactobacillus plantarum strains for lowering cholesterol 1
  45. A randomized crossover study to evaluate LDL-cholesterol lowering effect of a generic product of simvastatin (Unison company) compared to simvastatin (Zocor) in …
  46. A randomized, double-blind, placebo-controlled trial investigating cholesterollowering effects and safety of yellow yeast rice in adults with mild to moderate …
  47. A randomized, placebo-controlled, double-blind crossover study to assess a unique phytosterol ester formulation in lowering LDL cholesterol utilizing a novel virtual …
  48. A rational policy for measuring and lowering cholesterol
  49. A retrospective cohort study of the potency of lipid-lowering therapy and race-gender differences in LDL cholesterol control
  50. A review of available cholesterollowering medicines in South Africa
  51. A ruthenium derivative of quercetin with enhanced cholesterollowering activity
  52. A spread containing bioactive milk peptides Ile–Pro–Pro and Val–Pro–Pro, and plant sterols has antihypertensive and cholesterollowering effects
  53. A study of lactobacillus acidophilus as a cholesterol lowering agent in hypercholesterolemic individuals.
  54. A STUDY ON cholesterol lowering EFFECT OF PLEUROTUS SAJOR-CAJU MUSHROOM IN HYPERcholesterolEMIC RATS
  55. A study on screening of cholesterollowering lactic acid bacteria
  56. A survey of cholesterol lowering therapies and achievement of targets for cardiovascular prevention in type 2 diabetes in Italy
  57. A sustainable approach for the extraction of cholesterollowering compounds from an olive by-product based on CO 2-expanded ethyl acetate
  58. A synthetic farnesoid X receptor (FXR) agonist promotes cholesterol lowering in models of dyslipidemia
  59. A test of two educational strategies for lowering blood cholesterol at the worksite
  60. A Transcriptomics-Informed Genetic Association Study Identifies RHOA in Simvastatin-Induced Low-Density Lipoprotein cholesterol lowering
  61. A9125 Major Outcomes of Blood-pressure and cholesterol lowering in High-risk Hypertensive Patients with a High–normal Level of Total cholesterol
  62. Ability of Lactobacillus plantarum JR64 isolated from noni juice in lowering cholesterol in vivo
  63. Absolute benefit from cholesterol lowering in diabetic patients with coronary heart disease
  64. Abstract P088: The cholesterollowering Effect of Phytosterols across Different Dose Ranges: A Meta-analysis of Randomized Controlled Trials
  65. Acalypha Indica and Gemfibrozil lowering cholesterol and Triglyceride Levels in High Fructose-cholesterol diet Induced Rats
  66. ACAT inhibitor pactimibe sulfate (CS-505) reduces and stabilizes atherosclerotic lesions by cholesterollowering and direct effects in apolipoprotein E-deficient mice
  67. ACAT inhibitors: the search for novel cholesterol lowering agents
  68. Achievement of LDL-cholesterol target levels and other cardiovascular risk factor targets in patients with type 2 diabetes treated with lipid-lowering medications …
  69. Acquired lecithin: cholesterol acyltransferase deficiency as a major factor in lowering plasma HDL levels in chronic kidney disease
  70. Activation of GPR55 receptors exacerbates oxLDL-induced lipid accumulation and inflammatory responses, while reducing cholesterol efflux from human …
  71. Activation of liver X receptor decreases BACE1 expression and activity by reducing membrane cholesterol levels
  72. Activity of a streptococcal cholesterollowering protein vs. hdl from apo ai-deficient mice in vitro and in vivo
  73. Activity of psyllium hydrophilic colloid for reducing serum cholesterol in sea quail fed a diet supplemented with cholesterol.
  74. Activity of Sambiloto Extract (Andrographis paniculata Ness) in Reducing Total Blood cholesterol Levels Hypercholesterolemia Rats
  75. Activity Test of Suji Leaf Extract (Dracaena angustifolia Roxb.) on in vitro cholesterol lowering
  76. Acute cholesterol lowering with LDL-apheresis improves endothelial function of the epicardial coronary artery in patients with hypercholesterolemia
  77. Acyl-CoA: cholesterol acyltransferase inhibitor avasimibe reduces atherosclerosis in addition to its cholesterollowering effect in ApoE* 3-Leiden mice
  78. Adding monounsaturated fatty acids to a dietary portfolio of cholesterollowering foods in hypercholesterolemia
  79. Adding MUFA to a dietary portfolio of cholesterollowering foods reduces apoAI fractional catabolic rate in subjects with dyslipidaemia
  80. Additive effect of homocysteine‐and cholesterollowering therapy on endothelium‐dependent vasodilation in patients with cardiovascular disease
  81. Additive effect of plant sterol-ester margarine and cerivastatin in lowering low-density lipoprotein cholesterol in primary hypercholesterolemia
  82. Adeno-associated virus serotype 8 gene therapy leads to significant lowering of plasma cholesterol levels in humanized mouse models of homozygous and …
  83. Adherence to cholesterollowering diets
  84. AdipoRon Attenuates Wnt Signaling by Reducing cholesterol-Dependent Plasma Membrane Rigidity
  85. Advance in cholesterollowering effect of phytosterols [J]
  86. Advances in cholesterollowering interventions
  87. Advances in techniques for reducing cholesterol in egg yolk: A review
  88. Advances in the effects study of the cholesterol-reducing microbial [J]
  89. Aerobic exercise training selectively changes oxysterol levels and metabolism reducing cholesterol accumulation in the aorta of dyslipidemic mice
  90. After ENHANCE: is more LDL cholesterol lowering even better?
  91. Aggressive cholesterol lowering delays saphenous vein graft atherosclerosis in women, the elderly, and patients with associated risk factors: NHLBI post coronary …
  92. Aggressive lipid lowering in postcoronary angioplasty patients with elevated cholesterol (the Lovastatin Restenosis Trial)
  93. Aggressive lowering of fibrinogen and cholesterol in the prevention of graft vessel disease after heart transplantation
  94. Air Force Members’ Guide for Reducing cholesterol Ratio
  95. Algal sterols are as effective as β-sitosterol in reducing plasma cholesterol concentration
  96. Alirocumab for low-density lipoprotein cholesterol lowering
  97. All cholesterollowering interventions are expected to reduce stroke: Confirmatory data from IMPROVE-IT
  98. Aloe-emodin exerts cholesterollowering effects by inhibiting proprotein convertase subtilisin/kexin type 9 in hyperlipidemic rats
  99. Alternative approaches to cholesterollowering therapy
  100. Alternative approaches to lowering cholesterol
  101. Amaranth oil increased fecal excretion of bile acid but had no effect in reducing plasma cholesterol in hamsters
  102. Amaranth protein presents cholesterollowering effect
  103. AMPK enhances insulin-stimulated GLUT4 regulation via lowering membrane cholesterol
  104. An anti-atherogenic effect of Schistosoma mansoni infections in mice associated with a parasite-induced lowering of blood total cholesterol
  105. An application of the transtheoretical model of behavior change to the adoption of cholesterollowering behaviors by college students.
  106. An audit of secondary prevention of ischaemic heart disease using aspirin and cholesterollowering
  107. An audit of the effectiveness of PCSK9 inhibition in reducing cholesterol in patients attending lipid clinics
  108. An economic evaluation of lovastatin for cholesterol lowering and coronary artery disease reduction
  109. An educational intervention for reducing the intake of dietary fats and cholesterol among middle-aged and older women
  110. An Evaluation of cholesterollowering Effect of Soy Protein and Isoflavones on Postmenopausal Women and Hypercholesterolemic Humans.
  111. An evidence-based guide to cholesterollowering guidelines
  112. An Immunomodulating Fatty Acid Analogue Targeting Mitochondria Exerts Anti-Atherosclerotic Effect beyond Plasma cholesterollowering Activity in apoE …
  113. An in vitro study of the probiotic potential of a bile-salt-hydrolyzing Lactobacillus fermentum strain, and determination of its cholesterollowering properties
  114. An in vivo assessment of the cholesterollowering efficacy of Lactobacillus plantarum ECGC 13110402 in normal to mildly hypercholesterolaemic adults
  115. An innovative lipid-lowering approach to enhance attainment of low-density lipoprotein cholesterol goals
  116. An overview of trials of cholesterol lowering and risk of stroke
  117. An update on the clinical development of proprotein convertase subtilisin kexin 9 inhibitors, novel therapeutic agents for lowering low‐density lipoprotein cholesterol
  118. Anacetrapib reduces progression of atherosclerosis, mainly by reducing non-HDL-cholesterol, improves lesion stability and adds to the beneficial effects of …
  119. Analysis of plant sterol and stanol esters in cholesterollowering spreads and beverages using high-performance liquid chromatography− atmospheric pressure …
  120. Angiographic trials testing the efficacy of cholesterol lowering in reducing progression or inducing regression of coronary atherosclerosis
  121. Animal models: new cholesterol raising and lowering nutrients
  122. Anti-hyperlipidemia of garlic by reducing the level of total cholesterol and low-density lipoprotein: A meta-analysis
  123. Anti-inflammatory and cholesterol-reducing properties of apolipoprotein mimetics: a review
  124. Anti-inflammatory salicylate beneficially modulates pre-existing atherosclerosis through quenching of NF-κB activity and lowering of cholesterol
  125. Anti-obesity and cholesterollowering effects of germinated brown rice in rats fed with high fat and cholesterol diets
  126. Anti-obesity and LDL-cholesterol lowering effects of silkworm hemolymph in C57BL/6N mice fed high fat diet
  127. Anti-obesity and lipid lowering effects of Cymodocea nodosa sulphated polysaccharide on high cholesterol-fed-rats
  128. Antiamnesic effect of petroleum ether extract of Murraya Koenigii (Linn) leaves involving possible Anticholinesterase and cholesterol lowering mechanism
  129. Antibacterial and cholesterol Reducing Lactic Acid Bacteria from Silk Worm(Bombyx mori) Gut Environment- A Review
  130. Antidiabetic and cholesterol lowering activities of the stem bark of Ficus bengalensis L.
  131. Antihyperglycemic, cholesterollowering and HDL-raising effects of cumin (Cuminum cyminum) seeds in type-2 diabetes
  132. Antihyperlipidemic therapies targeting PCSK9: Novel therapeutic agents for lowering low-density lipoprotein cholesterol
  133. Antihypertensive and cholesterollowering effects of a spread containing bioactive peptides IPP and VPP and plant sterols
  134. Antiobesity and cholesterollowering effects of bifidobacteria animalis DY-64 in rats fed a high-fat/high-cholesterol diet
  135. Antiobesity and cholesterollowering Effects of Dendropanax morbifera Water Extracts in Mouse 3T3-L1 Cells
  136. Antioxidant activity and lipid-lowering effect of essential oils extracted from Ocimum sanctum L. leaves in rats fed with a high cholesterol diet
  137. Antioxidant activity and the potential for cholesterollowering of phenolic extract of Morus alba, Morus multicaulis, and Morus laevigata leaves from Yunnan (China)
  138. ANTIOXIDANT ACTIVITY, cholesterol lowering EFFECT AND CHEMICAL INVESTIGATION OF PO-SA (STEM)
  139. Antioxidant and cholesterol lowering properties of 2, 6-di-t-butyl-4-[(dimethylphenylsilyl) methyloxy] phenol and derivatives: a new class of anti-atherogenic …
  140. Antioxidant and cholesterollowering Effects of Lactic Acid Bacteria Isolated from Kelp Saccharina japonica Kimchi
  141. Antioxidant and cholesterol-reducing Properties of Enterococcus gallinarum m661 [J]
  142. Antioxidant and Lipid lowering Effects of Elaeocarpus Ganitrus in cholesterol Fed Rabbits
  143. Antioxidant, cholesterol reducing, immunomodulating and other health promoting properties of herbal enriched designer eggs
  144. Antioxidants and cholesterol-reducing agents with antiatherogenic activity contained in plant raw materials
  145. Antioxidative and cholesterollowering effects of lemon essential oil in hypercholesterolemia-induced rabbits
  146. Aortic vascular calcification: cholesterol lowering does not reduce progression in patients with familial hypercholesterolemia—or does it?
  147. ApoA-IV phenotype affects diet-induced plasma LDL cholesterol lowering.
  148. APOE genotype, cholesterol level, lipid-lowering treatment, and dementia: the Three-City Study
  149. APOE4 genotype exerts greater benefit in lowering plasma cholesterol and apolipoprotein B than wild type (E3/E3), after replacement of dietary saturated fats with low …
  150. Apolipoprotein E mimetics and cholesterollowering properties
  151. Apolipoprotein E promotes the regression of atherosclerosis independently of lowering plasma cholesterol levels
  152. Applicability of cholesterollowering primary prevention trials to a general population: the Framingham Heart Study
  153. Application of Actinomycetes in the Production of Pravastatin, a novel cholesterollowering agent (in Japanese with English abstract)
  154. Application of Bile Salt Hydrolase Enzyme in cholesterol lowering
  155. Appropriate use of cholesterollowering therapy
  156. ARBITER 2: targeting HDL to retard atherosclerosis progression: Arterial Biology for the Investigation of the Treatment Effects of Reducing cholesterol (ARBITER) 2
  157. ARBITER: Arterial Biology for the Investigation of the Treatment Effects of Reducing cholesterol: a randomized trial comparing the effects of atorvastatin and …
  158. Are cholesterol treatment targets a deterrent to optimal lipid-lowering therapy?
  159. Are cholesterollowering medications and antihypertensive agents preventing stroke in ways other than by controlling the risk factor?
  160. Are early clinical effects of cholesterol lowering mediated through effects on inflammation?
  161. Are oat products effective cholesterollowering agents?
  162. Are plant-based diets efficacious in lowering total serum cholesterol and low-density lipoprotein levels?
  163. Are we aggressive enough in lowering cholesterol?
  164. Aronia berry polyphenol consumption reduces plasma total and low-density lipoprotein cholesterol in former smokers without lowering biomarkers of inflammation and …
  165. Arterial Stiffness Interferes with LDL‐cholesterol lowering by Canola Oil in Persons with Mild Hypercholesterolemia
  166. ASGR1-a new target for lowering non-HDL cholesterol
  167. Assess the effectiveness of cocoa powder in reducing cholesterol level among the hypertensive clients at the rural area, Medavakkam, Chennai
  168. Assess the effectiveness of cocoa powder in reducing cholesterol levels among the Hypertensive clients at the rural area, Medavakkam, Chennai.
  169. Assessing heart disease risk in primary care: cholesterol lowering should be just one part of a multiple risk factor intervention
  170. Assessing possible hazards of reducing serum cholesterol
  171. Assessing the efficacy of cholesterollowering treatment.
  172. Assessing the genetic impacts of 144 candidate polymorphisms on the low-density lipoprotein cholesterol lowering efficacy of atorvastatin in Han Chinese
  173. Assessment of probiotic, antifungal and cholesterol lowering properties of Pediococcus pentosaceus KCC‐23 isolated from Italian ryegrass
  174. Assessment of the dietary intake in participants of the cholesterol lowering Intervention Program.
  175. Assessment of the longer-term effects of a dietary portfolio of cholesterollowering foods in hypercholesterolemia
  176. Association between calcific aortic stenosis and hypercholesterolemia: Is there a need for a randomized controlled trial of cholesterollowering therapy?
  177. Association between cholesterol synthesis/absorption markers and effects of cholesterol lowering by atorvastatin among patients with high risk of coronary …
  178. Association between low-density lipoprotein cholesterollowering genetic variants and risk of type 2 diabetes: a meta-analysis
  179. Association between lowering low-density lipoprotein cholesterol with pravastatin and primary prevention of cardiovascular disease in mild to moderate …
  180. Association of genetically enhanced lipoprotein lipase–mediated lipolysis and low-density lipoprotein cholesterollowering alleles with risk of coronary disease and …
  181. Association of lowering low‐density lipoprotein cholesterol with contemporary lipid‐lowering therapies and risk of diabetes mellitus: a systematic review and meta …
  182. Association of the TNF-α-C-857T Polymorphism With Resistance to the cholesterollowering Effect of HMG-CoA Reductase Inhibitors in Type 2 Diabetic Subjects
  183. Atherosclerosis, acute coronary events, and cholesterollowering: a new paradigm
  184. Atherosclerosis/Coronary Heart Disease: Short-term cholesterol lowering Decreases Size and Severity of Perfusion Abnormalities by Positron Emission Tomography …
  185. Atorvastatin has cardiac safety at intensive cholesterol‐reducing protocols for long term, yet its cancer‐treatment doses with chemotherapy may cause cardiomyopathy …
  186. Atorvastatin increases HDL cholesterol by reducing CETP expression in cholesterol-fed APOE* 3-Leiden. CETP mice
  187. Atorvastatin more effective in reducing LDL cholesterol
  188. ATTENUATED RESPONSE OF LIPID PLAQUE TO cholesterol lowering THERAPY IN DIABETIC PATIENT: AN OPTICAL COHERENCE TOMOGRAPHY …
  189. Attitude changes of general practitioners towards lowering LDL cholesterol
  190. Automated outreach to increase primary adherence to cholesterollowering medications
  191. Azalanstat (RS-21607), a lanosterol 14α-demethylase inhibitor with cholesterollowering activity
  192. Bacterial production of the fungus‐derived cholesterollowering agent mevinolin
  193. Bacteroides sp. strain D8, the first cholesterol-reducing bacterium isolated from human feces
  194. Balance of unsaturated fatty acids is important to a cholesterollowering diet: comparison of mid-oleic sunflower oil and olive oil on cardiovascular disease risk factors
  195. Baseline low-density lipoprotein cholesterol is an important predictor of the benefit of intensive lipid-lowering therapy: a PROVE IT–TIMI 22 (Pravastatin or Atorvastatin …
  196. Baseline low-density lipoprotein cholesterol predicts the hemoglobin A1c-lowering effect of dapagliflozin in Japanese patients with type 2 diabetes mellitus
  197. Baseline low-density lipoprotein cholesterol to predict the extent of cardiovascular benefit from lipid-lowering therapies: a review
  198. Beclobrate and eniclobrate hydrochloride, new diphenylmethane derivatives as agents for lowering cholesterol and triglyceride levels. Part I: Synthesis and …
  199. Behavioral implications of lowering cholesterol levels: a double-blind pilot study
  200. Bempedoic Acid CLEAR Serenity Study Results Published in the JAHA Demonstrated Significant LDL-cholesterol lowering and
  201. Bempedoic acid for lowering LDL cholesterol
  202. Bempedoic Acid: A Novel LDL cholesterollowering Agent
  203. Beneficial effect of cholesterollowering therapy on coronary endothelium-dependent relaxation in hypercholesterolaemic patients
  204. Beneficial effects of aggressive low-density lipoprotein cholesterol lowering in women with stable coronary heart disease in the Treating to New Targets (TNT) study
  205. Beneficial effects of cholesterollowering therapy in hyperlipidemia patients-A six months report
  206. Beneficial effects of cholesterollowering therapy on the coronary endothelium in patients with coronary artery disease
  207. Beneficial effects of probiotic cholesterollowering strain of Enterococcus faecium WEFA23 from infants on diet-induced metabolic syndrome in rats
  208. Benefits and risks of lowering serum cholesterol
  209. Benefits of lipid lowering on vascular reactivity in patients with coronary artery disease and average cholesterol levels: a mechanism for reducing clinical events?
  210. Benefits of lipid-lowering therapy in men with elevated apolipoprotein B are not confined to those with very high low density lipoprotein cholesterol
  211. Benefits of lowering cholesterol in chronic kidney disease
  212. Benefits of lowering cholesterol in chronic kidney disease
  213. Benefits of lowering cholesterol in chronic kidney disease–Authors’ reply
  214. Benefits of reducing low density lipoprotein cholesterol concentrations to< 100 mg/dL
  215. Berberine Analogues as a novel class of the low-density-lipoprotein receptor up-regulators: synthesis, structure− activity relationships, and cholesterollowering
  216. Berberine, a natural cholesterol reducing product, exerts antitumor cytostatic/cytotoxic effects independently from the mevalonate pathway
  217. Beyond cholesterol lowering: pleiotropic effects of bile acid binding resins against cardiovascular disease risk factors in patients with metabolic syndrome
  218. Beyond cholesterollowering effects of plant sterols: clinical and experimental evidence of anti-inflammatory properties
  219. Beyond the cholesterollowering effect of soy protein: a review of the effects of dietary soy and its constituents on risk factors for cardiovascular disease
  220. Bezalip has been shown to be more effective than Clofibrate in reducing cholesterol, triglyceride, LDL ai VLDL and in raising the protective factor HDL1, 2
  221. Bile acid binding resin improves hepatic insulin sensitivity by reducing cholesterol but not triglyceride levels in the liver
  222. Bile tolerance, Bile Deconjugation and cholesterol reducing properties of Lactobacillus strains isolated from traditional fermented foods
  223. Biochemical basis for a cholesterollowering activity of 2-[2′-(1′, 3′-dioxolane)]-2-methyl-4-(2′-oxo-1′-pyrrolidinyl)-6-nitro-2H-1-benzopyran (SKP-450), a novel …
  224. Biochemical characterization of cholesterol-reducing Eubacterium.
  225. Biological evaluation of biscuits prepared from citrus peels as a lowering cholesterol
  226. Biologics inch toward cholesterollowering market
  227. Biology of proprotein convertase subtilisin kexin 9: beyond low-density lipoprotein cholesterol lowering
  228. Blepharoptosis and cholesterollowering Medications: A Retrospective Study
  229. Blockage of hydroxyl group partially abolishes the cholesterollowering activity of β-sitosterol
  230. Blood cholesterol and lipid-lowering effects of carrageenan on human volunteers.
  231. Blood cholesterol lowering effect of adenantherapavonina seed extract on atherogenic diet induced hyperlipidemia in rats
  232. Blood lipids and stroke: what more can we do besides reducing low-density lipoprotein cholesterol?
  233. Blood pressure and cholesterollowering efficacy of a fixed-dose combination with irbesartan and atorvastatin in patients with hypertension and …
  234. Blood pressure and low-density lipoprotein cholesterol control status in Chinese hypertensive dyslipidemia patients during lipid-lowering therapy
  235. Blood pressure and low-density lipoprotein-cholesterol lowering for prevention of strokes and cognitive decline: a review of available trial evidence
  236. Blood sugar and total cholesterol lowering effect of Glycine soja (Sieb and Zucc.), Mucuna pruriens (DC) and Dolichos biflorus (Linn.) seed diets in normal fasting
  237. Blood-pressure and cholesterol lowering in persons without cardiovascular disease
  238. Blood-Pressure and cholesterol lowering in the HOPE-3 Trial.
  239. Blood-pressure and cholesterol lowering in the HOPE-3 Trial.
  240. Body mass index impacts the choice of lipid‐lowering treatment with no correlation to blood cholesterol–Findings from 52 916 patients in the Dyslipidemia …
  241. Body-weight-loss and cholesterollowering effects of Cheonggukjang (a fermented soybean paste) given to rats fed a high-fat/high-cholesterol diet
  242. Brain cholesterol x: effect of scheduling on the sterol lowering capability of methylphenidate (Ritalin).
  243. Breast cancer; role of tamoxifen as selective estrogen receptor modulator in preventing bone loss, reducing serum cholesterol and activity of liver enzymes in patients …
  244. But will lowering cholesterol raise cancer rates?
  245. Caffeine-free hawk tea lowers cholesterol by reducing free cholesterol uptake and the production of very-low-density lipoprotein
  246. Calcium supplementation increases circulating cholesterol by reducing its catabolism via GPER and TRPC1-dependent pathway in estrogen deficient women
  247. Can a cholesterollowering diet cause gallstones?
  248. Can any agreement be reached on cholesterol lowering?
  249. Can cholesterollowering be harmful?
  250. Cancer among men on cholesterollowering diets: experience from five clinical trials
  251. Candidate‐Gene Study of Functional Polymorphisms in SLCO1B1 and CYP3A4/5 and the cholesterollowering Response to Simvastatin
  252. Carboxymethylation of polysaccharide from Morchella angusticepes Peck enhances its cholesterollowering activity in rats
  253. Cardiovascular Benefit of cholesterollowering Therapy
  254. Cardiovascular benefit of cholesterollowering therapy: does improved endothelial vasodilator function matter?
  255. Cardiovascular event rates and trajectories of LDL-cholesterol levels and lipid-lowering therapy in patients with atherosclerotic cardiovascular disease: a population …
  256. Cardiovascular mortality after intensive LDL-cholesterol lowering: Does baseline LDL-cholesterol really matter?
  257. Cardiovascular outcomes associated with lowering low-density lipoprotein cholesterol in rheumatoid arthritis and matched nonrheumatoid arthritis
  258. Cardiovascular outcomes of PCSK9 inhibitors: with special emphasis on its effect beyond LDL-cholesterol lowering
  259. Cerivastatin induces carotid artery plaque stabilization independently of cholesterol lowering in patients with hypercholesterolaemia
  260. Cerivastatin prevents angiotensin II-induced renal injury independent of blood pressure-and cholesterollowering effects
  261. Challenges to implementing expanded team models: lessons from a centralised nurse-led cholesterollowering programme
  262. Changes in cholesterollowering medications use over a decade in community-dwelling older adults
  263. Changes in flow-mediated brachial artery vasoactivity with lowering of desirable cholesterol levels in healthy middle-aged men
  264. Changes in vitamin and mineral intakes and serum concentrations among free-living men on cholesterollowering diets: the dietary Alternatives Study
  265. Characterisation of an extract and fractions of Azadirachta indica flower on cholesterol lowering property and intestinal motility
  266. Characterisation of Lactobacillus fermentum SM‐7 isolated from koumiss, a potential probiotic bacterium with cholesterollowering effects
  267. Characterisation of non human origin probiotic Lactobacillus plantarum with cholesterollowering property
  268. Characteristics associated with compliance to cholesterol lowering eating patterns
  269. Characteristics of cholesterollowering Lactobacillus casei subsp. casei strain GL-03 isolated from cheese
  270. Characteristics of growth and the cholesterol-reducing ability in meat of native lactic acid bacteria
  271. Characterization and application of a novel cholesterol-reducing anaerobe, Eubacterium coprostanoligenes ATCC 51222
  272. CHARACTERIZATION OF A cholesterol-REDUCING ANAEROBE
  273. Characterization of Eubacterium coprostanoligenes sp. nov., a cholesterol-reducing anaerobe
  274. Characterization of juice fermented with Lactobacillus plantarum EM and its cholesterollowering effects on rats fed a high‐fat and high‐cholesterol diet
  275. Characterization of Lactobacillus plantarum Lp27 isolated from Tibetan kefir grains: A potential probiotic bacterium with cholesterollowering effects
  276. Characterization of Lactobacillus plantarum PH04, a potential probiotic bacterium with cholesterollowering effects
  277. Characterization of low‐density lipoprotein cholesterollowering efficacy for atorvastatin in a population‐based DNA biorepository
  278. Characterization of starter kimchi fermented with Leuconostoc kimchii GJ2 and its cholesterollowering effects in rats fed a high‐fat and high‐cholesterol diet
  279. Characterization of the cholesterol-reducing activity in a cell-free supernatant of Lactobacillus acidophilus ATCC 43121
  280. Chemerin Inhibiting ABCAl Expression and Reducing cholesterol Efflux in THP-1-derived Macrophage Foam Cells Mediated by NF-κB Pathway
  281. Chemical and microbiological considerations of phytosterols and their relative efficacies in functional foods for the lowering of serum cholesterol levels in humans: A …
  282. Chemical composition of soybean oil extracted from hypocotyle-enriched soybean raw material and its cholesterol lowering effects in rats
  283. Chemoenzymatic synthesis of statine side chain building blocks and application in the total synthesis of the cholesterollowering compound solistatin
  284. Chimeric apolipoproteins as novel plasma cholesterol lowering agents (1002.2)
  285. Chitosan, cholesterol lowering, and caloric loss
  286. Chlorogenic acid exhibits cholesterol lowering and fatty liver attenuating properties by up‐regulating the gene expression of PPAR‐α in hypercholesterolemic rats …
  287. Choice of the optimal medium for the growth of cholesterol-reducing Lactobacillus casei WB
  288. Cholestanol: a serum marker to guide LDL cholesterollowering therapy
  289. cholesterol (Blood lipid) lowering potential of Rosuvastatin chitosan nanoparticles for atherosclerosis: Preclinical study in rabbit model
  290. cholesterol absorption inhibition: a strategy for cholesterollowering therapy.
  291. cholesterol absorption inhibition: filling an unmet need in lipid-lowering management
  292. cholesterol and Cognition: Rationale for the AD cholesterollowering Treatment Trial and Sex‐Related Differences in β‐Amyloid Accumulation in the Brains of …
  293. cholesterol and fat lowering with hydrophobic polysaccharide derivatives
  294. cholesterol and fat lowering with hydrophobic polysaccharide derivatives
  295. cholesterol and strokes: cholesterol lowering is indicated for strokes due to carotid atheroma
  296. cholesterol and triglycerides lowering activities of caraway fruits in normal and streptozotocin diabetic rats
  297. cholesterol and Visceral Fat lowering Effects of Combined Lactic Acid Bacteria (Lactobacillus casei WK3, Enterococcus faecium WK5, Bifidobacterium longum WK9 …
  298. cholesterol depletion by mβcd enhances cell membrane tension and its variations-reducing integrity
  299. cholesterol Depletion Impairs Vascular Reactivity to Endothelin-1 by Reducing Store-Operated Ca2+ Entry Dependent on TRPC1
  300. cholesterol depletion uncouples β-dystroglycans from discrete sarcolemmal domains, reducing the mechanical activity of skeletal muscle
  301. cholesterol efflux from bovine sperm: II. Effect of reducing sperm cholesterol on penetration of zona‐free hamster and in vitro matured bovine ova
  302. cholesterol efflux from bovine sperm. I. Induction of the acrosome reaction with lysophosphatidylcholine after reducing sperm cholesterol
  303. cholesterol ester transfer protein polymorphism rs5882 is associated with triglyceride-lowering in response to plant sterol consumption
  304. cholesterol goal achievement and lipid-lowering therapy in patients with stable or acute coronary heart disease in Singapore: results from the Dyslipidemia …
  305. cholesterol induced heart valve inflammation and injury: efficacy of cholesterol lowering treatment
  306. cholesterol lowering
  307. cholesterol lowering a practical guide to therapy
  308. cholesterol lowering action and antioxidant status improving efficacy of noodles made from unmarketable oak mushroom (Lentinus edodes) in high cholesterol fed …
  309. cholesterol lowering action of HOE 402 in the normolipidemic and hypercholesterolemic golden Syrian hamster
  310. cholesterol lowering activity of formulated green caviar (Caulerpa lentillifera J. Agardh., Caulerpaceae) seaweed extract tablet in hypercholesterolemia-induced …
  311. cholesterol lowering activity of mango ginger (Curcuma amada Roxb.) in induced hypercholesterolemic rats
  312. cholesterol lowering activity of ropy fermented milk
  313. cholesterol lowering activity of soy‐derived glyceollins in golden hamster model
  314. cholesterol lowering activity of the aqueous fruit extract of Trichosanthes dioica Roxb. in normal and streptozotocin diabetic rats
  315. cholesterol lowering After Heart Transplantation is Associated with a Lower Incidence of Transplant Coronary Artery Disease.
  316. cholesterol lowering after participation in the Scandinavian Simvastatin Survival Study (4S) in Finland
  317. cholesterol lowering and antioxidant potential of probiotic bacteria isolated from locally fermented milk product kalarei
  318. cholesterol lowering and Antioxidative Effect of Pregerminated Brown Rice in Hypercholesterolemic Rats
  319. cholesterol lowering and bile acid excretion in the hamster with cholestyramine treatment
  320. cholesterol lowering and cerebrospinal fluid neurotransmitters: Increased levels of the anxiogenic cholecystokinin-tetrapeptide during simvastatin …
  321. cholesterol lowering and coronary artery disease: mechanisms of risk reduction
  322. cholesterol lowering and Coronary Revascularization: Finally a Marriage to Sustain?
  323. cholesterol lowering and emotional distress: Current status and future directions.
  324. cholesterol lowering and endothelial function
  325. cholesterol lowering and ezetimibe
  326. cholesterol lowering and inhibition of sterol absorption by Lactobacillus reuteri NCIMB 30242: a randomized controlled trial
  327. cholesterol lowering and life expectancy: a critical evaluation
  328. cholesterol lowering and morbidity and mortality.
  329. cholesterol lowering and mortality: the importance of considering initial level of risk.
  330. cholesterol lowering and mortality: time for a new paradigm?
  331. cholesterol lowering and prevention of CHD
  332. cholesterol lowering and Prevention of Stroke: An Overview
  333. cholesterol lowering and secondary prevention of CHD–the evidence of benefit is unequivocal
  334. cholesterol lowering and the reduction of CHD incidence and total mortality: results from a meta-analysis of randomized trials
  335. cholesterol lowering and the reduction of coronary heart disease risk
  336. cholesterol lowering and the risk of coronary heart disease
  337. cholesterol lowering and the risk of stroke
  338. cholesterol lowering and the risk of stroke-Reply
  339. cholesterol lowering and the use of healthcare resources: results of the Scandinavian Simvastatin Survival Study
  340. cholesterol lowering and the vessel wall: new insights and future perspectives
  341. cholesterol lowering and vascular protective effects of ethanolic extract of dried fruit of Crataegus pinnatifida, hawthorn (Shan Zha), in diet-induced …
  342. cholesterol lowering as a treatment for established coronary heart disease.
  343. cholesterol lowering Atherosclerosis Study (CLAS)
  344. cholesterol lowering Atherosclerosis Study (CLAS)
  345. cholesterol lowering attenuates pressure overload-induced heart failure in mice with mild hypercholesterolemia
  346. cholesterol lowering benefits of soy and linseed enriched foods
  347. cholesterol lowering by a-linolenic acid
  348. cholesterol lowering by atorvastatin parallels rapid changes in intima-media thickness and diamter of carotid arteries
  349. cholesterol lowering by Citrus
  350. cholesterol lowering by diet: what can be achieved?
  351. cholesterol lowering by Pediococcus acidilactici LAB4 and Lactobacillus plantarum LAB12 in adult zebrafish is associated with improved memory and involves an …
  352. cholesterol lowering Capability of some Lactobacillus Strains and its Effect on Mice Fed a High cholesterol diet
  353. cholesterol lowering Capacity of Lactic Acid Bacteria Isolated from Fermented Tapai
  354. cholesterol lowering diets and coronary heart disease: Advice should now be to increase intake of vegetable oils and fish
  355. cholesterol lowering diets and coronary heart disease: diet alone substantially reduces cholesterol in hypercholesterolaemia
  356. cholesterol lowering diets and coronary heart disease. dietary advice should focus on promoting antioxidants and the right sort of fats.
  357. cholesterol lowering does have a role in secondary prevention.
  358. cholesterol lowering effect in the gall bladder of dogs by a standardized infusion of Herniaria hirsuta L.
  359. cholesterol lowering effect in the gall bladder of dogs by Herniaria hirsuta
  360. cholesterol lowering effect of a soy drink enriched with plant sterols in a French population with moderate hypercholesterolemia
  361. cholesterol lowering effect of Aporosa lindleyana in male Wistar rats.
  362. cholesterol lowering effect of cashew leaf (Anacardium occidentale) extract on egg yolk induced hypercholesterolaemic rabbits
  363. cholesterol lowering EFFECT OF CHITOSAN NANOPARTICLES USING PARIJOTO FRUITS EXTRACT
  364. cholesterol lowering effect of Citrus paradisi (Grape fruit) peel extract in hypercholestrolemic patients in an urban community: A randomized control trial.
  365. cholesterol lowering effect of Cnidoscolous aconitifolius leave extracts in egg yolk induced hypercholesterolemia in rabbit
  366. cholesterol lowering Effect of Colchicine.
  367. cholesterol lowering effect of dietary weight loss and orlistat treatment–efficacy and limitations
  368. cholesterol lowering effect of dietary yeast and yeast fractions
  369. cholesterol lowering effect of Enterococcus faecium ID9201 isolated from breast milk-fed Korean infant
  370. cholesterol lowering Effect of Ethanol Extracts of Salted and Fermented Small Shrimp in Rats Administered a High Fat diet
  371. cholesterol lowering effect of guava leaves (Psidium guajava) extract on egg yolk induced hypercholestero-laemic rabbits
  372. cholesterol lowering effect of jackbean (Canavalia ensiformis) seed protein.
  373. cholesterol lowering effect of lactic acid bacteria isolated from the human intestine.
  374. cholesterol lowering effect of Lactobacillus plantarum isolated from human feces
  375. cholesterol lowering effect of metformin in combined hyperlipidemia: placebo controlled double blind trial
  376. cholesterol lowering effect of neomycin and N-methylated neomycin in germfree chicks.
  377. cholesterol lowering effect of plant stanol ester yoghurt drinks with added camelina oil
  378. cholesterol lowering effect of SG-GN3, the extract of salted and fermented small shrimps, Acetes japonicus, in Triton WR-1339 or high cholesteroldiet induced …
  379. cholesterol lowering Effect of Simvastatin in Patients with Normal and Impaired Renal Function
  380. cholesterol lowering effect of spirulina.
  381. cholesterol lowering effect of subchronic inhalation particulate matter 10 coal dust on rats
  382. cholesterol lowering effect of sulfur-containing amino acids added to a soybean protein diet in rats
  383. cholesterol lowering effect of Tamarind (Tamarindus indica)
  384. cholesterol lowering effect of the methanol insoluble materials from the quinoa seed pericarp
  385. cholesterol lowering effect of the recombinant α’E peptide from 7S soy globulin in cholesterol‐fed rats upon chronic treatment
  386. cholesterol lowering effects of a choleretic phloracetophenone in hypercholesterolemic hamsters
  387. cholesterol lowering effects of acacia nilotica subalata in normal and type 2 diabetic male rats
  388. cholesterol lowering Effects of Milk with Added Phytosterols
  389. cholesterol lowering effects of milk with added plant sterols
  390. cholesterol lowering effects of mono-lactose-appended β-cyclodextrin in Niemann–Pick type C disease-like HepG2 cells
  391. cholesterol lowering effects of nuts compared with a Canola oil enriched cereal of similar fat composition
  392. cholesterol lowering effects of red koji
  393. cholesterol lowering effects of rhubarb stalk fiber in hypercholesterolemic men.
  394. cholesterol lowering effects of simvastatin in patients with non-insulin dependent diabetes mellitus
  395. cholesterol lowering efficacy of plant stanol ester in a new type of product matrix, a chewable dietary supplement
  396. cholesterol lowering efficacy of plant sterols: mechanisms of action.
  397. cholesterol lowering Efficacy of Simvastatin at Doses of 80 and 160 mg/d in a new low systemic exposure formulation
  398. cholesterol lowering for all: a closer look
  399. cholesterol lowering for secondary prevention of coronary artery disease: Assessment of screening and treatment practices in Hamilton
  400. cholesterol lowering for the prevention of stroke
  401. cholesterol lowering guidelines: from whence we came and where we are now
  402. cholesterol lowering Herbal Program
  403. cholesterol lowering improves endothelial function
  404. cholesterol lowering in 2015: still answering questions about how and in whom
  405. cholesterol lowering in atherosclerosis
  406. cholesterol lowering in Cancer Prevention and Therapy
  407. cholesterol lowering in intermediate-risk persons without cardiovascular disease
  408. cholesterol lowering in low density lipoprotein receptor knockout mice overexpressing apolipoprotein E.
  409. cholesterol lowering in older patients
  410. cholesterol lowering in patients with CHD and metabolic syndrome
  411. cholesterol lowering in pigs through enhanced bacterial bile salt hydrolase activity
  412. cholesterol lowering in the elderly population
  413. cholesterol lowering in the elderly: results of the cholesterol Reduction in Seniors Program (CRISP) pilot study
  414. cholesterol lowering in the management of coronary artery disease: the clinical implications of recent trials
  415. cholesterol lowering in the management of coronary heart disease
  416. cholesterol lowering in the older population: time for reassessment?
  417. cholesterol lowering in the Patient with Coronary Heart Disease: Physician Monograph
  418. cholesterol lowering margarine is effective
  419. cholesterol lowering margarine launched in United Kingdom
  420. cholesterol lowering margarine launched in United Kingdom
  421. cholesterol lowering margarine may not be useful in healthy fat modified diet
  422. cholesterol lowering mechanism of soybean protein hydrolysate
  423. cholesterol lowering modulates T cell function in vivo and in vitro
  424. cholesterol lowering Potential of Allium Sativum Essential Oil in Type 2 Diabetic Patients
  425. cholesterol lowering potential of Lactobacillus brevis
  426. cholesterol lowering POTENTIAL OF SEABUCKTHORN
  427. cholesterol lowering potentials of a blend of standardized methanol extracts of moringa oleifera leaves and fruits in albino wistar rats
  428. cholesterol lowering property of garlic (Allium sativum) on patients with hypercholesterolemia
  429. cholesterol lowering property of lactobacillus plantarum isolated from cow milk
  430. cholesterol lowering reduces the incidence of and may improve event-free survival after coronary revascularization
  431. cholesterol lowering therapies and achievement of targets for primary and secondary cardiovascular prevention in type 2 diabetes: unmet needs in a large …
  432. cholesterol lowering therapy after myocardial infarction. Consequences of the CARE study
  433. cholesterol lowering therapy inhibits the low‐flow mediated vasoconstriction of the brachial artery in hypercholesterolaemic subjects
  434. cholesterol lowering therapy: treat to target or reduce the global risk? The unresolved problem of residual risk
  435. cholesterol lowering treatment and mortality.
  436. cholesterol lowering treatment restores blood global DNA methylation in chronic kidney disease (CKD) patients
  437. cholesterol lowering trials in coronary heart disease: frequency of citation and outcome.
  438. cholesterol lowering trials: advice for the British physician
  439. cholesterol lowering Trials: Advice for the British Physician
  440. cholesterol lowering with Antacid
  441. cholesterol lowering with bile salt hydrolase-active probiotic bacteria, mechanism of action, clinical evidence, and future direction for heart health applications
  442. cholesterol lowering with EVOLocumab to prevent cardiac allograft Vasculopathy in De‐novo heart transplant recipients: Design of the randomized controlled …
  443. cholesterol lowering with high-viscosity hydroxypropylmethylcellulose
  444. cholesterol lowering with pravastatin improves resistance artery endothelial function in subjects with normal coronary arteriograms
  445. cholesterol lowering with pravastatin improves resistance artery endothelial function: report of six subjects with normal coronary arteriograms
  446. cholesterol lowering with simvastatin and ezetimibe inhibits cholesterol crystal formation and associated inflammation
  447. cholesterol lowering with simvastatin improves prognosis of diabetic patients with coronary heart disease: a subgroup analysis of the Scandinavian Simvastatin …
  448. cholesterol lowering, cardiovascular diseases, and the rosuvastatin-JUPITER controversy: a critical reappraisal
  449. cholesterol lowering, fecal bile acid, and sterol changes during neomycin and colchicine
  450. cholesterol lowering, low cholesterol, and mortality
  451. cholesterol lowering, low cholesterol, and noncardiovascular disease.
  452. cholesterol lowering, Nutrition and Stroke Prevention
  453. cholesterol lowering: practical approaches
  454. cholesterol lowering: role in cancer prevention and treatment
  455. cholesterol lowering: should it continue to be the last thing we do?
  456. cholesterol lowering: to live longer, start younger?
  457. cholesterol profile in women with premature menopause after risk reducing salpingo-oophorectomy
  458. cholesterol reducing agents inhibit assembly of type I parainfluenza viruses
  459. cholesterol reducing and bile-acid binding properties of taioba (Xanthosoma sagittifolium) leaf in rats fed a high-fat diet
  460. cholesterol reducing food certainly is useful
  461. cholesterol screening and cholesterol lowering treatment.
  462. cholesterol side chain analogs but not its ether analogs possess cholesterollowering activity
  463. cholesterol sulphate affects production of steroid hormones by reducing steroidogenic acute regulatory protein level in adrenocortical cells
  464. cholesterol target value attainment and lipid-lowering therapy in patients with stable or acute coronary heart disease: results from the Dyslipidemia International Study …
  465. cholesterol-Absorber Status Modifies the LDL cholesterollowering Effect of a Mediterranean-Type diet in Adults with Moderate Cardiovascular Risk Factors
  466. cholesterol-and apolipoprotein-lowering effect of plant stanol ester in healthy Japanese men and women.
  467. cholesterollowering Abilities of a Novel Proprietary Preparation (CholesLo™)-A Randomized, Double-Blind, Placebo-Controlled Study.
  468. cholesterollowering ability of a phytostanol softgel supplement in adults with mild to moderate hypercholesterolemia
  469. cholesterollowering action and antioxidative effects of microbial gum in C57BL/6N mice fed a high fat diet
  470. cholesterollowering action of a novel nutraceutical combination in uremic rats: Insights into the molecular mechanism in a hepatoma cell line
  471. cholesterollowering action of BNA-based antisense oligonucleotides targeting PCSK9 in atherogenic diet-induced hypercholesterolemic mice
  472. cholesterollowering action of diets rich in polyunsaturated fatty acids
  473. cholesterollowering action of guar gum in the rat: Changes in bile acids and sterols excretion and in enterohepatic cycling of bile acids
  474. cholesterollowering action of plant sterols
  475. cholesterollowering action of psyllium mucilloid in the hamster: sites and possible mechanisms of action
  476. cholesterollowering ACTIVITY AND ANTIOXIDANT PROPERTIES OF SYNBIOTIC PRODUCT «NӘR»
  477. cholesterollowering activity of Artocarpus ovatus Blanco (Moraceae) ethanolic leaf extract in animal models
  478. cholesterollowering activity of lactic acid bacteria and yeast when used as probiotics in laying quail (Coturnix coturnix japonica).
  479. cholesterollowering activity of lactic acid bacteria probiotic strains in vivo
  480. cholesterollowering activity of Lactobacillus gasseri: in vitro and in vivo results.
  481. cholesterollowering activity of Lactobacillus plantarum HLX37 in vitro and in vivo
  482. cholesterollowering activity of linear-and gel-type sodium polyacrylate as dietary fiber models
  483. cholesterollowering activity of naringenin via inhibition of 3-hydroxy-3-methylglutaryl coenzyme A reductase and acyl coenzyme A: cholesterol acyltransferase in rats
  484. cholesterollowering Activity of Persea americana Mill.
  485. cholesterollowering activity of sesamin is associated with down-regulation on genes of sterol transporters involved in cholesterol absorption
  486. cholesterollowering activity of soy-derived glyceollins in the golden Syrian hamster model
  487. cholesterollowering activity of tartary buckwheat protein
  488. cholesterollowering activity of the aqueous extract of Spergularia purpurea in normal and recent-onset diabetic rats
  489. cholesterollowering activity of the major polyphenols in grape seed
  490. cholesterollowering activity of various undigested fractions of soybean protein in rats
  491. cholesterollowering agents: PCSK9 inhibitors today and tomorrow
  492. cholesterollowering and anti-obesity effects of Polymnia sonchifolia Poepp. & Endl. powder in rats fed a high fat-high cholesterol diet
  493. cholesterollowering and antioxidant status-improving efficacy of germinated giant embryonic rice (Oryza sativa L.) in high cholesterol-fed rats
  494. cholesterollowering and blood pressure effects of immune milk
  495. cholesterollowering and gallstone-preventing action of chitosans with different degrees of deacetylation in hamsters fed cholesterol-rich diets
  496. cholesterollowering and HDL-raising properties of lecithinated soy proteins in type II hyperlipidemic patients
  497. cholesterollowering and hepatoprotective effect of fruit juice extract of Azadirachta indica on Plasmodium berghei infected mice
  498. cholesterollowering and High-Density Lipoprotein-Raising Properties of Lecithinated Soy Proteins in Type II Hyperlipidemic Patients
  499. cholesterollowering and lipid oxidation reduction potentials of traditional seasonings in Salchichon dry-fermented sausages
  500. cholesterollowering and liver-protective effects of cooked and germinated mung beans (Vigna radiata L.)
  501. cholesterollowering and vascular reactivity in relation to coronary heart disease.
  502. cholesterollowering benefits of a whole grain oat ready-to-eat cereal
  503. cholesterollowering benefits of oat-containing cereal in Hispanic Americans
  504. cholesterollowering bile acid-binding agents: novel lipophilic polyamines
  505. cholesterollowering blockbuster candidates speed into Phase III trials
  506. cholesterollowering by rice bran and rice bran oil unsaponifiable matter in hamsters
  507. cholesterollowering Clinical Trials: Where Do We Go From Here?
  508. cholesterollowering Decreased mTOR Complex 2 Signaling and Enhanced Antitumor Immunity
  509. cholesterollowering diets Change Vitamin and Mineral Intakes
  510. cholesterollowering diets may increase the food costs for Danish children. A cross-sectional study of food costs for Danish children with and without familial …
  511. cholesterollowering diets: a review of the evidence
  512. cholesterollowering effect of a low-fat diet containing lean beef is reversed by the addition of beef fat
  513. cholesterollowering effect of a new fermented milk product in healthy 44-year old Danish men
  514. cholesterollowering effect of a theaflavin-enriched green tea extract: a randomized controlled trial
  515. cholesterollowering effect of agemaki, a kind of shellfish, in mice
  516. cholesterollowering effect of allicin on hypercholesterolemic ICR mice
  517. cholesterollowering effect of Aralia elata (Miq.) Seem via the activation of SREBP-2 and the LDL receptor
  518. cholesterollowering effect of astringent persimmon fruits (Diospyros kaki Thunb.) extracts
  519. cholesterollowering effect of barley bran flour and oil
  520. cholesterollowering effect of beta glucan extracted from Saccharomyces cerevisiae in rats
  521. cholesterollowering Effect of Beta Glucan Extracted from Saccharomyces cerevisiae in Rats.
  522. cholesterollowering effect of bezafibrate is independent of peroxisome proliferator-activated receptor activation in mice
  523. cholesterollowering effect of black tea polyphenols, theaflavins, theasinensin A and thearubigins, in rats fed high fat diet
  524. cholesterollowering effect of calcium alginate in rats
  525. cholesterollowering effect of Clostridium butyricum in cholesterol-fed rats
  526. cholesterollowering effect of colestipol hydrochloride given twice daily in hypercholesterolemic patients
  527. cholesterollowering effect of concentrated pomegranate juice consumption in type II diabetic patients with hyperlipidemia
  528. cholesterollowering effect of continuous enteral nutrition in man
  529. cholesterollowering effect of diet with added sweet potato (Ipomea batatas) vines in rabbits
  530. cholesterollowering effect of dietary Lupinus angustifolius proteins in adult rats through regulation of genes involved in cholesterol homeostasis
  531. cholesterollowering effect of extruded amaranth (Amaranthus caudatus L.) in hypercholesterolemic rabbits
  532. cholesterollowering effect of ezetimibe in uridine diphosphate glucuronosyltransferase 1A-deficient (Gunn) rats
  533. cholesterollowering effect of food bars containing guar gum in healthy women and men
  534. cholesterollowering effect of garlic
  535. cholesterollowering effect of garlic extracts and organosulfur compounds: human and animal studies
  536. cholesterollowering effect of hydroxychloroquine in patients with rheumatic disease: reversal of deleterious effects of steroids on lipids
  537. cholesterollowering effect of kori-tofu protein and its high-molecular-weight fraction content
  538. cholesterollowering effect of lactic acid bacteria in mice with hyperlipidemia
  539. cholesterollowering effect of Lactobacillus plantarum NCU116 in a hyperlipidaemic rat model
  540. cholesterollowering effect of Lactobacillus rhamnosus BFE5264 and its influence on the gut microbiome and propionate level in a murine model
  541. cholesterollowering effect of mevinolin, an inhibitor of 3-hydroxy-3-methylglutaryl-coenzyme a reductase, in healthy volunteers.
  542. cholesterollowering effect of N-(α-methylbenzyl) linoleamide (melinamide) in cholesterol-fed diabetic rats
  543. cholesterollowering effect of NK-104, a 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitor, in guinea pig model of hyperlipidemia
  544. cholesterollowering effect of non-viscous soluble dietary fiber NUTRIOSE (R) 6 in moderately hypercholesterolemic hamsters
  545. cholesterollowering effect of oat
  546. cholesterollowering Effect of Octaarginine-appended β-Cyclodextrin in Npc1-trap-CHO Cells
  547. cholesterollowering effect of organosulphur compounds from garlic: a possible mechanism of action.
  548. cholesterollowering effect of phytosterol-containing lactic-fermented milk powder in hamsters
  549. cholesterollowering effect of plant sterols
  550. cholesterollowering effect of platycodin D in hypercholesterolemic ICR mice
  551. cholesterollowering effect of policosanol on rabbits with hypercholesterolaemia induced by a wheat starch-casein diet
  552. cholesterollowering effect of probiotic yogurt in comparison with ordinary yogurt in mildly to moderately hypercholesterolemic subjects
  553. cholesterollowering effect of rice bran protein containing bile acid-binding proteins
  554. cholesterollowering effect of rice protein by enhancing fecal excretion of lipids in rats
  555. cholesterollowering effect of rolled oats
  556. cholesterollowering effect of skim milk from immunized cows in hypercholesterolemic patients
  557. cholesterollowering effect of soy protein in normocholesterolemic and hypercholesterolemic men
  558. cholesterollowering effect of soyabean lecithin in normolipidaemic rats by stimulation of biliary lipid secretion
  559. cholesterollowering effect of soybean oligopeptides
  560. cholesterollowering effect of soybean protein isolate in chicks is partly lost by microbial protease digestion
  561. cholesterollowering effect of spreads enriched with microcrystalline plant sterols in hypercholesterolemic subjects
  562. cholesterollowering effect of stanol ester in a US population of mildly hypercholesterolemic men and women: a randomized controlled trial
  563. cholesterollowering effect of sulfaguanidine in mice and rats
  564. cholesterollowering effect of taurine and its mechanism in high-cholesterol Hep G2 cells
  565. cholesterollowering effect of the food for heart nutrition education program
  566. cholesterollowering effect of the mushroom Pleurotus ostreatus in hereditary hypercholesterolemic rats
  567. cholesterollowering effect of the regulatory peptide Pro-Gly-Pro-Leu
  568. cholesterollowering effect of whole lupin (Lupinus albus) seed and its protein isolate
  569. cholesterollowering effect of β-glucan from oat bran in mildly hypercholesterolemic subjects may decrease when β-glucan is incorporated into bread and cookies
  570. cholesterollowering effects and potential mechanisms of chitooligosaccharide capsules in hyperlipidemic rats
  571. cholesterollowering effects and potential mechanisms of different polar extracts from Cyclocarya paliurus leave in hyperlipidemic mice
  572. cholesterollowering effects and utilization of protein, lipid, fiber and energy in rats fed unprocessed and baked oat bran
  573. cholesterollowering Effects in Rat Liver Fed Barley and Barley Fraction with cholesterol
  574. cholesterollowering effects of a 10 mg daily dose of lovastatin in patients with initial total cholesterol levels 200 to 240 mg/dl (5.18 to 6.21 mmol/liter)
  575. cholesterollowering effects of a new isolated soy protein with high levels of nondenaturated protein in hypercholesterolemic patients
  576. cholesterollowering effects of a proprietary Chinese red-yeast-rice dietary supplement
  577. cholesterollowering effects of a putative probiotic strain Lactobacillus plantarum EM isolated from kimchi
  578. cholesterollowering effects of Bacillus coagulans B37 and Bacillus pumilus B9 strains in a rat animal model.
  579. cholesterollowering effects of barley dietary fibre in humans: scientific support for a generic health claim
  580. cholesterollowering effects of bovine serum immunoglobulin in participants with mild hypercholesterolemia
  581. cholesterollowering effects of certain grains and of oat fractions in the chick.
  582. cholesterollowering effects of dietary blue lupin (Lupinus angustifolius L.) in intact and ileorectal anastomosed pigs
  583. cholesterollowering effects of dietary citrus juices and their flavonoids. Studies in rats, mice and rabbits
  584. cholesterollowering effects of dietary fiber
  585. cholesterollowering effects of dietary fiber: a meta-analysis
  586. cholesterollowering effects of dietary lupin (Lupinus albus var Multolupa) in chicken diets
  587. cholesterollowering effects of dietary pomegranate extract and inulin in mice fed an obesogenic diet
  588. cholesterollowering effects of dl-N-(α-methylbenzyl)-linoleamide and its optically active isomers in cholesterolfed animals
  589. cholesterollowering Effects of Extract from Garcinia daedalanthera in Hyperlipidemic rats
  590. cholesterollowering effects of guar gum: changes in bile acid pools and intestinal reabsorption
  591. cholesterollowering effects of high-protein soya milk
  592. cholesterollowering effects of isolated soybean protein hydrolyzate with bound phospholipids in rats
  593. cholesterollowering Effects of Lactobacilli and Bifidobacteria Probiotics in vitro and in vivo
  594. cholesterollowering effects of Lactobacillus brevis isolated from turnip “tsuda kabu”
  595. cholesterollowering effects of Lactobacillus species
  596. cholesterollowering effects of maitake (Grifola frondosa) fiber, shiitake (Lentinus edodes) fiber, and enokitake (Flammulina velutipes) fiber in rats
  597. cholesterollowering effects of modified animal fats in postmenopausal women.
  598. cholesterollowering effects of N-methylated neomycin and basic antibiotics
  599. cholesterollowering effects of NTE-122, a novel acyl-CoA: cholesterol acyltransferase (ACAT) inhibitor, on cholesterol diet-fed rats and rabbits
  600. cholesterollowering effects of oat β-glucan
  601. cholesterollowering effects of oat β-glucan: a meta-analysis of randomized controlled trials
  602. cholesterollowering effects of piceatannol, a stilbene from wine, using untargeted metabolomics
  603. cholesterollowering effects of plant sterol esters and non-esterified stanols in margarine, butter and low-fat foods
  604. cholesterollowering effects of plant sterol esters differ in milk, yoghurt, bread and cereal
  605. cholesterollowering effects of plant sterols in one serve of wholegrain wheat breakfast cereal biscuits—A randomised crossover clinical trial
  606. cholesterollowering effects of plant steryl and stanyl laurate by oral administration in mice
  607. cholesterollowering effects of policosanol in rabbits.
  608. cholesterollowering effects of probiotics and prebiotics: a review of in vivo and in vitro findings
  609. cholesterollowering effects of probiotics–a review
  610. cholesterollowering effects of psyllium hydrophilic mucilloid for hypercholesterolemic men
  611. cholesterollowering effects of psyllium hydrophilic mucilloid: adjunct therapy to a prudent diet for patients with mild to moderate hypercholesterolemia
  612. cholesterollowering effects of psyllium intake adjunctive to diet therapy in men and women with hypercholesterolemia: meta-analysis of 8 controlled trials
  613. cholesterollowering effects of psyllium seed associated with urea metabolism
  614. cholesterollowering effects of psyllium-enriched cereal as an adjunct to a prudent diet in the treatment of mild to moderate hypercholesterolemia
  615. cholesterollowering effects of ready-to-eat cereal containing psyllium
  616. cholesterollowering effects of rice bran and rice bran oil fractions in hypercholesterolemic hamsters
  617. cholesterollowering effects of soluble-fiber cereals as part of a prudent diet for patients with mild to moderate hypercholesterolemia
  618. cholesterollowering effects of soybean, potato and rice proteins depend on their low methionine contents in rats fed a cholesterol-free purified diet
  619. cholesterollowering effects of unripe black raspberry water extract
  620. cholesterollowering effects ohypercholesterolemiain patients with mild to moderate hypercholesterolemia
  621. cholesterollowering efficacy of a microencapsulated bile salt hydrolase-active Lactobacillus reuteri NCIMB 30242 yoghurt formulation in hypercholesterolaemic …
  622. cholesterollowering efficacy of a sitostanol-containing phytosterol mixture with a prudent diet in hyperlipidemic men
  623. cholesterollowering efficacy of Lactobacillus plantarum CECT 7527, 7528 and 7529 in hypercholesterolaemic adults
  624. cholesterollowering efficacy of plant sterol-enriched flavored milk, yogurt, fruit bar, and soya milk in mild hypercholesterolemic Indian subjects
  625. cholesterollowering efficacy of plant sterols in low-fat yogurt consumed as a snack or with a meal
  626. cholesterollowering efficacy of plant sterols/stanols provided in capsule and tablet formats: results of a systematic review and meta-analysis
  627. cholesterollowering efficacy of unrefined bran oil from the pigmented black rice (Oryza sativa L cv. Suwon 415) in hypercholesterolemic rats
  628. cholesterollowering food additives: lipase-catalysed preparation of phytosterol and phytostanol esters
  629. cholesterollowering foods and reduction in serum cholesterol levels
  630. cholesterollowering foods and reduction in serum cholesterol levels—reply
  631. cholesterollowering gene therapy counteracts the development of non-ischemic cardiomyopathy in mice
  632. cholesterollowering Gene Therapy Prevents Heart Failure with Preserved Ejection Fraction in Obese Type 2 Diabetic Mice
  633. cholesterollowering gene therapy prevents HFpEF in obese type 2 diabetic mice
  634. cholesterollowering in hamsters fed rice bran at various levels, defatted rice bran and rice bran oil
  635. cholesterollowering in infancy?
  636. cholesterollowering in man
  637. cholesterollowering Independent Effects of Pravastatin on the Artery Wall of Atherosclerotic Primates.
  638. cholesterollowering independent regression and stabilization of atherosclerotic lesions by pravastatin and by antimonocyte chemoattractant protein-1 therapy in …
  639. cholesterollowering injectables: more harm than good
  640. cholesterollowering intervention and coronary artery disease after cardiac transplantation
  641. cholesterollowering Intervention Program: effect of the step I diet in community office practices
  642. cholesterollowering interventions and stroke: insights from a meta-analysis of randomized controlled trials
  643. cholesterollowering interventions and stroke: Insights from IMPROVE-IT
  644. cholesterollowering MECHANISMS OF PHYTOCHEMICALS: A REVIEW.
  645. cholesterollowering medications reduce the risk of age-related maculopathy progression
  646. cholesterollowering nature of unsaturated fat in rats may be due to its inability to increase hepatic iron
  647. cholesterollowering nutraceuticals affecting vascular function and cardiovascular disease risk
  648. cholesterollowering nutraceuticals and functional foods
  649. cholesterollowering of Pantethine is Due to the Hydrolysis Product Cysteamine
  650. cholesterollowering pattern affects the progression of atherosclerosis in apolipoprotein E deficient mice
  651. cholesterollowering phytosterols: factors affecting their use and efficacy
  652. cholesterollowering potential in human subjects of fat from pigs fed rapeseed oil
  653. cholesterollowering Potential of Probiotic Yogurts Containing Lactobacillus acidophilus and Streptococcus Thermophiles on Mild Hypercholesterolemic Male …
  654. cholesterollowering potentials of lactic acid bacteria based on bile-salt hydrolase activity and effect of potent strains on cholesterol metabolism in vitro and in …
  655. cholesterollowering potentials of Lactobacillus strain overexpression of bile salt hydrolase on high cholesterol diet-induced hypercholesterolemic mice
  656. cholesterollowering probiotics as potential biotherapeutics for metabolic diseases
  657. cholesterollowering probiotics: in vitro selection and in vivo testing of bifidobacteria
  658. cholesterollowering probiotics: in vitro selection and in vivo testing of bifidobacteria
  659. cholesterollowering properties and safety of chitosan
  660. cholesterollowering properties of amaranth flakes, crude and refined oils in hamsters
  661. cholesterollowering properties of amaranth grain and oil in hamsters
  662. cholesterollowering PROPERTIES OF DEFATTED KENAF SEED MEAL AND ITS PHENOLICS-SAPONINS-RICH EXTRACT IN A RAT MODEL
  663. cholesterollowering properties of different pectin types in mildly hyper-cholesterolemic men and women
  664. cholesterollowering properties of Ganoderma lucidum in vitro, ex vivo, and in hamsters and minipigs
  665. cholesterollowering properties of lupin peptides: molecular and functional investigations at Hepg2 cell line
  666. cholesterollowering properties of oat β-glucan and the promotion of cardiovascular health: did Health Canada make the right call?
  667. cholesterollowering properties of oats: Effects of processing and the role of oat components
  668. cholesterollowering properties of plant sterols esterified with beef tallow fatty acids in hamsters
  669. cholesterollowering proteins and peptides.
  670. cholesterollowering therapy
  671. cholesterollowering therapy
  672. cholesterollowering therapy after heart transplantation: a 12-month randomized trial.
  673. cholesterollowering therapy and cell membranes. Stable plaque at the expense of unstable membranes?
  674. cholesterollowering therapy evokes time-limited changes in serotonergic transmission
  675. cholesterollowering therapy for primary prevention: still much we don’t know
  676. cholesterollowering therapy for smokers and non-smokers: a life-table analysis
  677. cholesterollowering therapy for the treatment of nonalcoholic fatty liver disease: an update
  678. cholesterollowering therapy in secondary prevention: Remaining issues
  679. cholesterollowering therapy in women and elderly patients with myocardial infarction or angina pectoris: findings from the Scandinavian Simvastatin Survival Study …
  680. cholesterollowering Therapy Interventions
  681. cholesterollowering therapy may retard the progression of diabetic nephropathy
  682. cholesterollowering therapy with pravastatin in heart-transplant patients taking cyclosporine A
  683. cholesterollowering therapy with pravastatin in older patients (aged 65 to 75) in the lipid study
  684. cholesterollowering therapy; a recommendation from the Health Council
  685. cholesterollowering Therapy: Evaluation of Clinical Trial Evidence
  686. cholesterollowering Therapy: Is Therereallya Controversy?
  687. cholesterollowering therapy: new data on tolerability and noncompliance
  688. cholesterollowering therapy: Old evidence, new guidelines–Which one to follow? A critical appraisal
  689. cholesterollowering treatment in chronic kidney disease: Multistage pairwise and network meta-analyses
  690. cholesterollowering treatment is associated with improvement in coronary vascular remodeling and endothelial function in patients with normal or mildly diseased …
  691. cholesterollowering treatment with PCSK9-inhibitors
  692. cholesterol-metabolizing cytochromes P450: implications for cholesterol lowering
  693. cholesterol-Reducing Activity in a Cell-Free Supernatant of Lactobacillus reuteri
  694. cholesterol-reducing agents for treatment of aneurysmal subarachnoid hemorrhage: systematic review and meta-analysis of randomized controlled trials
  695. cholesterol-reducing bacterium from human feces.
  696. cholesterol-reducing effect of ergosterol is modulated via inhibition of cholesterol absorption and promotion of cholesterol excretion
  697. cholesterol-reducing flavonoids found in citrus peels
  698. cholesterol-reducing Lactic Acid Bacteria Screening and Research [J]
  699. cholesterol-Reducing of Lactobacillus Plantarum
  700. cholesterollowering effect of an acyl‐coenzyme A: cholesterol acyltransferase inhibitor, FR145237, in hypercholesterolemic rabbits fed a high‐cholesterol diet and a …
  701. cholesterollowering effect of dextro‐thyroxine in patients with hypercholesterolemia and coronary diseasel
  702. cholesterollowering effect of plant sterols
  703. cholesterollowering effect of ursodeoxycholic acid in patients with primary biliary cirrhosis
  704. cholesterollowering effect of YM‐16638 in cynomolgus monkeys
  705. cholesterollowering Effects and Mechanisms in View of Bile Acid Pathway of Resveratrol and Resveratrol Glucuronides
  706. cholesterollowering effects of E nterococcus
  707. cholesterollowering effects of Northern wild rice in LDL receptor knockout mice
  708. cholesterollowering effects of rosuvastatin compared with atorvastatin in patients with type 2 diabetes–CORALL study
  709. cholesterollowering properties of whole cowpea seed and its protein isolate in hamsters
  710. cholesterollowering strategies reduce vascular LRP1 overexpression induced by hypercholesterolaemia
  711. cholesterollowering therapy with pravastatin in patients with average cholesterol levels and established ischaemic heart disease: is it cost‐effective?
  712. cholesterol‐reducing agents for aneurysmal subarachnoid haemorrhage
  713. cholesterol–GalNAc dual conjugation strategy for reducing renal distribution of antisense oligonucleotides
  714. cholesterollowering effect of oat flour supplementationon lipid profile of mild hyperlipidemic male subjects
  715. cholesterol, cholesterol lowering, and endothelial function
  716. cholesterol, copper and Aβ in controls, MCI, AD and the AD cholesterollowering treatment trial (ADCLT)
  717. cholesterol, triglycerides and ldl lowering effects of generic products of simvastatin and hdl effect as compared to original brand of simvastatin in hypercholesterolemic …
  718. cholesterol: Its low density lipoproteins and natural approaches in lipid lowering therapy
  719. cholesterol/HDL-c ratio lowering effect of green tea in rats exposed to depot medroxiprogesterone acetate
  720. Cholesteryl ester transfer protein gene polymorphism is a determinant of HDL cholesterol and of the lipoprotein response to a lipid-lowering diet in type 1 diabetes
  721. Choosing hamsters but not rats as a model for studying plasma cholesterollowering activity of functional foods
  722. Chymase in exocytosed rat mast cell granules effectively proteolyzes apolipoprotein AI-containing lipoproteins, so reducing the cholesterol efflux-inducing ability of …
  723. Clinical and cost-effectiveness of an intervention for reducing cholesterol and cardiovascular risk for people with severe mental illness in English primary care …
  724. Clinical application of bergamot (Citrus bergamia) for reducing high cholesterol and cardiovascular disease markers
  725. Clinical benefits and cost-effectiveness of lowering serum cholesterol levels: the case of simvastatin and cholestyramine in the Netherlands
  726. Clinical benefits of cholesterol lowering treatments. Meta-analysis of randomized therapeutic trials
  727. Clinical reality of lowering total and LDL cholesterol
  728. Clinical trial of plantstanol-ester induced cholesterollowering in NIDDM-patients
  729. Clinical trials of cholesterol lowering intervention for cardiovascular prevention in elderly
  730. Co-administration of cholesterollowering probiotics and anthraquinone from Cassia obtusifolia L. ameliorate non-alcoholic fatty liver
  731. Co-administration of ezetimibe enhances proteinuria-lowering effects of pitavastatin in chronic kidney disease patients partly via a cholesterol-independent manner
  732. Cognition after lowering LDL-cholesterol with evolocumab
  733. Colesevelam hydrochloride: a non-absorbed, polymeric cholesterollowering agent
  734. Colesevelam hydrochloride: usefulness of a specifically engineered bile acid sequestrant for lowering LDL-cholesterol
  735. Combined effect of vegetable protein (soy) and soluble fiber added to a standard cholesterollowering diet
  736. Combined lowering effects of rosuvastatin and L. acidophilus on cholesterol levels in rat
  737. Combining cholesterollowering strategies with imaging data: a visible benefit?
  738. Comment on:” A comparison of the LDL-cholesterol lowering efficacy of plant stanols and plant sterols over a continuous dose range: results of a meta-analysis of …
  739. Commentary to part two: Does lowering cholesterol cause increases in depression, suicide, and accidents?
  740. Common genetic variation in the ABCB1 gene is associated with the cholesterollowering effect of simvastatin in males
  741. Compactin (ML-236B) and related compounds as potential cholesterollowering agents that inhibit HMG-CoA reductase
  742. Comparative cholesterol lowering properties of vegetable oils: beyond fatty acids
  743. Comparative cholesterollowering activity of citrus and tomato pectin
  744. Comparative cholesterollowering effects of barley β-glucan and barley oil in golden Syrian hamsters
  745. Comparative Effectiveness of Atorvastatin (Low Vs High Dose) in lowering Low-Density Lipoprotein cholesterol in Intermediate Risk Cardiovascular Patients
  746. Comparative of in vitro antioxidant and cholesterollowering activities of fermented goat & cow milk
  747. Comparative studies on the serum cholesterol lowering action of whey protein and soybean protein in rats
  748. Comparative Study on Acute Toxicity, Antioxidant and cholesterol lowering Activities of Po-Sa (Leaves And Stem)
  749. Comparison between the plasma cholesterollowering effects of glycine and taurine in rats fed on high cholesterol diets
  750. Comparison of Antioxidant and cholesterollowering Activity of Mulberry (Morus alba L.)
  751. Comparison of cholesterollowering effect of β-glucan in cereals and bread
  752. Comparison of cholesterollowering efficacy and anti-atherogenic properties of hydrogenated versus non-hydrogenated (Phytrol™) tall oil-derived phytosterols in apo …
  753. Comparison of cholesterollowering regimens.
  754. Comparison of docosahexaenoic acid with eicosapentaenoic acid on the lowering effect of endogenous plasma cholesterol in adult mice
  755. Comparison of effects of ezetimibe/simvastatin versus simvastatin versus atorvastatin in reducing C-reactive protein and low-density lipoprotein cholesterol levels
  756. Comparison of hesperetin and its metabolites for cholesterollowering and antioxidative efficacy in hypercholesterolemic hamsters
  757. Comparison of LDL-cholesterol analytical performance using direct homogeneous enzymatic assay and Friedwald formular for cost reducing apply to the annual …
  758. Comparison of monounsaturated fatty acids and carbohydrates for lowering plasma cholesterol
  759. Comparison of monounsaturated fatty acids and carbohydrates for reducing raised levels of plasma cholesterol in man
  760. COMPARISON OF ROSUVASTATIN WITH ATORVASTATIN IN lowering LOW DENSITY LIPOPROTEIN cholesterol AMONG DYSLIPIDEMIC PATIENTS
  761. Comparison of the cholesterollowering effects and toxicity of D-003 and lovastatin in normocholesterolaemic rabbits
  762. Comparison of the cholesterollowering Effects between Loquat Leaf and Fruit Extract in Rats Fed a High-cholesterol diet
  763. Comparison of the effectiveness of individual versus group counseling on reducing low density lipoprotein cholesterol levels.
  764. Comparison of the effects of plant sterol ester and plant stanol ester-enriched margarines in lowering serum cholesterol concentrations in hypercholesterolaemic …
  765. Comparison of the lowering effect on blood cholesterol of clofibrate and simvastatin
  766. Comparison of therapeutic effect lowering low density lipoprotein cholesterol in Uygur and Kazak na-tionality patients with coronary heart disease from Xinj iang
  767. Comparison of three cholesterollowering diets in normolipidemic men
  768. comparison of various cholesterol lowering diets in young healthy volunteers: effects on serum lipoproteins and on other risk indicators for cardiovascular diseases
  769. Complementary cholesterollowering response of a phytosterol/α-lipoic acid combination in obese zucker rats
  770. Complementary low-density lipoprotein-cholesterol lowering and pharmacokinetics of adding bempedoic acid (ETC-1002) to high-dose atorvastatin background …
  771. Complete genome sequence of Lactobacillus plantarum EM, a putative probiotic strain with the cholesterollowering effect and antimicrobial activity
  772. Components characterization of total tetraploid jiaogulan (Gynostemma pentaphyllum) saponin and its cholesterollowering properties
  773. Concept and protocol to isolate cholesterol-reducing bacteria from carnivores
  774. Concordance of diet with the recommended cholesterol lowering diet in patients with coronary heart disease
  775. Configuring users of cholesterol lowering foods: A review of biomedical discourse
  776. CONSISTENT LOW-DENSITY LIPOPROTEIN cholesterol lowering EFFICACY OF ALIROCUMAB IN HIGH AND VERY HIGH CARDIOVASCULAR RISK …
  777. Consumer attitudes and understanding of cholesterollowering claims on food: randomize mock-package experiments with plant sterol and oat fibre claims
  778. Consumption of a dietary portfolio of cholesterol lowering foods improves blood lipids without affecting concentrations of fat soluble compounds
  779. Consumption of restructured meat products with added walnuts has a cholesterollowering effect in subjects at high cardiovascular risk: a randomised, crossover …
  780. Continuous dose-response relationship of the LDL-cholesterollowering effect of phytosterol intake
  781. Control Measures and Mechanisms for Reducing Egg cholesterol Content [J]
  782. Control measures and mechanisms for reducing egg cholesterol content.
  783. Control of plasma cholesterollowering action of probucol with various lipid carrier systems
  784. Coronary atherosclerosis reduced in patients with familial hypercholesterolemia after intensive cholesterol lowering with low-density lipoprotein-apheresis: 1-year …
  785. Coronary heart disease risk factors and LDL cholesterollowering efficacy of fibrates and simvastatin
  786. Coronary risk assessment methods and cholesterol lowering
  787. Correction to Lancet Psychiatry 2018; 5: 145–54. Clinical and cost-effectiveness of an intervention for reducing cholesterol and cardiovascular risk for people with …
  788. Correction: activation of GPR55 receptors exacerbates oxLDL-induced lipid accumulation and inflammatory responses, while reducing cholesterol efflux from human …
  789. Correlates of LDL-cholesterol goal attainment in patients under lipid lowering therapy
  790. Correlation of Serum Lipoproteins with Total Serum cholesterol Values before and during Treatment with cholesterollowering Agents
  791. Correlation of the plasma cholesterollowering effect of dietary glycine with the alteration of hepatic phospholipid composition in rats
  792. Cost and health implications of cholesterol lowering.
  793. Cost effectiveness of cholesterol Appraising medical research lowering articles
  794. Cost effectiveness of cholesterollowering therapy in The Netherlands: simvastatin versus cholestyramine
  795. Cost effectiveness of incremental programmes for lowering serum cholesterol concentration: is individual intervention worth while?
  796. Cost effectiveness of lowering cholesterol
  797. Cost effectiveness of lowering cholesterol. Cost consequence analysis may be more useful to decision makers.
  798. Cost effectiveness of lowering cholesterol. Costs in general practice.
  799. Cost effectiveness of lowering cholesterol. Full treatment of the costs and benefits is needed.
  800. Cost-effectiveness analysis of cholesterollowering therapies in Spain
  801. Cost-effectiveness analysis of low density lipoprotein cholesterollowering therapy in hypertensive patients with type 2 diabetes in Korea: single-pill regimen …
  802. Cost-effectiveness of cholesterol lowering: results from the Scandinavian Simvastatin Survival Study (4S)
  803. Cost-effectiveness of cholesterollowering therapies according to selected patient characteristics
  804. Cost-effectiveness of cholesterollowering therapy with pravastatin in patients with previous acute coronary syndromes aged 65 to 74 years compared with younger …
  805. Cost-effectiveness of lowering of blood cholesterol using simvastatin and cholestyramine
  806. Creative approaches to cholesterol lowering used in the dietary Intervention Study in Children
  807. Critical review of 2016 ACC guidelines on therapies for cholesterol lowering with reference to laboratory testing
  808. Curcumin potentiates cholesterollowering effects of phytosterols in hypercholesterolaemic individuals. A randomised controlled trial
  809. Current strategies for atherosclerosis and lowering cholesterol
  810. Cutaneous microvascular responses are improved after cholesterollowering in patients with peripheral vascular disease and hypercholesterolaemia
  811. Cyclodextrin (CD) complexes of cholesterol–their potential use in reducing dietary cholesterol intake
  812. Cyclosporine A Impairs the Macrophage Reverse cholesterol Transport in Mice by Reducing
  813. Cyclosporine A impairs the macrophage reverse cholesterol transport in mice by reducing sterol fecal excretion
  814. CYP7A1 polymorphism influences the LDL cholesterollowering response to atorvastatin
  815. CYP7A1-rs3808607 and APOE isoform associate with LDL cholesterol lowering after plant sterol consumption in a randomized clinical trial
  816. D-Allulose Alters Serum cholesterol Levels Partly Via Reducing Serum Pcsk9 Levels In Hamsters.
  817. D-glucaric acid content of various fruits and vegetables and cholesterollowering effects of dietary D-glucarate in the rat
  818. Dadih (L. acidophilus), contained a cholesterol reducing food
  819. Deaths from injury, violence, and suicide in secondary prevention trials of cholesterol lowering
  820. Decisions regarding cholesterollowering therapy in the elderly: the experience in a lipid clinic and a review of the literature
  821. Declaring war on undertreatment: rationale for an aggressive approach to lowering cholesterol
  822. Declining Total cholesterol Levels and Increasing Lipid lowering Therapy Use at Presentation in Patients With Acute Coronary Syndrome
  823. Deficiency in Hepatic MTTP Reverses Gallstone Susceptibility in L-Fabp Knockout Mice by Reducing Canalicular cholesterol Secretion
  824. Defining the role of bempedoic acid in lowering low-density lipoprotein cholesterol
  825. Depression and cholesterollowering chemotherapy: Potential influence of smoking cessation, depression history, and dietary change
  826. Depression and failure of cholesterol lowering after acute myocardial infarction
  827. Design and rationale of the ARBITER 6 trial (Arterial Biology for the Investigation of the Treatment Effects of Reducing cholesterol)-6-HDL and LDL Treatment …
  828. Design and rationale of the ARBITER trial (Arterial Biology for the Investigation of the Treatment Effects of Reducing cholesterol)—a randomized trial comparing the …
  829. Design, synthesis, and cholesterollowering efficacy for prodrugs of berberrubine
  830. Determinants of Responsiveness of LDL-cholesterol lowering to Lifestyle Modification in Hypercholesterolemic Patients.
  831. Determining Antibacterial and cholesterol lowering Effect of Lactic Acid Bacteria Isolated from Dairy Products in East Azerbaijan
  832. Determining the probiotic potential of cholesterol-reducing Lactobacillus and Weissella strains isolated from gherkins (fermented cucumber) and south Indian …
  833. Development and initial evaluation of a culturally sensitive cholesterollowering diet program for Mexican and African American patients with systemic lupus …
  834. Development and production of cholesterollowering Monascus-nata complex
  835. Development and testing of the cholesterollowering diet self-efficacy scale
  836. Development of types of psyllium-enriched bread as part of a cholesterol lowering diet.
  837. Development Technology of Functional Food of cholesterol lowering Yogurt
  838. Dextran sulphate: use as an anticoagulant, and action in lowering serum cholesterol
  839. Dextro-thyroxine as a cholesterollowering agent in patients with angina pectoris
  840. Dextrothyroxine for lowering serum cholesterol: Analysis of data on 6066 patients
  841. diet and probucol in lowering cholesterol concentrations: Additive effects on plasma cholesterol concentrations in patients with familial type II hyperlipoproteinemia
  842. diet enrichment with calcium and magnesium enhances the cholesterollowering effect of plant sterols in obese Zucker rats.
  843. diet modification in lowering plasma cholesterol levels: a randomised trial of three types of intervention
  844. diet therapy of hypercholesterolemia. Can the diet of persons who already follow a cholesterollowering diet be further improved by guidelines given by a clinical …
  845. dietary advice for lowering plasma cholesterol.
  846. dietary Aloe vera components’ effects on cholesterol lowering and estrogenic responses in juvenile goldfish, Carassius auratus
  847. dietary cholesterol and the Optimal diet for Reducing Risk of Atherosclerosis
  848. dietary cholesterol and the optimal diet for reducing risk of atherosclerosis.
  849. dietary D-allulose alters cholesterol metabolism in Golden Syrian hamsters partly by reducing serum PCSK9 levels
  850. dietary effects of seaweed Sargassum ilicifolium on reducing cholesterol level of white leg shrimp (Litopenaeus vannamei)
  851. dietary fiber for reducing blood cholesterol
  852. dietary fibers, prebiotics, and exopolysaccharides produced by lactic acid bacteria: potential health benefits with special regard to cholesterollowering effects
  853. dietary flaxseed independently lowers circulating cholesterol and lowers it beyond the effects of cholesterollowering medications alone in patients with peripheral …
  854. dietary high-polyphenols extra-virgin olive oil is effective in reducing cholesterol content in eggs
  855. dietary phytosterols as cholesterollowering agents in humans
  856. dietary restriction slightly affects glucose homeostasis and delays plasma cholesterol removal in rabbits with dietary lipid lowering
  857. dietary wheat bran oil is equally as effective as rice bran oil in reducing plasma cholesterol
  858. dietary α-linolenic acid is as effective as oleic acid and linoleic acid in lowering blood cholesterol in normolipidemic men
  859. dietary β‐sitosterol is more potent in reducing plasma cholesterol than sesamin in hypercholesterolemia hamsters
  860. diets for reducing the concentration of fat (cholesterol concentration) in the blood.
  861. Difference between calculated and direct-measured low-density lipoprotein cholesterol in subjects with diabetes mellitus or taking lipid-lowering medications
  862. Differences in Action of Atorvastatin and Ezetimibe in lowering Low-Density Lipoprotein cholesterol and Effect on Endothelial Function–Randomized Controlled Trial …
  863. Differences in synthesis and absorption of cholesterol of two effective lipid-lowering therapies
  864. Differential effects of dietary eicosapentaenoic and docosahexaenoic fatty acids on lowering of tri-glyceride and cholesterol levels in the serum of rats on …
  865. Differential response of cholesterol and particle measures of atherogenic lipoproteins to LDL-lowering therapy: implications for clinical practice
  866. Differential sensitivity to acute cholesterol lowering of activation mediated via the high‐affinity IgE receptor and Thy‐1 glycoprotein
  867. Differentiating the effects of raising low levels of high-density lipoprotein cholesterol versus lowering normal triglycerides: further insights from the Veterans Affairs …
  868. Digital gene-expression profiling analysis of the cholesterollowering effects of alfalfa saponin extract on laying hens
  869. Dillenia indica fruit extract has Glucose and cholesterol lowering effects
  870. Dimethyl sulfoxide as a cholesterollowering agent in cultured fibroblasts exposed to low density lipoproteins
  871. Dipeptidyl-peptidase IV (DPP4) inhibitors’ cholesterol lowering effect: a systematic review
  872. Disadvantages of Current LDL-cholesterol lowering and the Role of PCSK9 Inhibitors.
  873. Discontinuation rates of cholesterollowering medications: implications for primary care.
  874. Discussion of Evaluation of cholesterollowering and antioxidant properties of sugar cane policosanols in hamsters and humans
  875. Disparate effects of a triglyceride lowering diet and of bezafibrate on the HDL system: a study in patients with hypertriglyceridaemia and low HDL‐cholesterol levels
  876. Diverse conditions contribute to the cholesterollowering ability of different Lactobacillus plantarum strains
  877. DMP 504, a novel hydrogel bile acid sequestrant: III. Safety, tolerability, and cholesterollowering in healthy hypercholesterolemic subjects
  878. Do cholesterollowering agents affect brain activity? A comparison of simvastatin, pravastatin, and placebo in healthy volunteers.
  879. Does cholesterol lowering Increase Non—Illness-Related Mortality?-Reply
  880. Does cholesterol lowering prevent stroke?
  881. Does lowering cholesterol cause cancer?
  882. Does lowering of cholesterol levels influence functional properties of large arteries?
  883. Does lowering serum cholesterol levels lower coronary heart disease risk?
  884. Does reducing blood pressure and cholesterol provide any HOPE for preventing cognitive decline and dementia?
  885. Does reducing cholesterol improve CAD survival?
  886. Dose response to soluble fiber from psyllium in cholesterol lowering in the hamster
  887. Dose-dependent cholesterollowering effect of a mayonnaise-type product with a main component of diacylglycerol-containing plant sterol esters
  888. Dose-dependent cholesterollowering effects of D-003 on normocholesterolemic rabbits
  889. Dose-dependent LDL-cholesterol lowering effect by plant stanol ester consumption: clinical evidence
  890. Double-Blind Randomized Placebo Controlled Trial Demonstrating Serum cholesterol lowering Efficacy of a Smoothie Drink with Added Plant Stanol Esters in …
  891. DYNAMICS OF TOTAL cholesterol LEVELS AND ITS EFFECT ON MORTALITY IN PEOPLE OVER AGE 65 NOT RECEIVING LIPID-lowering THERAPY
  892. e39 Indications for lowering LDL cholesterol in rheumatoid arthritis: an unrecognised problem
  893. Editorial [Reducing Cardiovascular Risk: Is Low-Density Lipoprotein-cholesterol (LDL-C) lowering Enough?]
  894. Effect and mechanism of cholesterollowering by kluyveromyces from tibetan kefir
  895. Effect LDL-cholesterol lowering effect of hydroxytyrosol (HTEssence®): A randomized double-blind, placebo-controlled parallel study
  896. Effect of 2 different reducing diets on the concentration of HDL cholesterol in obese adolescents
  897. Effect of a cholesterol lowering compound on hippocampal synaptogenesis
  898. Effect of a cholesterollowering diet during pregnancy on maternal and fetal Doppler velocimetry: the CARRDIP study
  899. Effect of a cholesterollowering diet on maternal, cord, and neonatal lipids, and pregnancy outcome: a randomized clinical trial
  900. Effect of a culturally sensitive cholesterol lowering diet program on lipid and lipoproteins, body weight, nutrient intakes, and quality of life in patients with systemic …
  901. Effect of a dietary portfolio of cholesterollowering foods given at 2 levels of intensity of dietary advice on serum lipids in hyperlipidemia: a randomized controlled trial
  902. Effect of a lipid-lowering agent or a high-cholesterol diet on focal glomerulosclerosis in hyperlipidemic rats.
  903. Effect of a prudent reducing diet on the serum cholesterol of overweight middle-aged men.
  904. Effect of a serum cholesterollowering diet on composition of depot fat in man.
  905. Effect of anti‐oxidant treatment and cholesterol lowering on resting arterial tone, metabolic vasodilation and endothelial function in the human forearm: a randomized …
  906. Effect of antibiotics as cholesterollowering agents
  907. Effect of apolipoprotein E phenotype on diet-induced lowering of plasma low density lipoprotein cholesterol.
  908. Effect of biological and analytical variation in cholesterol measurement on the cost-effectiveness of cholesterollowering therapy
  909. Effect of blending and lipase catalyzed interesterification reaction on the cholesterol lowering properties of palm oil with rice bran oil in rats
  910. Effect of broccoli sprouts on cholesterollowering and anti-obesity effects in rats fed high fat diet
  911. Effect of cholesterol lowering agent (Lipolax) on some physiological parameters in some infertile obese PCOS Egyptian women undergoing ICSI
  912. Effect of cholesterol lowering multiplex lactic acid bacteria on lipid metabolism in a hamster model
  913. Effect of cholesterol lowering on intravascular pools of TFPI and its anticoagulant potential in type II hyperlipoproteinemia
  914. Effect of cholesterol lowering treatment on plasma markers of endothelial dysfunction in chronic kidney disease
  915. Effect of cholesterol lowering treatment on positive exercise tests in patients with hypercholesterolaemia and normal coronary angiograms
  916. Effect of cholesterol reducing therapy with 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor on secondary prevention after myocardial infarction in Japanese …
  917. Effect of cholesterollowering agents
  918. Effect of cholesterollowering diet on mortality from coronary heart disease and other causes.
  919. Effect of cholesterollowering diet on mortality from coronary heart-disease and other causes: a twelve-year clinical trial in men and women
  920. Effect of cholesterollowering diet on production of adrenal cortical hormones in man
  921. Effect of cholesterollowering diets on indices of depression and hostility
  922. Effect of cholesterollowering medications on progression of mild atherosclerotic lesions of the carotid arteries and on the risk of stroke
  923. Effect of cholesterollowering starter cultures in smoked sausages on the formation of bioactive peptides and lipid profile in triton-induced hyperlipidemic rats
  924. Effect of cholesterollowering therapy on coronary endothelial vasomotor function in patients with coronary artery disease
  925. Effect of cholesterollowering therapy on endothelial function
  926. Effect of cholesterollowering treatment on coronary heart disease morbidity and mortality: the evidence from trials, and beyond
  927. Effect of cholesterol-reducing lactobacillus on cholesterol of chicken.
  928. Effect of combination cholesterollowering therapy and triglyceride-lowering therapy on medical costs in patients with type 2 diabetes mellitus
  929. Effect of combined antihypertensive and cholesterol lowering treatment on the arterial elasticity in middle-old-aged hypertension patients
  930. Effect of combining psyllium fiber with simvastatin in lowering cholesterol
  931. Effect of cream pasteurization, microfiltration and enzymatic proteolysis on in vitro cholesterollowering activity of buttermilk solids
  932. Effect of crilvastatin, a new cholesterol lowering agent, on unesterified LDL‐cholesterol metabolism into bile salts by rat isolated hepatocytes
  933. Effect of dietary carbohydrate on cholesterol lowering action of blackgram fiber
  934. Effect of different herbs and spices on cholesterol lowering in broiler: An overview
  935. Effect of dried mushroom, Lentinus edodes (Berk.) Sing., on cholesterol metabolism in rats. 2. Fractionation of the cholesterol-reducing fraction. 1.
  936. EFFECT OF EAR ACUPUNCTURE ON REDUCING WEIGHT AND LEVELS OF THE SERUM TOTAL cholesterol AND TRIGLYCERIDE
  937. Effect of enzymatic hydrolysis on cholesterollowering activity of oat β-glucan
  938. Effect of ethanol extract of Coccinia grandis Lin leaf on glucose and cholesterol lowering activity
  939. Effect of feeding of a cholesterol-reducing bacterium, Eubacterium coprostanoligenes, to germ-free mice
  940. EFFECT OF FEEDING ON SOME dietARY FIBERS FOR REDUCING BLOOD cholesterol
  941. Effect of Goat Milk Yogurt towards Reducing Uric Acid, cholesterol, and Blood Glucose Level
  942. Effect of HMGCR Variant Alleles on Low‐Density Lipoprotein cholesterollowering Response to Atorvastatin in Healthy Korean Subjects
  943. Effect of Honey Eurya Spp. in Jiangxi on the Immunity and cholesterollowering Function of Animals
  944. Effect of intensive LDL cholesterol lowering with PCSK9 monoclonal antibodies on tendon xanthoma regression in familial hypercholesterolemia
  945. Effect of long term, non cholesterol lowering dose of fluvastatin treatment on oxidative stress in brain and peripheral tissues of streptozotocin-diabetic rats
  946. Effect of long-term cholesterollowering treatment with HMG-CoA reductase inhibitor (simvastatin) on myocardial perfusion evaluated by thallium-201 single photon …
  947. Effect of Lotus Leaf Alkaloid on Kunming Mice cholesterollowering and Reducing Weight
  948. Effect of Lotus Leaf Alkaloid on Reducing Weight of Kunming Mice cholesterollowering
  949. Effect of low dose atorvastatin versus diet-induced cholesterol lowering on atherosclerotic lesion progression and inflammation in apolipoprotein E* 3–Leiden …
  950. Effect of Low-density Lipoprotein cholesterol lowering With Alirocumab on Stroke in ODYSSEY OUTCOMES
  951. Effect of low‐density lipoprotein cholesterol lowering by ezetimibe/simvastatin on outcome incidence: Overview, meta‐analyses, and meta‐regression analyses of …
  952. Effect of lowering LDL cholesterol substantially below currently recommended levels in patients with coronary heart disease and diabetes: the Treating to New Targets …
  953. Effect of lowering serum cholesterol on the composition of surfactant in adult rat lung
  954. Effect of mushrooms on cholesterol metabolism in rats. 4. Separation of the plasma cholesterol reducing substances from mushroom. 2.
  955. Effect of mushrooms on cholesterol metabolism in rats. 5. Separation of the plasma cholesterol-reducing substances from mushroom.
  956. Effect of nonpharmacologic intervention on lowering plasma cholesterol levels
  957. Effect of oat and tartary buckwheat–based food on cholesterollowering and gut microbiota in hypercholesterolemic hamsters
  958. Effect of perilla oil on reducing triglyceride and cholesterol level in serum of hyperlipidemia model rats
  959. Effect of pharmacist interventions on reducing low-density lipoprotein cholesterol (LDL-C) levels: A systematic review and meta-analysis
  960. Effect of pharmacologic lipid lowering on health‐related quality of life in older persons: results from the cholesterol Reduction in Seniors Program (CRISP) Pilot Study
  961. Effect of phytosterols on reducing low-density lipoprotein cholesterol in dogs
  962. Effect of plant sterols in combination with other cholesterollowering foods
  963. Effect Of Pomegranate (Punica granatum L.) Fraction In Reducing Total Blood cholesterol Levels and Triglyceride in Mice (Mus muscullus L.)
  964. Effect of prebiotics on bacteriocin production and cholesterol lowering activity of Pediococcus acidilactici LAB 5
  965. Effect of soluble dietary fiber from rice bran on reducing cholesterol content and rheological property of mayonnaise
  966. Effect of supplementary antioxidant vitamin intake on carotid arterial wall intima-media thickness in a controlled clinical trial of cholesterol lowering
  967. Effect of time of administration on cholesterollowering by psyllium: a randomized cross-over study in normocholesterolemic or slightly hypercholesterolemic …
  968. Effect of β-glucan molecular weight and viscosity on the mechanism of cholesterol lowering in humans
  969. Effect on hematologic risk factors for coronary heart disease of a cholesterol reducing diet
  970. Effect on non-vascular outcomes of lowering LDL cholesterol in patients with chronic kidney disease: results from the Study of Heart and Renal Protection
  971. Effective in vivo cholesterol and triglycerides lowering activities of hydroethanolic extract of Launaea taraxacifolia leaves
  972. Effective lowering of cholesterol With Portfolio diet in a Highly Trained Young Man
  973. Effective lowering of plasma, LDL, and esterified cholesterol in LDL receptor–knockout mice by adenovirus-mediated gene delivery of apoB mRNA editing enzyme …
  974. Effectiveness of a low saturated fat, low cholesterol, weight-reducing diet for the control of hypertriglycer-idemia
  975. Effectiveness of a nutritional education program in lowering blood cholesterol levels in a public health center
  976. Effectiveness of adherence to lipid lowering therapy on LDL-cholesterol in patients with very high cardiovascular risk: a real-world evidence study in primary care
  977. Effectiveness of an alimentary educational program in lowering children’s cholesterol levels in primary school
  978. Effectiveness of atorvastatin for reducing low-density lipoprotein cholesterol to National cholesterol Education Program treatment goals.
  979. Effectiveness of Boiled Water of Breadfruit Leaf (Artocarpus Altilis) on Reducing cholesterol Levels in The Blood of Mice (Mus Musculus)
  980. Effectiveness of chitosan as a dietary supplement in lowering cholesterol in murine models: A meta-analysis
  981. EFFECTIVENESS OF cholesterol FEEDBACK IN REDUCING BLOOD cholesterol LEVELS
  982. Effectiveness of customary use of phytosterol/-stanol enriched margarines on blood cholesterol lowering
  983. Effectiveness of dietetic counselling in lowering plasma cholesterol of children affected by hypercholesterolemia
  984. Effectiveness of low-dose lovastatin in lowering serum cholesterol: Experience with 56 patients
  985. Effectiveness of probucol in reducing plasma low-density lipoprotein cholesterol oxidation in hypercholesterolemia
  986. Effectiveness of rosuvastatin versus atorvastatin in reducing lipid levels and achieving low-density-lipoprotein cholesterol goals in a usual care setting
  987. Effects of a dietary portfolio of cholesterollowering foods vs lovastatin on serum lipids and C-reactive protein
  988. Effects of a high cholesterol-reducing Lactobacillus acidophilus strain and Staphyloccus xylose on the physico-chemical quality and harmful biogenic amines of …
  989. Effects of aggressive cholesterol lowering and low-dose anticoagulation on clinical and angiographic outcomes in patients with diabetes: the Post Coronary Artery …
  990. Effects of anti-oxidative and cholesterol lowering capacities of selected edible-medicinal mushrooms towards amelioration of alzheimer’s disease/Mohammad Azizur …
  991. Effects of antrodia camphorata mycelia extract containing antroquinonol on lowering low-density lipoprotein cholesterol: a randomized double-blind study
  992. Effects of cholesterol lowering on the progression of coronary atherosclerosis in women: a Canadian Coronary Atherosclerosis Intervention Trial (CCAIT) Substudy
  993. Effects of cholesterollowering diets on the risk for cancer and other non-cardiovascular diseases.
  994. Effects of cholesterollowering probiotics on the metabolism of bile acid in a rat model of non-alcoholic fatty liver disease and the possible mechanism
  995. Effects of cholesterollowering treatments on oxidative modification of plasma intermediate density lipoprotein plus low density lipoprotein fraction in type 2 …
  996. Effects of cholesterollowering treatments on oxidative modification of plasma intermediate density lipoprotein plus low density lipoprotein fraction in Type 2 diabetic …
  997. Effects of cholesterollowering with simvastatin on stroke and other major vascular events in 20 536 people with cerebrovascular disease or other high-risk conditions
  998. Effects of diacylglycerol containing phytosterol on reducing blood cholesterol level
  999. Effects of different intensive lipid-lowering regimens on cholesterol metabolism makers and their ratios in patients after percutaneous coronary intervention [J]
  1000. Effects of feeding cholesterol raising and cholesterol lowering diets on albino rats.
  1001. Effects of Fiber Consumption in lowering cholesterol Level
  1002. Effects of gender, apolipoprotein E phenotype and cholesterollowering by plant stanol esters in children: The STRIP study
  1003. Effects of including soy protein in a blood cholesterollowering diet on markers of cardiac risk in men and in postmenopausal women with and without hormone …
  1004. Effects of internet-based tailored advice on the use of cholesterollowering interventions: a randomized controlled trial
  1005. Effects of lactic acid bacteria isolated from fermented mustard on lowering cholesterol
  1006. Effects of Lactobacillus paragasseri Y20 on cholesterollowering, intestinal microbiota and liver metabolism in rats with hypercholesterolaemia
  1007. Effects of long term cholesterol lowering on coronary atherosclerosis in patient risk factor subgroups: the Simvastatin/enalapril Coronary Atherosclerosis Trial (SCAT).
  1008. Effects of Lovastatin on progression of coronary artery disease and restenosis after PTCA: The cholesterol lowering atherosclerosis PTCA trial (CLAPT)
  1009. Effects of lowering average or below-average cholesterol
  1010. Effects of lowering average or below-average cholesterol levels on the progression of carotid atherosclerosis: results of the LIPID atherosclerosis substudy
  1011. Effects of lowering elevated LDL cholesterol on the cardiovascular risk of lipoprotein (a)
  1012. Effects of lowering LDL cholesterol on progression of kidney disease
  1013. Effects of natural antioxidants in reducing lipid and cholesterol oxidation in irradiated chicken breast meat.
  1014. Effects of plant sterols and stanols beyond low-density lipoprotein cholesterol lowering
  1015. Effects of prebiotic carbohydrates on the growth promotion and cholesterollowering abilities of compound probiotics in vitro
  1016. Effects of prospective, randomized cholesterollowering dietary intervention and apolipoprotein E phenotype on serum lipoprotein (a) concentrations of infants aged 7 …
  1017. Effects of simvastatin and ezetimibe in lowering low-density lipoprotein cholesterol in subjects with type 1 and type 2 diabetes mellitus
  1018. Effects of soybean-germ oil on reducing serum cholesterol level
  1019. Effects of soybean-germ oil on reducing serum cholesterol levels in a double-blind controlled trial in healthy humans
  1020. Effects of the cholesterollowering compound methyl‐β‐cyclodextrin in models of α‐synucleinopathy
  1021. Effects of Therapeutic lowering of Non-High Density Lipoprotein cholesterol on Cardiovascular Outcomes Among Women versus Men: A Meta-Regression Analysis
  1022. Effects on 11-year mortality and morbidity of lowering LDL cholesterol with simvastatin for about 5 years in 20 536 high-risk individuals: a randomised …
  1023. Efficacy and safety of cholesterollowering treatment
  1024. Efficacy and safety of different doses of alirocumab in reducing low-density lipoprotein cholesterol levels: a network meta-analysis
  1025. Efficacy and safety of different doses of evolocumab in reducing low-density lipoprotein cholesterol levels: A meta-analysis
  1026. Efficacy and safety of ETC-1002, a novel investigational low-density lipoprotein-cholesterollowering therapy for the treatment of patients with hypercholesterolemia …
  1027. Efficacy and Safety of Evolocumab in Reducing Low-Density Lipoprotein cholesterol Levels in Chinese Patients with Non-ST-segment Elevation Acute Coronary …
  1028. Efficacy and safety of further lowering of low-density lipoprotein cholesterol in patients starting with very low levels: a meta-analysis
  1029. Efficacy and safety of lowering dietary intake of fat and cholesterol in children with elevated low-density lipoprotein cholesterol: the dietary Intervention Study in …
  1030. Efficacy and safety of lowering dietary intake of fat and cholesterol in children with elevated low-density lipoprotein cholesterol: The dietary Intervention Study in …
  1031. Efficacy and safety of lowering dietary intake of total fat, saturated fat, and cholesterol in children with elevated LDL cholesterol: the dietary Intervention Study in …
  1032. Efficacy and safety of lowering LDL cholesterol in older patients: a systematic review and meta-analysis of randomised controlled trials
  1033. Efficacy and safety of more intensive lowering of LDL cholesterol
  1034. Efficacy and safety of more intensive lowering of LDL cholesterol–Authors’ reply
  1035. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170 000 participants in 26 randomised trials
  1036. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials.
  1037. Efficacy and safety of rosuvastatin vs. atorvastatin in lowering LDL cholesterol
  1038. Efficacy of chenodeoxycholic acid and ursodeoxycholic acid for lowering cholesterol saturation index of gallbladder in patients with a sphincterotomy
  1039. Efficacy of cholesterollowering treatment in Japanese elderly patients with coronary artery disease and normal cholesterol level using 3-hydroxy-3-methylglutaryl …
  1040. Efficacy of combination of ezetimibe and simvastatin versus atorvastatin in reducing low density lipoprotein-cholesterol in male patients of hypercholesterolemia, at …
  1041. Efficacy of ezetimibe for reducing serum low‐density lipoprotein cholesterol levels resistant to lifestyle intervention in patients with non‐alcoholic fatty liver disease
  1042. Efficacy of garlic supplementation in lowering serum cholesterol levels
  1043. Efficacy of Individualized dietary Advice for lowering cholesterol
  1044. Efficacy of Individualized dietary Advice for lowering cholesterol-Reply
  1045. Efficacy of low-dose simvastatin in cholesterollowering treatment in elderly
  1046. Efficacy of lowering Low-density Lipoprotein cholesterol in Elderly Subjects: A Systematic Review and Meta-analysis of Randomized Controlled Trials
  1047. Efficacy of moderate-intensity physical activity in lowering non-high-density lipoprotein cholesterol in stage 2 essential hypertensive patients
  1048. Efficacy of Myrmecodia Platytyrae (MyP) Water Extract in Reducing cholesterol Level in Hypercholesterolemia Induced Sprague Dawley Rat
  1049. Efficacy of Psyllium in Reducing Serum cholesterol Levels in Hypercholesterolemic Patients on High or Low-Fat diets
  1050. Efficacy of psyllium in reducing serum cholesterol levels in hypercholesterolemic patients on high-or low-fat diets
  1051. Efficacy of simvastatin for lowering cholesterol in non-insulin dependent diabetic patients with hypercholesterolemia
  1052. Efficacy of yogurt drink with added plant stanol esters (Benecol®, Colanta) in reducing total and LDL cholesterol in subjects with moderate …
  1053. EGCG reducing the susceptibility to cholesterol gallstone formation through the regulation of inflammation
  1054. Egg yolk cholesterol lowering effects of garlic and tea
  1055. Egg yolk cholesterol lowering effects of garlic and tea
  1056. Eicosapentaenoic acid membrane incorporation impairs cholesterol efflux from cholesterol-loaded human macrophages by reducing the cholesteryl ester mobilization …
  1057. Eicosapentaenoic acid reduced the progression of the coronary atherosclerosis in the patients with optimal LDL cholesterol lowering therapy
  1058. Elevated cholesterol Inhibits The Surface Tension Reducing Activity Of Human Pulmonary Surfactant
  1059. Emerging lipid lowering agents targeting LDL cholesterol
  1060. Encapsulation of Lactic Acid Bacteria Isolated from Tapai and the Effects on cholesterol lowering Ability and Survivability in Simulated Gastric Conditions
  1061. Enhanced cholesterol‐and triglyceride‐lowering effect of West African green tea
  1062. Enhanced low density lipoprotein-cholesterol lowering efforts by consuming plant stanols as part of a low saturated fat diet
  1063. Enhanced plasma cholesterol lowering effect of retrovirus-mediated LDL receptor gene transfer to WHHL rabbit liver after improved surgical technique and …
  1064. Enhancement of antioxidant activity in O/W emulsion and cholesterol-reducing capacity of epigallocatechin by derivatization with representative phytosterols
  1065. Enhancement of Galloylation efficacy of Stigmasterol and β-Sitosterol followed by evaluation of cholesterol-reducing activity
  1066. Enoyl-ACP reductase gene mRNA expression analysis in different cholesterollowering ability of Lactobacillus plantarum
  1067. Enrichment of vitamin B12 and B6 and lowering cholesterol levels of eggs by lactic acid bacteria
  1068. Environmental estrogens: effects on cholesterol lowering and bone in the ovariectomized rat
  1069. EPA and DHA Have Differential Effects on cholesterol Ester Transfer Protein and Lipoprotein Lipase Activities Following Plasma Triglycerides lowering
  1070. Escape phenomenon occurs by lowering cholesterol with a hydroxymethylglutaryl coenzyme A (HMG-CoA) reductase inhibitor in patients with familial …
  1071. Estimating the benefits of cholesterol lowering: are risk factors for coronary heart disease multiplicative?
  1072. Estimation of cholesterol by the Liebennann Burchaid reaction. Significance of the lowering of the ratio of ester to total cholesterol in some pathological bloods.
  1073. Estrogen decreases atherosclerosis in part by reducing hepatic acyl-CoA: cholesterol acyltransferase 2 (ACAT2) in monkeys
  1074. Ethanolamine plasmalogens prevent the oxidation of cholesterol by reducing the oxidizability of cholesterol in phospholipid bilayers
  1075. Ethyl acetate extract of crabapple fruit is the cholesterollowering fraction
  1076. Eulipidemic effects of berberine administered alone or in combination with other natural cholesterollowering agents
  1077. Evaluating the efficacy of the National cholesterol Education Program adult treatment guidelines: cholesterol lowering intervention program
  1078. Evaluating the safety of Liptruzet (ezetimibe and atorvastatin): what are the potential benefits beyond low-density lipoprotein cholesterollowering effect?
  1079. Evaluation and Application of Different cholesterollowering Lactic Acid Bacteria as Potential Meat Starters
  1080. Evaluation and application of different cholesterollowering lactic acid bacteria as potential meat starters
  1081. Evaluation of bile salt hydrolases, cholesterollowering capabilities, and probiotic potential of Enterococcus faecium isolated from rhizosphere
  1082. Evaluation of Brewer’s spent grain as a plasma lipid lowering agent in rats fed cholesterol enriched diets
  1083. Evaluation of cholesterol lowering property and antibacterial activity of two potential lactic acid bacteria isolated from the intestine of snakehead fish (Channa …
  1084. Evaluation of cholesterol lowering property of selected herbs in ghee (heat clarified milk fat)
  1085. Evaluation of cholesterol lowering treatment of patients with familial hypercholesterolemia: a large cross-sectional study in The Netherlands
  1086. Evaluation of cholesterollowering activity of a galenic, comparable to a dietary supplement, containing monacolin k and policosanol in subjects with mild to moderate …
  1087. Evaluation of cholesterollowering activity of standardized extract of Mangifera indica in albino Wistar rats
  1088. Evaluation of hesperetin 7-O-lauryl ether as lipid-lowering agent in high-cholesterol-fed rats
  1089. Evaluation of lipid and cholesterollowering effect of bioflavonoids from bergamot extract
  1090. Evaluation of Lipid-lowering Therapy and cholesterol Goal Attainment in Finland
  1091. Evaluation of proprotein convertase Subtilisin/Kexin Type 9: focus on potential clinical and therapeutic implications for low‐density lipoprotein cholesterol lowering
  1092. Evaluation of the cholesterollowering effectiveness of pantethine in women in perimenopausal age
  1093. Evaluation of the clinical efficacy and potential mechanism of the cholesterol lowering effect of soy protein
  1094. Evaluation of the in vitro cholesterollowering activity of the probiotic strain Bacillus coagulansMTCC 5856
  1095. Evaluation of the shortened cholesterollowering diet self-efficacy scale
  1096. Evidence for a cholesterollowering gene in a French-Canadian kindred with familial hypercholesterolemia
  1097. Evidence for cholesterollowering activity by Bifidobacterium bifidum PRL2010 through gut microbiota modulation
  1098. Evidence for feedback regulation following cholesterol lowering therapy in a prostate cancer xenograft model
  1099. Evidence for more intensive cholesterol lowering
  1100. Evidence supporting cholesterollowering therapy for postmenopausal women with heart disease-Reply
  1101. Evolocumab (Repatha®): a human monoclonal antibody against PCSK9 protein as potent cholesterollowering therapy
  1102. Evolocumab: Second-in-class agent for lowering cholesterol
  1103. EVOLVD: cholesterol lowering with EVOLocumab to prevent cardiac allograft vasculopathy in de-novo heart transplant recipients: rationale and design of a …
  1104. Experimental Study of Enhanced External Counterpulsation (EECP) on Reducing Atherosclerostic Vascular Disease in High cholesterol-Fed Pigs
  1105. Expert perspective: reducing cardiovascular risk in metabolic syndrome and type 2 diabetes mellitus beyond low-density lipoprotein cholesterol lowering
  1106. Exploration of dual-function evaluation model of health food for auxiliary glycemia-lowering and auxiliary cholesterollowering.
  1107. Extent of undertreatment and overtreatment with cholesterollowering therapy according to European guidelines in 92,348 Danes without ischemic cardiovascular …
  1108. Extraction process and cholesterollowering property of dietary fiber from cassava pulp
  1109. Extrusion and boiling improve rat body weight gain and plasma cholesterol lowering ability of peas and chickpeas
  1110. Ezetimibe and plaque regression: cholesterol lowering or pleiotropic effects?
  1111. Ezetimibe in diabetes: more than cholesterol lowering?
  1112. Ezetimibe monotherapy for cholesterol lowering in 2,722 people: systematic review and meta‐analysis of randomized controlled trials
  1113. Ezetimibe: a novel cholesterollowering agent that highlights novel physiologic pathways
  1114. Ezetimibe: a novel option for lowering cholesterol
  1115. Ezetimibe: cholesterol lowering and beyond
  1116. Facing the challenge of lowering blood pressure and cholesterol in the same patient: report of a Symposium at the European Society of Hypertension
  1117. Factor VII coagulant activity and cholesterol changes in premenopausal women consuming a long-term cholesterollowering diet.
  1118. Factor VIIc (FVII) response to cholesterollowering diets covaries with changes in total cholesterol (TC) and triglycerides (TG)
  1119. Failure of cholesterollowering by psyllium
  1120. Family cooperation and effectiveness in a cholesterollowering diet.
  1121. Family diet pattern for lowering the serum cholesterol level
  1122. Fargesin alleviates atherosclerosis by promoting reverse cholesterol transport and reducing inflammatory response
  1123. Fat type in phytosterol products influence their cholesterollowering potential: A systematic review and meta-analysis of RCTs
  1124. Fats for the food industry: implications for cholesterollowering
  1125. Fatty acid composition of cholesteryl esters in cholesterol-fed rabbits treated with lipid-lowering agent (ethyl 2-(p-chlorophenoxy) isobutyrate)
  1126. FATTY ACID COMPOSITION OF CHOLESTERYL ESTERS IN cholesterol-FED RABBITS TREATED WITHLIPID-lowering AGENT (ETHYL 2-(p …
  1127. Fatty acid modification of yolk lipids and cholesterollowering eggs.
  1128. Fatty acid moieties have little effect on cholesterollowering potency of plant sterol esters
  1129. Fenofibrate increases HDL-cholesterol by reducing cholesteryl ester transfer protein expression
  1130. FENOFIBRATE INCREASES HDL-cholesterol BY REDUCING CHOLESTERYL ESTER TRANSFER PROTEIN EXPRESSION
  1131. Fenofibrate reduces atherogenesis in ApoE* 3Leiden mice: evidence for multiple antiatherogenic effects besides lowering plasma cholesterol
  1132. Fermentable carbohydrates exert a more potent cholesterollowering effect than cholestyramine
  1133. Fermentation of resistant rice starch produces propionate reducing serum and hepatic cholesterol in rats
  1134. Fluvastatin reduces tissue factor expression and macrophage accumulation in carotid lesions of cholesterol-fed rabbits in the absence of lipid lowering
  1135. Follow-up study of patients randomized in the Scandinavian simvastatin survival study (4S) of cholesterol lowering
  1136. Food combinations for cholesterol lowering
  1137. Food processing reduces size of soluble cereal β-glucan polymers without loss of cholesterol-reducing properties
  1138. Formal preparation of semisynthetic analogues of the cholesterollowering agent mevinolin
  1139. Formulation and Evaluation of Lactic Acid Bacteria Fermented Brassica juncea (Mustard Greens) Pickle with cholesterol lowering Property
  1140. Frequency of citation and outcome of cholesterol lowering trials: Author’s reply
  1141. Frequency of citation and outcome of cholesterol lowering trials.
  1142. Frequency of citation and outcome of cholesterol lowering trials.
  1143. Frequency of citation and outcome of cholesterol lowering trials.
  1144. Frequent cholesterol feedback as an aid in lowering cholesterol levels
  1145. FRI0528 HIGH INTENSIVE THERAPEUTIC lowering OF SYSTEMIC cholesterol DOES NOT AMELIORATE OA DEVELOPMENT IN KNEE JOINTS OF …
  1146. Functional food, uncertainty and consumers’ choices: A lab experiment with enriched yoghurts for lowering cholesterol
  1147. Functional foods to increase the efficacy of diet in lowering serum cholesterol
  1148. Functional foods: cholesterollowering benefits of plant sterols
  1149. Functional foods: cholesterollowering benefits of plant sterols
  1150. Functional Foods: cholesterollowering benefits of plant sterols—reply by Thurnham
  1151. Functional probiotic assessment and in vivo cholesterollowering efficacy of Weissella sp. associated with arid lands living-hosts
  1152. Functional Probiotic Characterization and In Vivo cholesterollowering Activity of Lactobacillus helveticus Isolated from Fermented Cow Milk S
  1153. Functions and Fermentation Characteristics of High cholesterol-Reducing Lactic Acid Bacteria
  1154. Further LDL cholesterol lowering through targeting PCSK9 for coronary artery disease
  1155. Further studies on the cholesterollowering effect of apple in human. Biochemical mechanims involved
  1156. Future approaches to reducing low-density lipoprotein cholesterol
  1157. Garlic powder as blood serum and egg yolk cholesterol lowering agent
  1158. GCG‐rich tea catechins are effective in lowering cholesterol and triglyceride concentrations in hyperlipidemic rats
  1159. Gemfibrozil—the effect on biliary cholesterol saturation of a new lipid-lowering agent and its comparison with clofibrate
  1160. Genetic variation at the SLCO1B1 gene locus and low density lipoprotein cholesterol lowering response to pravastatin in the elderly
  1161. Genetic variation of pln loci among probiotic Lactobacillus plantarum group strains with antioxidant and cholesterollowering ability
  1162. Genetically-enhanced LPL mediated lipolysis, LDL cholesterol lowering alleles and risk of coronary disease and type 2 diabetes
  1163. Genetically-predicted life-long lowering of low-density lipoprotein cholesterol is associated with decreased frailty: A Mendelian randomization study in UK …
  1164. Genome Shuffling of Mangrove Endophytic Aspergillus luchuensis MERV10 for Improving the cholesterollowering Agent Lovastatin under Solid State Fermentation
  1165. Getting the Message to Physicians about the Effectiveness of Registered dietitians in lowering Blood cholesterol Levels
  1166. Ginkgo biloba extract (Egb 761) inhibits β-amyloid production by lowering free cholesterol levels
  1167. Give diet a chance in lowering cholesterol levels
  1168. Given that lowering raised cholesterol concentrations isa good thing for middle aged people with coronary heart disease, what is the upper age limit for such an …
  1169. Glucose and Low-Density Lipoprotein cholesterol lowering in Elderly Patients with Type 2 Diabetes
  1170. Goals for cholesterol lowering
  1171. Greater Dissociation of Apolipoprotein B and LDL cholesterol Targets in Diabetes Versus Nondiabetes Patients Receiving Lipid-lowering Therapy
  1172. Growth of cholesterol-reducing Eubacterium on cholesterol-brain agar.
  1173. Growth-depressing and cholesterollowering effects of Quillaja and tea saponins in chicks as influenced by diet composition
  1174. Guest Editorial: Blood cholesterol lowering in Elderly Patients
  1175. GUGULIPID: A Natural cholesterollowering Agent
  1176. GW24-e1865 Association between cholesterol synthesis/absorption markers and effects of cholesterol lowering by atorvastatin among patients with high risk of …
  1177. GW24-e2397 Rosuvastatin could modulate insulin signalling and inhibit atherosclerosis beyond its plasma cholesterollowering effect in insulin-resistant mice
  1178. Hazards of reducing cholesterol.
  1179. Health Canada’s proposal to accept a health claim about soy products and cholesterol lowering
  1180. HEALTH-ECONOMIC BENEFITS OF LOW-DENSITY LIPOPROTEIN cholesterol lowering IN HIGH RISK PATIENTS: A DISCRETE-EVENT SIMULATION …
  1181. Healthy drinks made from okra and green tea extract for reducing blood cholesterol
  1182. Heat Shock Protein 27 Immune Complex Upregulates LDLR Expression Thereby Reducing Plasma cholesterol and Atherogenesis
  1183. Heat Shock Protein 27 versus Estrogen Therapy for Post-Menopausal Atherosclerosis: Rethinking Mechanisms of cholesterol lowering
  1184. Heat-epimerized tea catechins have the same cholesterollowering activity as green tea catechins in cholesterol-fed rats
  1185. Hepatic expression of apolipoprotein E inhibits progression of atherosclerosis without reducing cholesterol levels in LDL receptor-deficient mice
  1186. Hepatic lipidomics analysis reveals the antiobesity and cholesterollowering effects of tangeretin in high-fat diet-fed rats
  1187. Heterogeneous pools of cholesterol side-chain cleavage activity in adrenal mitochondria from ACTH-treated rats: differential responses to different reducing …
  1188. High dietary intake of phytosterol esters decreases carotenoids and increases plasma plant sterol levels with no additional cholesterol lowering
  1189. High Performance Liquid Chromatography–An Effective Tool for Quality Control of Natural cholesterollowering Agents
  1190. High Performance thin layer chromatographic quantification of key cholesterol reducing compound (− sitosterol) from leaf, bark, fruit and root of Terminalia arjuna, T …
  1191. High Serum Total cholesterol: An Indicator for Monitoring cholesterol lowering Efforts: US Adults, 2005-2006
  1192. High-intensive therapeutic lowering of systemic cholesterol does not ameliorate osteoarthritis development in knee joints of humanized dyslipidemic mice
  1193. High-molecular-weight hydroxypropylmethylcellulose: a cholesterollowering agent
  1194. High‐risk patients benefit from lowering of LDL‐cholesterol
  1195. Higher Non-High Density Lipoprotein cholesterol Thresholds Are More Predictive of Need for Lipid-lowering Pharmacotherapy in Children
  1196. Hippocampal volume change in the Alzheimer disease cholesterollowering Treatment trial.
  1197. Histamine and cholesterol lowering abilities of lactic acid bacteria isolated from artisanal Pico cheese
  1198. History and development of plant sterol and stanol esters for cholesterollowering purposes
  1199. HMG CoA reductase inhibitors lower LDL cholesterol without reducing Lp (a) levels.
  1200. HMG-CoA reductase inhibitor augments the serum total cholesterollowering effect of human adipose tissue-derived multilineage progenitor cells in hyperlipidemic …
  1201. HMG-CoA reductase inhibitor, fluvastatin, has cholesterollowering independent “direct” effects on atherosclerotic vessels in high cholesterol diet-fed rabbits
  1202. HMG-CoA Reductase inhibitory activity of Gnetum gnemon seed extract and identification of potential inhibitors for lowering cholesterol level
  1203. HOE 402 lowers serum cholesterol levels by reducing VLDL-lipid production, and not by induction of the LDL receptor, and reduces atherosclerosis in wild-type and …
  1204. How does fenofibrate exert its cholesterollowering effect?(author’s transl)
  1205. How is cholesterol lowering therapy implemented among patients with coronary heart disease in Iceland?
  1206. How much in vitro cholesterol reducing activity of Lactobacilli predicts their in vivo cholesterol function?
  1207. How much information do patients prefer when discussing cholesterol lowering medications? Results from an internet based nationally representative survey
  1208. HSP27 immunization attenuates atherogenesis by markedly reducing plasma PCSK9 and cholesterol levels
  1209. Hydrogenated fats’ role in cholesterollowering diets.
  1210. Hydrolysis of phytosterol esters in the intestine is required for their cholesterol lowering effects
  1211. Hydrophobically modified celluloses as novel cholesterollowering polymers
  1212. HYDROPHOBICALLY MODIFIED CHITOSAN AS BIO-BASED MATERIAL FOR lowering cholesterol LEVEL
  1213. Hydrophobically modified poly (Allylamine) hydrogels containing internal quaternary ammonium groups as cholesterol lowering agents: synthesis, characterization …
  1214. Hydroxychloroquine reduces low-density lipoprotein cholesterol levels in systemic lupus erythematosus: a longitudinal evaluation of the lipid-lowering effect
  1215. Hypercholesterolaemia of prolonged fasting and cholesterol lowering of re-feeding in lean human subjects
  1216. Hypocholesterolemic Action of Fermented Brown Rice Supplement in cholesterol‐Fed Rats: cholesterollowering Action of Fermented Brown Rice
  1217. Identical LDL-cholesterol lowering but non-identical effects on NF-κB activity: High dose simvastatin vs combination therapy with ezetimibe
  1218. Identification of a cholesterol reducing lactic acid bacteria and its tolerance in in vitro gastroenteric environment [J]
  1219. Identification of a novel cholesterollowering dipeptide, phenylalanine-proline (FP), and its down-regulation of intestinal ABCA1 in hypercholesterolemic rats …
  1220. Identification of gallbladder mucin-bilirubin complex in human cholesterol gallstone matrix. Effects of reducing agents on in vitro dissolution of matrix and intact …
  1221. Identification of Lactobacillus strains from breast-fed infant and investigation of their cholesterol-reducing effects
  1222. identification of lunasin as the active component in soy protein responsible for reducing LDL cholesterol and risk of cardiovascular disease
  1223. Identification of two herbal compounds with potential cholesterollowering activity
  1224. Identification, Physico-chemical Characteristics of Strain Gan-1 and its Effect of cholesterol Reducing in Vitro
  1225. Identifying patients for aggressive cholesterol lowering: the risk curve concept
  1226. Ileorectostomy or cecectomy but not colectomy abolishes the plasma cholesterollowering effect of dietary beet fiber in rats
  1227. Impact of blood pressure lowering, cholesterol lowering and their combination in Asians and non-Asians in those without cardiovascular disease: an analysis of the …
  1228. Impact of cholesterol lowering treatment on plasma kynurenine and tryptophan concentrations in chronic kidney disease: relationship with oxidative stress …
  1229. Impact of cholesterollowering educational program on total blood cholesterol levels of fifth-grade children.
  1230. Impact of computer-generated personalized goals on cholesterol lowering
  1231. Impact of enhanced compliance initiatives on the efficacy of rosuvastatin in reducing low density lipoprotein cholesterol levels in patients with primary …
  1232. Impact of enhanced compliance initiatives on the efficacy of rosuvastatin in reducing low density lipoprotein cholesterol levels in patients with primary …
  1233. Impact of fermented milk on human health: cholesterollowering and immunomodulatory properties of fermented milk
  1234. Impact of intensive LDL cholesterol lowering on coronary artery atherosclerosis progression: a serial CT angiography study
  1235. Impact of Lipid Monitoring on Treatment Intensification of cholesterol lowering Therapies (from the Veterans Affairs Healthcare System)
  1236. Impact of lipid-lowering therapy on mortality according to the baseline non-HDL cholesterol level: a meta-analysis
  1237. Impact of lowering Low-Density Lipoprotein cholesterol with Contemporary Lipid-lowering Medicines on Cognitive Function: A Systematic Review and Meta …
  1238. Impact of nutritional counseling in reducing serum cholesterol in public health service patients
  1239. Impact of Residual Risks After Achievement of Appropriate Low-Density Lipoprotein cholesterol lowering Management in Secondary Prevention of Japanese …
  1240. Impact of the 2013 cholesterol guideline on patterns of lipid-lowering treatment in patients with atherosclerotic cardiovascular disease or diabetes after 1 year
  1241. Impact of the pattern of basal cholesterol synthesis and absorption on the LDL cholesterol lowering efficacy of atorvastatin in Chinese population
  1242. Implementation of blood cholesterollowering diets using nutrition labels
  1243. Implementation of cholesterollowering Therapy to Reduce Cardiovascular Risk in Persons Living with HIV
  1244. Implementing phytosterols into medical practice as a cholesterollowering strategy: overview of efficacy, effectiveness, and safety
  1245. Implications of the obesity epidemic for lipid-lowering therapy: non-HDL cholesterol should replace LDL cholesterol as the primary therapeutic target
  1246. Improved neurocognitive functions correlate with reduced inflammatory burden in atrial fibrillation patients treated with intensive cholesterol lowering therapy
  1247. Improvement in coronary flow reserve determined by positron emission tomography after 6 months of cholesterollowering therapy in patients with early stages of …
  1248. Improvement in erectile function in a rat model of high cholesterol diet‐induced atherosclerosis by atorvastatin in a manner that is independent of its lipid‐lowering
  1249. Improvement of atherosclerosis and stiffness of the thoracic descending aorta with cholesterollowering therapies in familial hypercholesterolemia
  1250. Improvement of coronary prognosis by reducing LDL-cholesterol
  1251. Improvement of erythrocyte deformability by cholesterollowering therapy with pravastatin in hypercholesterolemic patients
  1252. Improvement to the surface tension reducing capability of human pulmonary surfactant with elevated levels of cholesterol via addition of surfactant protein A
  1253. Improvements in hostility and depression in relation to dietary change and cholesterol lowering: the Family Heart Study
  1254. Improving adherence to a cholesterollowering diet: a behavioral intervention study
  1255. Improving adherence to cholesterol lowering medications among minority populations in Florida: a randomized trial
  1256. In cholesterol lowering, moderation kills
  1257. In Silico and Wet Lab Studies Reveal the cholesterol lowering 5 Efficacy of Lauric Acid a Medium Chain Fat of Coconut Oil
  1258. In silico and wet lab studies reveal the cholesterol lowering efficacy of lauric acid, a medium chain fat of coconut oil
  1259. In vestigating the lowest t hreshold of vascular b en efits from LDL cholesterol lowering with a PC S K9 mAb i nhibi t or (alirocumab) in health y volunteers–a …
  1260. In vitro activity of fluvastatin, a cholesterollowering agent, and synergy with flucanazole and itraconazole against Candida species and Cryptococcus neoformans.
  1261. In vitro and in vivo cholesterol lowering ability of Lactobacillus pentosus KF923750
  1262. In vitro assessment of pediococci-and lactobacilli-induced cholesterollowering effect using digitally enhanced high-performance thin-layer chromatography and …
  1263. In vitro characterization of lactic acid bacteria from Indonesian kefir grains as probiotics with cholesterollowering effect
  1264. In vitro cholesterollowering activity of Lactobacillus plantarum and Lactobacillus paracasei strains isolated from the Italian Castelmagno PDO cheese
  1265. In Vitro cholesterollowering Mechanisms of Selected Lactobacillus and Bifidobacterium Species and Effects of Physical Treatment
  1266. In vitro cholesterollowering properties of Lactobacillus plantarum AN6 isolated from aji‐narezushi
  1267. In vitro evaluation of the cholesterol-reducing ability of a potential probiotic Bacillus spp
  1268. In vitro hypoglycemic and cholesterol lowering effects of dietary fiber prepared from cocoa (Theobroma cacao L.) shells
  1269. In vitro hypoglycemic, cholesterollowering and fermentation capacities of fiber-rich orange pomace as affected by extrusion
  1270. In vitro screening of lactic acid bacteria for cholesterollowering activity and the underlying mechanism.
  1271. In vitro study of bile salt hydrolase (BSH) activity of BSH isogenic Lactobacillus plantarum 80 strains and estimation of cholesterol lowering through enhanced BSH …
  1272. In vivo antioxidant, organ protective, ameliorative and cholesterol lowering potential of ethanolic and methanolic extracts of “Ata-Ofa” polyherbal tea (A …
  1273. In vivo safety assessment of Lactobacillus fermentum strains, evaluation of their cholesterollowering ability and intestinal microbial modulation
  1274. In with the Good and out with the Bad: The Role of SR-BI in lowering Blood cholesterol Levels
  1275. Incorporation of Almonds in a cholesterollowering diet Improves non‐ABCA1‐mediated cholesterol Efflux in Normal Weight Adults
  1276. Increased ether lipid cytotoxicity by reducing membrane cholesterol content
  1277. Increased prevalence of cholelithiasis in men ingesting a serum-cholesterollowering diet
  1278. Increasing physician involvement in cholesterollowering practices: the role of knowledge, attitudes and perceptions
  1279. Increasing physician involvement in cholesterollowering practices
  1280. Increasing plasma fibrinogen, but unchanged levels of intraplatelet cyclic nucleotides, plasma endothelin-1, factor VII, and neopterin during cholesterol lowering with …
  1281. Increasing serum half-life and extending cholesterol lowering in vivo by engineering antibody with pH-sensitive binding to PCSK9
  1282. INCREASING STORAGE CAPABILITY AND cholesterol REDUCING IN FERMENTED CAMEL MEAT BY LACTOBACILLUS CASEI
  1283. Indications for lowering LDL cholesterol in rheumatoid arthritis: an unrecognized problem.
  1284. Individual responses to a cholesterollowering diet in 50 men with moderate hypercholesterolemia
  1285. Individual responsiveness to a cholesterollowering diet in postmenopausal women with moderate hypercholesterolemia
  1286. Individual Responsiveness to a cholesterollowering diet in Postmenopausal Women with Moderate Hypercholesterolemia.
  1287. Influence of a cholesterollowering strain Lactobacillus plantarum LP3 isolated from traditional fermented yak milk on gut bacterial microbiota and metabolome of rats …
  1288. Influence of aqueous extracts from Salvadora persica L.(Chewing sticks) on lowering cholesterol in diabetics’ male rats
  1289. Influence of body mass index and serum lipids on the cholesterollowering effects of almonds in free-living individuals
  1290. Influence of cholesterol lowering on plasma membrane lipids and cationic transport systems.
  1291. Influence of cholesterol lowering therapy and antioxidant supplementation on coronary artery bypass graft (CABG) occlusion 2 years after surgery
  1292. Influence of cholesterol on survival after stroke. Beneficial effects of cholesterol lowering on atherosclerosis may not lessen with age.
  1293. Influence of cholesterol screening and nutritional counseling in reducing cholesterol levels in children
  1294. Influence of cholesterollowering on plasma membrane lipids and function.
  1295. Influence of CYP2C9 polymorphisms on the pharmacokinetics and cholesterollowering activity of (−)‐3s,5r‐fluvastatin and (+)‐3r,5s‐fluvastatin in healthy …
  1296. Influence of feeding β-cyclodextrin on reducing the content of cholesterol in pork
  1297. Influence of LDL-cholesterol lowering on cardiovascular outcomes in patients with diabetes mellitus undergoing coronary revascularization
  1298. Influence of magnesium and calcium on the serum cholesterol level lowering (II)
  1299. Influence of magnesium and calcium on the serum cholesterol level lowering (III)-Influence of Korea ginseng
  1300. Influence of polymorphisms and cholesterollowering treatment on SCARB1 mRNA expression
  1301. Influence of reducing fat on leptin and cholesterol in adolescent girl students [J]
  1302. Influence of stigmastanol and stigmastanyl-phosphorylcholine, two plasma cholesterol lowering substances, on synthetic phospholipid membranes. A 2H-and 31P …
  1303. Influence of the SLCO1B1*1b and *5 haplotypes on pravastatin’s cholesterol lowering capabilities and basal sterol serum levels
  1304. Inhibition of intestinal cholesterol absorption might explain cholesterollowering effect of telmisartan
  1305. Inhibition of macrophage proliferation dominates plaque regression in response to cholesterol lowering
  1306. Inhibition of melanin synthesis in zebrafish by low-temperature maintenance and lowering of serum cholesterol
  1307. Inhibitors of Acyl-CoA:cholesterol O-Acyl Transferase (ACAT) as Hypocholesterolemic Agents. CI-1011: An Acyl Sulfamate with Unique cholesterollowering
  1308. Inhibitory effects of tangeretin and trans-ethyl caffeate on the HMG-CoA reductase activity: Potential agents for reducing cholesterol levels
  1309. Insights from recent meta-analysis: role of high-density lipoprotein cholesterol in reducing cardiovascular events and rates of atherosclerotic disease progression
  1310. Insulin-sensitizing and cholesterollowering effects of chromium (D-Phenylalanine) 3
  1311. Intake occasion affects the serum cholesterol lowering of a plant sterol-enriched single-dose yoghurt drink in mildly hypercholesterolaemic subjects
  1312. Intense cholesterol lowering therapy with a HMG-CoA reductase inhibitor does not improve nitric oxide dependent endothelial function in type-2-diabetes
  1313. Intensity of lipid-lowering therapy and low-density lipoprotein cholesterol goal attainment among the elderly before and after the 2004 National cholesterol Education …
  1314. Intensive cholesterol lowering: no longer a myth
  1315. Intensive cholesterollowering therapy improves large artery elasticity in acute myocardial infarction patients
  1316. Intensive LDL cholesterollowering treatment beyond current recommendations for the prevention of major vascular events: a systematic review and meta-analysis of …
  1317. Intensive LDL-cholesterol lowering and inhibition of inflammation to further reduce cardiovascular risk?
  1318. Intensive LDL-cholesterol lowering therapy and neurocognitive function
  1319. Intensive lowering of LDL cholesterol with 80 mg versus 20 mg simvastatin daily in 12,064 survivors of myocardial infarction: a double-blind randomised trial.
  1320. Intensive lowering of low-density lipoprotein cholesterol levels for primary prevention of coronary artery disease
  1321. Intensively lowering both low-density lipoprotein cholesterol and blood pressure does not reduce cardiovascular risk in Japanese coronary artery disease patients
  1322. Interaction of the cholesterol reducing agent simvastatin with zwitterionic DPPC and charged DPPG phospholipid membranes
  1323. Interactions between common genetic polymorphisms in ABCG5/G8 and CYP7A1 on LDL cholesterollowering response to atorvastatin
  1324. Interactions of cholesterol reducing agent simvastatin with charged phospholipid model membranes
  1325. Interactions of cholesterol reducing agent simvastatin with phospholipid model membranes
  1326. Interindividual variability in the cholesterollowering effect of supplementation with plant sterols or stanols
  1327. Interrelation of cholesterollowering, antioxidant activity and DNA damage protection to the different solvent extracts of mulberry (Morus alba L.)
  1328. Intestinal CREBH overexpression prevents high-cholesterol diet-induced hypercholesterolemia by reducing Npc1l1 expression
  1329. Intestine-specific DGAT1 deficiency improves atherosclerosis in apolipoprotein E knockout mice by reducing systemic cholesterol burden
  1330. Intima-media thickness after cholesterol lowering in familial hypercholesterolemia. A three-year ultrasound study of common carotid and femoral arteries
  1331. Intracellular cholesterol lowering as Novel Target for Anti‐Atherosclerotic Therapy
  1332. Inverse relationship between high-density lipoprotein cholesterol raising and high-sensitivity C-reactive protein reduction in older patients treated with lipid-lowering
  1333. Investigating the effect of operational factors on reducing cream cholesterol by beta-cyclodextrin using response surface method
  1334. Investigation of a probiotic yeast as a cholesterol lowering agent on rats fed on a high cholesterol enriched diet
  1335. Investigation of a Probiotic Yeast as a cholesterol lowering Agent on Rats Fed on a High cholesterol Enriched diet
  1336. Investigation of the cholesterollowering action of insoluble fibre derived from the peel of Citrus sinensis L. cv. Liucheng
  1337. Investigation of the role of amla in modulating cholesterol metabolism, and understanding its mechanism of action in reducing Alzheimer’s risk
  1338. Investigation on the lipid-and cholesterollowering abilities of biocellulose
  1339. Involvement of post-digestion’hydrophobia’peptides in plasma cholesterollowering effect of dietary plant proteins
  1340. Iron and zinc status of women and men who followed cholesterollowering diets
  1341. Is cholesterol lowering an alternative to revascularization in some patients with coronary artery disease?
  1342. Is cholesterol lowering following UVA blood irradiation an effect of citrate?
  1343. Is direct method of low density lipoprotein cholesterol measurement appropriate for targeting lipid lowering therapy?
  1344. Is fat globule membrane essential for cholesterollowering effect of milk?
  1345. Is intensive cholesterol lowering detrimental in multiple sclerosis?
  1346. Is intensive LDL-cholesterol lowering beneficial and safe?
  1347. Is lowering blood cholesterol levels safe?
  1348. Is moderate drinking as effective as cholesterol lowering in reducing mortality in high-risk coronary patients?
  1349. Is red yeast rice safe and effective for lowering serum cholesterol?
  1350. Is reducing low-density lipoprotein cholesterol all that matters?
  1351. Is soy protein effective in reducing cholesterol and improving bone health?
  1352. Is the Australian National Heart Foundation programme effective in reducing cholesterol levels among general practice patients?
  1353. Is there a correlation between LDL-cholesterol lowering and angiographically (QCA) determined coronary progression?
  1354. Isoflavones enhance the plasma cholesterollowering activity of 7S protein in hypercholesterolemic hamsters
  1355. Isolation and Biological Characteristics of cholesterollowering LAB from Fermented Food
  1356. Isolation and Characteristics of cholesterollowering L. casei subsp. casei Strain GL-03 Isolated from Cheese
  1357. Isolation and characterization of cholesterollowering lactic acid bacteria from kimchi
  1358. Isolation and characterization of new strains of cholesterol-reducing bacteria from baboons.
  1359. Isolation and characterization of unique cholesterol-reducing anaerobes
  1360. Isolation and identification of cholesterol lowering probiotic bacteria from palm wine (Raffia mambillensis)
  1361. Isolation and Identification of cholesterol lowering Probiotic Yeast from Palm Raffia (Raffia mambillensis) Wine
  1362. Isolation and identification of cholesterol-reducing lactic acid bacteria from indigenously fermented pickles and dried-sausage
  1363. Isolation and Identification of cholesterol-Reducing Lactic Acid Bacteria from Pig
  1364. Isolation and identification of cholesterol-reducing lactic acid bacteria from Tibet kefir
  1365. Isolation and identification of cholesterol-reducing Lactic acid bacteria.
  1366. Isolation and identification of lactic acid bacteria and the study of cholesterol-reducing effect from panda excrement
  1367. Isolation and identification of lactic acid bacteria from fermented vegetables juice and the investigation of cholesterol-reducing capability.
  1368. Isolation and selection of potential probiotic lactic acid bacteria from cassava pulp for cholesterol lowering property
  1369. Isolation of cholesterollowering Enterococcus faecium JB HML-11 from Human Colostrums
  1370. Isolation of cholesterollowering lactic acid bacteria from human intestine for probiotic use
  1371. Isolation of lactic acid bacteria with cholesterollowering activity from digestive tracts of Indonesian native chickens
  1372. Isolation of plasma cholesterollowering components from ningyotake (Polyporus confluens) mushroom
  1373. Isolation of potential probiotic Lactobacillus oris HMI68 from mother’s milk with cholesterol-reducing property
  1374. Isolation, Identification and cholesterollowering Characteristics of Lactic Acid Bacteria MR25
  1375. J-104,123, a novel and orally-active inhibitor of squalene synthase: Stereoselective synthesis and cholesterol lowering effects in dogs
  1376. JAMA: Effect of a dietary portfolio of cholesterollowering foods given at 2 levels of intensity of dietary advice on serum lipids in hyperlipidemia: a randomized …
  1377. Key points for maximum effectiveness and safety for cholesterollowering properties of plant sterols and use in the treatment of metabolic syndrome
  1378. KIF6, LPA, TAS2R50, and VAMP8 genetic variation, low density lipoprotein cholesterol lowering response to pravastatin, and heart disease risk reduction in the …
  1379. Lack of cholesterollowering efficacy of Cuban sugar cane policosanols in hypercholesterolemic persons
  1380. Lack of effect of lowering LDL cholesterol on cancer: meta-analysis of
  1381. Lack of efficacy of low-dose sitostanol therapy as an adjunct to a cholesterollowering diet in men with moderate hypercholesterolemia
  1382. Lack of serum cholesterollowering effect of skimmed milk and butter milk under controlled conditions
  1383. Lactic acid bacteria with cholesterollowering properties for dairy applications: In vitro and in situ activity
  1384. Lactobacillus attenuates progression of nonalcoholic fatty liver disease by lowering cholesterol and steatosis
  1385. Lactobacillus fermentum NCIMB 5221 and NCIMB 2797 as cholesterollowering probiotic biotherapeutics: in vitro analysis
  1386. Lactobacillus fermentum strains from human breast milk with probiotic properties and cholesterollowering effects
  1387. Lactobacillus plantarum strains as potential probiotic cultures with cholesterollowering activity
  1388. Lactobacillus reuteri attenuates cardiac injury without lowering cholesterol in low-density lipoprotein receptor-deficient mice fed standard chow
  1389. Lactostatin (IIAEK) and CSPHP: new cholesterollowering peptides derived from food proteins.
  1390. Lathosterol in plasma measures cholesterol synthesis and identifies the efficiency of dietary phytosterols in reducing the plasma cholesterol concentration
  1391. Lathosterol to cholesterol ratio in serum predicts cholesterol lowering response to plant sterol therapy in a dual center, randomized, single‐blind placebo controlled …
  1392. Lathosterol-to-cholesterol ratio in serum predicts cholesterollowering response to plant sterol consumption in a dual-center, randomized, single-blind placebo …
  1393. LDL cholesterol lowering by bile acid malabsorption during inhibited synthesis and absorption of cholesterol in hypercholesterolemic coronary subjects.
  1394. LDL cholesterol lowering in type 2 diabetes: what is the optimum approach?
  1395. LDL cholesterol lowering therapy: no target value but personalised treatment
  1396. LDL cholesterol lowering with Evolocumab and Outcomes in Patients with Peripheral Artery Disease: Insights from the FOURIER Trial
  1397. LDL cholesterol reduction by lipid lowering therapy after acute myocardial infarction is not significantly influenced by baseline systemic inflammation
  1398. LDL cholesterollowering effects of grape extract used as a dietary supplement on healthy volunteers
  1399. LDL cholesterollowering therapies: emphasis on proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors.
  1400. LDL kolesterolü düsürmenin ötesi/Beyond lowering LDL cholesterol
  1401. LDL-cholesterol goal attainment under persistent lipid-lowering therapy in northeast China: subgroup analysis of the dyslipidemia international study of China …
  1402. LDL-cholesterol lowering activity of a blend of rice bran oil and safflower oil (8: 2) in patients with hyperlipidaemia: a proof of concept, double blind, controlled …
  1403. LDL-cholesterol lowering Among Young Adults Who Experience a First Myocardial Infarction
  1404. LDL-cholesterol lowering and atherosclerosis-clinical benefit and possible mechanisms: an update
  1405. LDL-cholesterol lowering and clinical outcomes in hypercholesterolemic subjects with and without a familial hypercholesterolemia phenotype: Analysis from the …
  1406. LDL-cholesterol lowering and renal outcomes
  1407. LDL-cholesterol lowering effect of a generic product of simvastatin compared to simvastatin (Zocor™) in Thai hypercholesterolemic subjects–a randomized …
  1408. LDL-cholesterol lowering effect of a new dietary supplement: an open label, controlled, randomized, cross-over clinical trial in patients with mild-to-moderate …
  1409. LDL-cholesterol lowering for the Primary Prevention of Cardiovascular Disease Among Men with Primary Elevations of LDL-cholesterol Levels of 190 mg/dL or …
  1410. LDL-cholesterol lowering in chronic kidney disease stage V dialysis patients with hyperphosphataemia: a comparison of colestilan (COL) and sevelamer (SEV)
  1411. LDL-cholesterol lowering Increased Mortality in Mice with Inherited Cardiomyopathy
  1412. LDL-cholesterol lowering increases plasma apelin in isolated hypercholesterolemia
  1413. LDL-cholesterol lowering of plant sterols and stanols—Which factors influence their efficacy?
  1414. LDL-cholesterol lowering or HDL-cholesterol raising for cardiovascular prevention: A lesson from cholesterol turnover studies and others
  1415. LDL-cholesterol lowering strategies and population health-time to move to a cumulative exposure model.
  1416. Ldl-cholesterol lowering Treatment Changes Hematopoietic Stem Cell Behavior In Familial Hypercholesterolemia Patients
  1417. LDL-cholesterol lowering with evolocumab, and outcomes according to age and sex in patients in the FOURIER Trial
  1418. LDL-cholesterol lowering, transcapillary leakage of albumin and acetylcholine-mediated vasodilatation in atherosclerotic patients
  1419. LDL-cholesterollowering effect of a dietary supplement with plant extracts in subjects with moderate hypercholesterolemia
  1420. LDL-cholesterollowering effect of a mixed green vegetable and fruit beverage containing broccoli and cabbage in hypercholesterolemic subjects
  1421. LDL-cholesterollowering effect of monacolin K from red yeast rice extract–results of a randomized, placebo-controlled intervention study
  1422. LDL-cholesterollowering effect of plant sterols and stanols across different dose ranges: a meta-analysis of randomised controlled studies
  1423. LDL-cholesterollowering therapy
  1424. Ldl-receptor genotype dependent response to cholesterollowering therapy in patients with heterozygous familial hypercholesterolemia
  1425. Lean meat as part of a cholesterollowering diet
  1426. Leptin receptor polymorphism is associated with serum lipid levels and impairment of cholesterol lowering effect by simvastatin in Japanese men
  1427. Lessons from cholesterollowering trials
  1428. Letter by Alkhalil Regarding Article,“Low-Density Lipoprotein cholesterol lowering With Evolocumab and Outcomes in Patients With Peripheral Artery Disease …
  1429. Letter by Calabrò et al Regarding Article,“Low-Density Lipoprotein cholesterol lowering With Evolocumab and Outcomes in Patients With Peripheral Artery Disease …
  1430. Leuconostoc mesenteroides MKSR isolated from kimchi possesses α-glucosidase inhibitory activity, antioxidant activity, and cholesterollowering effects
  1431. Leukocyte ABCA1 impedes progression of established atherosclerotic lesions after dietary cholesterol lowering in LDLr-/-mice
  1432. Limitations of cholesterol lowering with PCSK9 inhibitors
  1433. Lipase inhibition and cholesterollowering activities of laccase-catalyzed catechin polymers
  1434. Lipase-catalyzed synthesis of canola phytosterols oleate esters as cholesterol lowering agents
  1435. Lipase-catalyzed synthesis of conjugated linoleyl β-sitosterol and its cholesterollowering properties in mice
  1436. Lipid and cholesterol lowering effect of green vs black tea-how much, how frequent: A literature review
  1437. Lipid binding from aqueous solution by lipid conjugated hydroxypropyl methylcellulose (HPMC): a novel food additive for reducing cholesterol and fat intestinal …
  1438. Lipid lowering and anti-atherosclerotic properties of Tinospora crispa aqueous extract on high-cholesterol diet-induced hyperlipidemic rabbits
  1439. Lipid lowering and Antioxidant Activities of Methanolic Extract of Ficus hispida Linn. Fruits in cholesterol Fed Rats
  1440. Lipid lowering and antioxidant effects of Amomum subulatum seeds (Family Zingiberaceae) in cholesterol fed rabbits
  1441. Lipid lowering and Antioxidant Effects of C. Verum on Liver in cholesterol fed Rabbits
  1442. Lipid lowering effect of S-methyl cysteine sulfoxide from Allium cepa Linn in high cholesterol diet fed rats
  1443. Lipid lowering effects of hydroalcoholic extract of Anethum graveolens L. and dill tablet in high cholesterol fed hamsters
  1444. Lipid lowering in patients with coronary artery disease: low density lipoprotein cholesterol and beyond
  1445. Lipid lowering Therapies And cholesterol Levels After St-Segment Elevation Myocardial Infarction: Single Center Experience Of Secondary Prevention
  1446. Lipid Monitoring and Treatment Intensification of cholesterol lowering Therapies-Insight From the Veterans Affairs Healthcare System
  1447. Lipid-lowering activity of Cow urine ark in guinea pigs fed with a high cholesterol diet
  1448. Lipid-lowering and antioxidant effects of an ethyl acetate extract of fenugreek seeds in high-cholesterol-fed rats
  1449. Lipid-lowering and antioxidant effects of hydroxytyrosol and its triacetylated derivative recovered from olive tree leaves in cholesterol-fed rats
  1450. Lipid-lowering and antioxidative activities of 3, 4-di (OH)-cinnamate and 3, 4-di (OH)-hydrocinnamate in cholesterol-fed rats
  1451. Lipid-lowering and antioxidative activities of aqueous extracts of Ocimum sanctum L. leaves in rats fed with a high-cholesterol diet
  1452. Lipid-lowering effect of bergamot polyphenolic fraction: role of pancreatic cholesterol ester hydrolase.
  1453. Lipid-lowering effects of Coriolus versicolor extract in poloxamer 407-induced hypercholesterolaemic rats and high cholesterol-fed rats
  1454. Lipid-lowering effects of methanolic extract of Vernonia amygdalina leaves in rats fed on high cholesterol diet
  1455. Lipid-lowering efficacy of hesperetin metabolites in high-cholesterol fed rats
  1456. Lipid-lowering intensification and low-density lipoprotein cholesterol achievement from hospital admission to 1-year follow-up after an acute coronary syndrome event …
  1457. Lipid-lowering therapies and achievement of LDL-cholesterol targets
  1458. Lipid-lowering Therapy and Low-Density Lipoprotein cholesterol (LDL-C) Goal Achievement in High-Cardiovascular-Risk Patients in Fuzhou, China
  1459. Lipid-lowering therapy and low-density lipoprotein cholesterol goal achievement in patients with acute coronary syndromes: The ACS patient pathway project
  1460. Lipid-lowering therapy and low-density lipoprotein cholesterol goal attainment after acute coronary syndrome: a Danish population-based cohort study
  1461. LIPID-lowering THERAPY PATTERNS AND LOW-DENSITY LIPOPROTEIN-cholesterol MANAGEMENT AMONG PATIENTS WITH ACUTE MYOCARDIAL …
  1462. lipid-lowering therapy: effect on cholesterol efflux from the cells
  1463. Lipid-lowering treatment and low-density lipoprotein cholesterol target achievement in patients with type 2 diabetes and acute coronary syndrome
  1464. Lipid-lowering treatment to the end? A review of observational studies and RCTs on cholesterol and mortality in 80+-year olds
  1465. Lipid‐lowering effect of eriocitrin, the main flavonoid in lemon fruit, in rats on a high‐fat and high‐cholesterol diet
  1466. LIPID‐lowering EFFECTS OF ARONIA MELANOCARPA FRUIT JUICE IN RATS FED cholesterol‐CONTAINING dietS
  1467. Lipid‐lowering therapy use and achievement of cholesterol targets in an Australian diabetes clinic
  1468. Lipids and cerebrovascular disease-New therapeutic options in lowering LDL-cholesterol
  1469. Lipids and cholesterollowering Activity of Red Cabbage Microgreens
  1470. Lipophilic 1, 1-bisphosphonates are potent squalene synthase inhibitors and orally active cholesterol lowering agents in vivo.
  1471. Lipoprotein (a)-and low-density lipoprotein–derived cholesterol in nephrotic syndrome: Impact on lipid-lowering therapy?
  1472. Liver lipid metabolism and effect of cholesterollowering agents in the hyperlipidemia induced in rats by implantation of the pituitary-derived MtT-F4 tumor
  1473. Long term cholesterol lowering therapy does not interfere with clinical response to anti CD20 therapy in patients with rheumatoid arthritis
  1474. Long-term blood cholesterollowering effects of a dietary fiber supplement
  1475. Long-term cholesterollowering effects of 4 fat-restricted diets in hypercholesterolemic and combined hyperlipidemic men: the dietary Alternatives Study
  1476. Long-term cholesterollowering effects of psyllium as an adjunct to diet therapy in the treatment of hypercholesterolemia
  1477. Long-term effects of a plant-based dietary portfolio of cholesterollowering foods on blood pressure
  1478. Long-term effects of cholesterol lowering and angiotensin-converting enzyme inhibition on coronary atherosclerosis: The Simvastatin/Enalapril Coronary …
  1479. Long-term effects on clinical outcomes of aggressive lowering of low-density lipoprotein cholesterol levels and low-dose anticoagulation in the post coronary artery …
  1480. Long-term hemostatic effects of cholesterollowering therapy with atorvastatin
  1481. Long-term low-density lipoprotein cholesterollowering efficacy, persistence, and safety of evolocumab in treatment of hypercholesterolemia: results up to 4 years from …
  1482. Long-term lowering of plasma cholesterol levels in LDL-receptor-deficient WHHL rabbits by gene therapy
  1483. Long-Term Safety and Effectiveness of cholesterol lowering with Pravastatin Treatment Over 11 Years: The Lipid Study Extension
  1484. Long-term safety and efficacy of a cholesterollowering diet in children with elevated low-density lipoprotein cholesterol: seven-year results of the dietary Intervention …
  1485. Long‐term cholesterollowering effect of colestipol resin in humans
  1486. Lovastatin efficacy in reducing low-density lipoprotein cholesterol levels on high-vs low-fat diets
  1487. Lovastatin for lowering cholesterol levels in non-insulin-dependent diabetes mellitus
  1488. Lovastatin: a new cholesterollowering agent.
  1489. Lovastatin: A new cholesterollowering agent
  1490. Lovastatin: an HMG-CoA reductase inhibitor for lowering cholesterol.
  1491. Low Density Lipoprotein cholesterol (LDL-C) lowering in a Population Represented in a Meta-Analysis of Major Randomized Trials is Associated with a Positive …
  1492. Low density lipoprotein cholesterol lowering: Are the treatment guidelines still appropriate?
  1493. Low Density Lipoprotein cholesterollowering Strategies and Population Health: Time to Move to a Cumulative Exposure Model
  1494. Low density lipoprotein-cholesterol lowering activity of a blend of rice bran oil and safflower oil (7: 3) in Indian patients with hyperlipidemia: a randomized …
  1495. Low density lipoprotein-cholesterol lowering mechanism and blood lipid profile managing effect of phytosterol in healthy normal and hypercholesterolemia: a meta …
  1496. LOW LDL-cholesterol TARGET VALUE ATTAINMENT AT THE TIME OF ACUTE CORONARY SYNDROME (ACS) AND EVEN 4 MONTHS AFTER THE ACUTE …
  1497. Low Levels of Low-Density Lipoprotein cholesterol and Endothelial Function in Subjects without Lipid-lowering Therapy
  1498. Low rates of both lipid-lowering therapy use and achievement of low-density lipoprotein cholesterol targets in individuals at high-risk for cardiovascular …
  1499. Low-Density Lipoprotein cholesterol and High-Sensitivity C-Reactive Protein lowering With
  1500. Low-density lipoprotein cholesterol goal attainment among post myocardial infarction patients on lipid lowering therapy at Siriraj Outpatient Clinic
  1501. Low-density lipoprotein cholesterol lowering efficacy of evolocumab may reduce need for apheresis in heterozygous familial hypercholesterolaemia patients …
  1502. Low-density lipoprotein cholesterol lowering for the prevention of cardiovascular outcomes in patients with ischemic stroke
  1503. Low-density lipoprotein cholesterol lowering in the prevention of CHD: how low should we go?
  1504. Low-density lipoprotein cholesterol lowering therapies: what is on the horizon?
  1505. Low-density lipoprotein cholesterol lowering therapy and established atherosclerosis
  1506. Low-density lipoprotein cholesterol lowering therapy for the secondary prevention of atherosclerotic cardiovascular disease
  1507. Low-density lipoprotein cholesterol lowering treatment: the current approach
  1508. Low-Density Lipoprotein cholesterol lowering With Evolocumab and Outcomes in Patients With Peripheral Artery Disease
  1509. Low-density lipoprotein cholesterol lowering with evolocumab and outcomes in patients with peripheral artery disease: insights from the FOURIER trial (Further …
  1510. Low-density lipoprotein cholesterol outcomes post-non-PCSK9i lipid-lowering therapies in atherosclerotic cardiovascular disease and probable heterozygous …
  1511. Low-density lipoprotein cholesterol target value attainment based on 2019 ESC/EAS guidelines and lipid-lowering therapy titration for patients with acute coronary …
  1512. Low-density lipoprotein cholesterollowering effects of AMG 145, a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 serine protease in patients …
  1513. Low-density lipoprotein receptor genotype-dependent response to cholesterol lowering by combined pravastatin and cholestyramine in familial hypercholesterolemia
  1514. Low-Density Lipoprotein-cholesterol lowering in Real-World Patients Treated With Evolocumab
  1515. Low-density lipoprotein-cholesterol lowering strategies for prevention of atherosclerotic cardiovascular disease: focus on siRNA treatment targeting PCSK9 …
  1516. Low-density lipoprotein-dependent and-independent effects of cholesterollowering therapies on C-reactive protein: a meta-analysis
  1517. Low-dose simvastatin is a well-tolerated and efficacious cholesterollowering agent in ciclosporin-treated kidney transplant recipients: double-blind, randomized …
  1518. Low‐density lipoprotein‐cholesterol lowering in individuals at intermediate cardiovascular risk: Percent reduction or target level?
  1519. lowering “desirable” cholesterol levels improves flow-mediated vasoactivity in healthy, middle-aged men
  1520. lowering blood cholesterol
  1521. lowering blood cholesterol to reduce coronary heart disease risk
  1522. lowering blood cholesterol: recent developments of significance to community health nurses.
  1523. lowering blood total cholesterol: a meta-analysis and policy statement
  1524. lowering cellular cholesterol inhibits signal transduction via glycosyl phosphatidyl-inositol (GPI)-anchored proteins
  1525. lowering cholesterol
  1526. lowering cholesterol 1998. cholesterol synthesis inhibitors compared
  1527. lowering cholesterol and death due to accidents, suicides: unresolved issues
  1528. lowering cholesterol and Death due to Accidents, Suicides: Unresolved Issues-Reply
  1529. lowering cholesterol and lowering costs
  1530. lowering cholesterol and lowering costs-Reply
  1531. lowering cholesterol and the incidence of coronary heart disease
  1532. lowering cholesterol concentrations and mortality
  1533. lowering cholesterol concentrations and mortality
  1534. lowering cholesterol concentrations and mortality
  1535. lowering cholesterol concentrations and mortality
  1536. lowering cholesterol concentrations and mortality
  1537. lowering cholesterol concentrations and mortality
  1538. lowering cholesterol concentrations and mortality
  1539. lowering cholesterol concentrations and mortality
  1540. lowering cholesterol concentrations and mortality: a quantitative review of primary prevention trials.
  1541. lowering cholesterol concentrations and mortality: Authors’ reply
  1542. lowering cholesterol does pay off
  1543. lowering cholesterol for prevention of coronary heart disease—problems and perspectives
  1544. lowering cholesterol in chronic kidney disease: is it safe and effective?
  1545. lowering cholesterol in high risk individuals and populations
  1546. lowering cholesterol in old age.
  1547. lowering cholesterol in quail eggs using some extracts
  1548. lowering cholesterol Levels in Children and Adolescents: A Role for the Occupational Health Nurse
  1549. lowering cholesterol naturally
  1550. lowering cholesterol The Secondary Prevention of Coronary Heart Disease
  1551. lowering cholesterol with Anticholest–a high fiber guar-apple pectin drink
  1552. lowering cholesterol with diet and Lovastatin
  1553. lowering cholesterol with granulocyte-macrophage colony-stimulating factor
  1554. lowering cholesterol With Granulocyte-Macrophage Colony-Stimulating Factor
  1555. lowering cholesterol with Lovastatin: The wrong approach
  1556. lowering cholesterol with PCSK9 inhibitors
  1557. lowering cholesterol, 1988. Rationale, mechanisms, and means.
  1558. lowering cholesterol: a review on the role of plant sterols
  1559. lowering cholesterol: effects on trauma death, cancer death and total mortality
  1560. lowering cholesterol: how low is low enough?
  1561. lowering effect of an isoflavone-rich fermented soybean extract on the serum cholesterol concentrations in female rats, with or without ovariectomy, but not in male …
  1562. lowering effect of dietary milk-whey protein v. casein on plasma and liver cholesterol concentrations in rats
  1563. lowering effect of dietary milk-whey protein versus casein on plasma and liver cholesterol concentrations in rats
  1564. lowering High cholesterol
  1565. lowering High Plasma cholesterol levels is not dangerous
  1566. lowering High Plasma cholesterol Levels Is Not Dangerous-Reply
  1567. lowering increased cholesterol–prolonging life?
  1568. lowering LDL cholesterol in adults: a prospective, community-based practice initiative
  1569. lowering LDL cholesterol is good, but how and in whom
  1570. lowering LDL cholesterol reduces atherosclerotic risk in patients with chronic kidney disease
  1571. lowering LDL cholesterol reduces cardiovascular risk independently of presence of inflammation
  1572. lowering LDL cholesterol with margarine containing plant stanol/sterol esters: is it still relevant in 2011?
  1573. lowering LDL cholesterol, but not raising LDL receptor activity, by ezetimibe
  1574. lowering LDL cholesterol, but not Raising LDL Receptor Activity, by Ezetimibe
  1575. lowering LDL cholesterol: questions from recent meta-analyses and subset analyses of clinical trial data issues from the Interdisciplinary Council on Reducing the …
  1576. lowering LDL-cholesterol IS PROTECTIVE FOR THE FRAILTY INDEX: A MENDELIAN RANDOMIZATION STUDY IN THE UK BIOBANK
  1577. lowering LDL-cholesterol: the lower the better?
  1578. lowering LDL‐cholesterol and CV Benefits: Is There a Limit to How Low LDL‐C Needs to be for Optimal Health Benefits?
  1579. lowering line tension with high cholesterol content induces a transition from macroscopic to nanoscopic phase domains in model biomembranes
  1580. lowering low density lipoprotein cholesterol with simvastatin, a hydroxy-3-methylglutaryl-coenzyme a reductase inhibitor, does not affect luteal function in …
  1581. lowering low-density lipoprotein cholesterol by PCSK9 inhibition in patients with diabetes on insulin therapy: is it efficacious and safe?
  1582. lowering Low-Density Lipoprotein cholesterol Concentration with Plant Stanol Esters to Reduce the Risk of Atherosclerotic Cardiovascular Disease Events at a …
  1583. lowering low-density lipoprotein cholesterol levels in patients with type 2 diabetes mellitus
  1584. lowering of blood pressure, plasma renin substrate, cholesterol and triglyceride by portacaval anastomosis in rats fed on a 60% sucrose/5% lard diet
  1585. lowering of cholesterol absorption and blood levels by ileal exclusion: experimental basis and preliminary clinical report
  1586. lowering of cholesterol bioaccessibility and serum concentrations by saponins: in vitro and in vivo studies
  1587. lowering of cholesterol levels and the risk of stroke
  1588. lowering of cholesterol levels through adding pectins and soybean proteins to a reducing diet (author’s transl)
  1589. lowering of HDL cholesterol in post-menopausal women by tibolone is not associated with changes in cholesterol efflux capacity or paraoxonase activity
  1590. lowering of HDL2-cholesterol and lipoprotein A-1 particle levels by increasing the ratio of polyunsaturated to saturated fatty acids
  1591. lowering of high density lipoprotein cholesterol levels: case report
  1592. lowering of human serum cholesterol by an oral hydrophilic colloid.
  1593. lowering of LDL cholesterol
  1594. lowering of LDL cholesterol
  1595. lowering of LDL cholesterol rather than moderate weight loss improves endothelium-dependent vasodilatation in obese women with previous gestational diabetes
  1596. lowering of LDL-cholesterol improves endothelial function by increased nitric oxide synthase activity
  1597. lowering of plasma cholesterol and enhanced sterol excretion with the consumption of polyunsaturated ruminant fats
  1598. lowering of plasma cholesterol in herbivores and omnivores by low molecular weight dextran
  1599. lowering of plasma cholesterol levels in animals by lovastatin and simvastatin
  1600. lowering of plasma cholesterol levels in free-living adolescent males; use of natural and synthetic polyunsaturated foods to provide balanced fat diets
  1601. lowering of plasma LDL cholesterol in hamsters by the tomato glycoalkaloid tomatine
  1602. lowering of Serum cholesterol and Triglyceride by Para-Aminosalicylic Acid in Hyperlipoproteinemia: Studies in Patients with Types II-A and II-B
  1603. lowering of serum cholesterol and triglyceride levels by balancing amino acid intake in the white rat
  1604. lowering of serum cholesterol and triglycerides and modulation of divalent cations by dietary phytate.
  1605. lowering of serum cholesterol by Lactobacillus sporogenes
  1606. lowering of serum cholesterol by Temoe Lawak Singer, a Curcuma mixture.
  1607. lowering of serum cholesterol by the administration of a plant sterol
  1608. lowering of serum cholesterol by ultraviolet irradiation.
  1609. lowering of serum cholesterol in hypercholesterolemic humans by tocotrienols (palmvitee)
  1610. lowering of serum total cholesterol to high density lipoprotein cholesterol ratios in hypercholesterolaemic patients by Abana: possible cardioprotective action
  1611. lowering of serum-cholesterol level in rats by intraperitoneal cod-liver oil.
  1612. lowering patients’ cholesterol
  1613. lowering patients’ cholesterol. Excluding patients from trials increases uncertainty.
  1614. lowering patients’ cholesterol. Extrapolating results of trial of simvastatin gives room for doubt.
  1615. lowering patients’ cholesterol. Few eligible patients currently receive treatment.
  1616. lowering plasma cholesterol by diet
  1617. lowering plasma cholesterol by raising LDL receptors
  1618. lowering plasma cholesterol by raising LDL receptors—revisited
  1619. lowering plasma cholesterol levels halts progression of aortic valve disease in mice
  1620. lowering risk without lowering cholesterol: Implications for national cholesterol policy
  1621. lowering SERUM cholesterol AND REGRESSION OF EXPERIMENTAL ATHEROSCLEROTIC PLAQUES INDUED BY ALFALFA SAPONINS [J]
  1622. lowering serum cholesterol level by feeding a 40% ethanol-eluted fraction from HP-20 resin treated with hot water extract of adzuki beans (Vigna angularis) to rats fed …
  1623. lowering SERUM cholesterol LEVELS BY dietARY MODIFICATION A CHANGE IN FOOD HABITS, NOT A SPECIAL diet
  1624. lowering serum cholesterol: it is time to proceed
  1625. lowering Targeted Atherogenic Lipoprotein cholesterol Goals for Patients at “Extreme” ASCVD Risk
  1626. lowering the cholesterol content of MA104 cells inhibits receptor-mediated transport of folate.
  1627. lowering the cost of lowering the cholesterol
  1628. lowering the repeat unplanned revascularization rate after coronary stenting by focusing on the long-term stable control of low-density lipoprotein cholesterol
  1629. lowering the triglyceride/high-density lipoprotein cholesterol and its association with the beneficial impact of pioglitazone on coronary atherosclerosis in the …
  1630. lowering the triglyceride/high-density lipoprotein cholesterol ratio is associated with the beneficial impact of pioglitazone on progression of coronary atherosclerosis in …
  1631. Lupin protein exerts cholesterollowering effects targeting PCSK9: From clinical evidences to elucidation of the in vitro molecular mechanism using HepG2 cells
  1632. Major benefits from cholesterollowering in patients with diabetes.
  1633. Managing comorbidities through cholesterollowering agents
  1634. Manufacture of Cheddar cheese using probiotic Lactobacillus plantarum K25 and its cholesterollowering effects in a mice model
  1635. Marked aortic valve stenosis progression after receiving long-term aggressive cholesterollowering therapy using low-density lipoprotein apheresis in a patient with …
  1636. Marked lowering of high-density lipoprotein cholesterol levels due to high dose bexarotene therapy
  1637. Marked Regression of Aortic Plaque by Intensive cholesterollowering Therapy—A Case of cholesterol Embolism
  1638. Maximal expected benefits from lowering cholesterol in primary prevention for a high-risk population
  1639. Maximal low density lipoprotein receptor activity and the effect of lipid lowering diet on total serum cholesterol
  1640. Maximal response to a plasma cholesterollowering diet is achieved within two weeks.
  1641. Mechanism for the cholesterollowering action of egg white protein in rats
  1642. Mechanism of serum cholesterollowering action of an anabolic steroid in contrast to a glucorticoid
  1643. Mechanism of the plasma cholesterol lowering effect of tazasubrate in rats: accelerated plasma cholesterol transport with increased liver lipoprotein receptor activity
  1644. Mechanisms of calcium intake in lowering serum cholesterol levels
  1645. Mechanisms of cholesterol and saturated fatty acid lowering by Quillaja saponaria extract, studied by in vitro digestion model
  1646. MECHANISMS OF cholesterollowering EFFECT OF BARLEY β-GLUAN
  1647. Mechanisms of cholesterollowering Effects of dietary Fiber
  1648. Mechanisms of cholesterollowering effects of dietary insoluble fibres: relationships with intestinal and hepatic cholesterol parameters
  1649. Mechanisms of cholesterollowering effects of lactobacilli and bifidobacteria strains as potential probiotics with their bsh gene analysis
  1650. Mechanisms of LDL-cholesterol lowering action of psyllium hydrophillic mucilloid in the hamster
  1651. Mechanisms of the triglyceride-and cholesterollowering effect of fenofibrate in hyperlipidemic type 2 diabetic patients
  1652. Mechanisms underlying the cholesterollowering properties of soluble dietary fibre polysaccharides
  1653. medicinal plants with cholesterollowering effect marketed in the Buenos Aires-La Plata conurbation, Argentina: An Urban Ethnobotany study
  1654. Mediterranean diet supplemented with cholesterollowering foods and health-related quality of life in adults with HIV infection
  1655. Meeting report.” MIRACL” study of” Myocardial Ischemia Reduction with Aggressive cholesterol lowering
  1656. Men and women–similar but not identical: insights into LDL-lowering therapy in women from the cholesterol Treatment Trialists Collaboration
  1657. Meta analysis of efficacy and safety of bempedoic acid in lowering low density lipoprotein cholesterol
  1658. Meta-analysis of the cholesterollowering effects of dietary fiber
  1659. Meta-analysis of the relation of body mass Index to cardiovascular outcomes in patients Receiving Intensive low-density Lipoprotein cholesterol lowering therapy
  1660. Meta-analysis, clinical trials, and transferability of research results into practice: the case of cholesterollowering interventions in the secondary prevention of coronary …
  1661. Metabolic Basis for the cholesterollowering Action of dietary Polyunsaturated Fatty Acids
  1662. Metabolic changes induced in elderly patients with a cholesterol lowering resin, cholestyramine
  1663. Metabolic disposition studies on simvastatin, a cholesterollowering prodrug.
  1664. Metabolic profile associated with glucose and cholesterol lowering effects of berberine in Sprague–Dawley rats
  1665. Metabolic response of soy pinitol on lipid‐lowering, antioxidant and hepatoprotective action in hamsters fed‐high fat and high cholesterol diet
  1666. Metabolites of Avena sativa with Blood cholesterol lowering Properties
  1667. Metformin exhibited anticancer activity by lowering cellular cholesterol content in breast cancer cells
  1668. Method of administration influences the serum cholesterollowering effect of psyllium
  1669. Method of reducing cholesterol in eggs
  1670. Mevinolin: a highly potent competitive inhibitor of hydroxymethylglutaryl-coenzyme A reductase and a cholesterollowering agent
  1671. Microbiological and Histopathological studies on cholesterol reducing effect of lactobacillus acidophilus
  1672. Microencapsulated genetically engineered Lactobacillus plantarum 80 (pCBH1) for bile acid deconjugation and its implication in lowering cholesterol
  1673. Microsomal triglyceride transfer protein inhibition: a novel treatment for lowering plasma cholesterol
  1674. Microsomal triglyceride transfer protein inhibitors: discovery and synthesis of alkyl phosphonates as potent MTP inhibitors and cholesterol lowering agents
  1675. Mipomersen, an apolipoprotein B synthesis inhibitor, for lowering of LDL cholesterol concentrations in patients with homozygous familial hypercholesterolaemia: a …
  1676. Mode of Action of cholesterollowering Agents: A Critique of Facts and Theories
  1677. Mode of action of probucol in reducing serum cholesterol in mice
  1678. Mode of action of the lipid-lowering agents, clofibrate and BM 15075, on cholesterol biosynthesis in rat liver
  1679. Modeling of the LDL cholesterollowering effect of atorvastatin in Korean dyslipidemic patients and non-patient volunteers.
  1680. Modelling total CHD burden and long-term benefit of cholesterol lowering in middle aged men with and without a history of cardiovascular disease.
  1681. Modelling total coronary heart disease burden and long-term benefit of cholesterol lowering in middle aged men with and without a history of cardiovascular disease
  1682. Modern concepts on cholesterol lowering and coronary heart disease
  1683. Modification of coronary artery disease progression by cholesterollowering therapy: the angiographic studies.
  1684. Modulated expression of genes associated with NO signal transduction contributes to the cholesterollowering effect of electro-acupuncture
  1685. Modulation of Adhesion Molecules by cholesterollowering Therapy in Mononuclear Cells from Hypercholesterolemic Patients
  1686. Modulation of gene expression in cholesterollowering effect of electroacupuncture at Fenglong acupoint (ST40): a cDNA microarray study
  1687. Molecular and vibrational dynamics in the cholesterollowering agent Lovastatin: solid-state NMR, inelastic neutron scattering, and periodic DFT study
  1688. Molecular identification of cholesterollowering lactic acid bacteria isolated from cocowater kefir
  1689. Molecular insights into the mechanisms underlying the cholesterollowering effects of phytosterols
  1690. Molecular mechanisms of cholesterollowering peptides derived from food proteins
  1691. Molecular mechanisms underlying the cholesterollowering effect of Ginkgo biloba extract in hepatocytes: a comparative study with lovastatin
  1692. Monascus fermentation of dioscorea for increasing the production of cholesterollowering agent—monacolin K and antiinflammation agent—monascin
  1693. Monounsaturated fatty acids for plasma cholesterollowering diets
  1694. More on the Chinese red-yeast-rice supplement and its cholesterollowering effect
  1695. More-intensive vs less-intensive LDL-cholesterol lowering reduces mortality
  1696. MP37-09 cholesterol lowering THERAPY PRIOR TO PROSTATECTOMY LOWERS PROLIFERATION RATES IN NORMAL GLAND AND LOW-GRADE …
  1697. MRC BHFHeart Protection Study of cholesterollowering therapy and of antioxidant vitamin supplementation in a wide range of patients at increased risk of coronary …
  1698. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20 536 high-risk individuals: a randomised placebocontrolled trial
  1699. MRC/BHF Heart Protection Study of cholesterollowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial
  1700. MRI of rabbit atherosclerosis in response to dietary cholesterol lowering
  1701. MTP inhibitor decreases plasma cholesterol levels in LDL receptor-deficient WHHL rabbits by lowering the VLDL secretion
  1702. Multifarious cholesterol lowering potential of lactic acid bacteria equipped with desired probiotic functional attributes
  1703. Multifunctional fat absorption and blood cholesterol reducing fo
  1704. Mutation Breeding of cholesterol-Reducing Lactobacillus acidophilus
  1705. Myocardial Ischemia and cholesterol lowering Therapy
  1706. Myocardial perfusion after cholesterol lowering
  1707. Mystery of cholesterollowering peptides, lactostatin and soystatin
  1708. N-cyclohexyl linoleamide: Metabolism and cholesterollowering effect in rats
  1709. Naringin administration inhibits platelet aggregation and release by reducing blood cholesterol levels and the cytosolic free calcium concentration in …
  1710. Natural cholesterollowering products: focus on probiotics
  1711. Naturally derived micelles for rapid in vitro screening of potential cholesterollowering bioactives
  1712. Need for large scale randomised evidence about lowering LDL cholesterol in people with diabetes mellitus: MRC/BHF heart protection study and other major trials
  1713. Need to individualise cholesterollowering therapy
  1714. Neurogenic regulation of lipid metabolism in the rabbit—A mechanism for the cholesterollowering effect of acupuncture
  1715. Neuroprotection by lowering cholesterol
  1716. Neuroprotection by lowering cholesterol: a decrease in membrane cholesterol content reduces transporter-mediated glutamate release from brain nerve …
  1717. New Approaches to cholesterol lowering: Efficacy and Safety
  1718. New cholesterollowering margarines: Are they better?
  1719. New features of the national cholesterol education program adult treatment panel III lipid‐lowering guidelines
  1720. New Guidelines for lowering Blood cholesterol
  1721. New Insight into Metformin-Induced cholesterol lowering Effect: Cross-Talk Between Glucose and cholesterol Homeostasis via ChREBP-Mediated PCSK9 …
  1722. New insight into the cholesterollowering effect of phytosterols in rat cardiomyocytes
  1723. New Insights into the Value of cholesterol lowering
  1724. New LDL-cholesterol lowering therapies: pharmacology, clinical trials, and relevance to acute coronary syndromes
  1725. New molecular targets for cholesterollowering therapy
  1726. New targets and emerging therapies for reducing LDL cholesterol
  1727. New therapies for reducing low-density lipoprotein cholesterol
  1728. Newer cholesterollowering agents: What you must know
  1729. Niacin reduces atherosclerosis development in APOE* 3Leiden. CETP mice mainly by reducing nonHDL-cholesterol
  1730. Niacin reduces atherosclerosis development in APOE* 3Leiden. CETP mice mainly by reducing nonHDL-cholesterol
  1731. NIH Consensus Development Conference on lowering blood cholesterol to prevent heart disease: implications for dietitians.
  1732. Nitric oxide donor molsidomine favors features of atherosclerotic plaque stability during cholesterol lowering in rabbits
  1733. No additional cholesterollowering effect observed in the combined treatment of red yeast rice and Lactobacillus casei in hyperlipidemic patients: A double-blind …
  1734. No limit to the benefits of LDL-cholesterol lowering
  1735. Non‐High‐Density Lipoprotein cholesterol: An Alternate Target for Lipid‐lowering Therapy
  1736. Non–High-Density Lipoprotein cholesterol and Guidelines for cholesterol lowering in Recent History
  1737. Noncholesterol sterols and cholesterol lowering by long-term simvastatin treatment in coronary patients: relation to basal serum cholestanol
  1738. Nonpharmacological approaches for reducing serum low-density lipoprotein cholesterol
  1739. Nonpharmacological cholesterollowering approach: Managing cholesterol naturally
  1740. Normalization of LDL receptor function by lymphocytes of patients with heterozygous familial hypercholesterolemia after treatment with plasma cholesterol lowering
  1741. Novel aspects of atherosclerosis: focusing on new target genes and the effect of cholesterollowering
  1742. Novel method for reducing plasma cholesterol: a ligand replacement therapy
  1743. Novel therapeutic agents for lowering low density lipoprotein cholesterol
  1744. Nutraceuticals and cholesterollowering action
  1745. Nutraceuticals with lipid-lowering activity: do they have any effect beyond cholesterol reduction?
  1746. Nutrient adequacy of diets of adults with hypercholesterolemia after a cholesterollowering intervenion: Long-term assessment
  1747. Nutrient intake and diet quality in patients with systemic lupus erythematosus on a culturally sensitive cholesterol lowering dietary program.
  1748. Nutrition education research project example: An experimental design to test the effectiveness of two nutrition education protocols in reducing serum cholesterol
  1749. Nutrition with pumpkin (Cucrbita pepo) cake as lowering cholesterol in rats
  1750. Nutritional influences on illness: nutrients for lowering cholesterol
  1751. Nutritional value and cholesterollowering effect of wild lettuce (Launaea taraxacifolia) leaf protein
  1752. Nutritive bambara groundnut powdered drink mix: characterization and in-vivo assessment of the cholesterollowering effect
  1753. Oat bran as a cholesterol-reducing dietary adjunct in a young, healthy population
  1754. Oat β-glucan: physico-chemical characteristics in relation to its blood-glucose and cholesterollowering properties
  1755. Observations on the cholesterollowering mechanism of nicotinic acid and nicotinyl alcohol tartrate
  1756. Omega-6 polyunsaturated fatty acids: Is a broad cholesterollowering health claim appropriate?
  1757. One Year Impact of the 2013 cholesterol Guidelines on Patterns of Lipid lowering Treatment
  1758. One‐year cholesterol lowering treatment reduces medial temporal lobe atrophy and memory decline in stroke‐free elderly with atrial fibrillation: evidence from a …
  1759. OP81 Estimating the Potential of Population Level Changes in cholesterol and Blood Pressure for Reducing UK Coronary Heart Disease Mortality Rates: A Novel …
  1760. Optimal serum cholesterol and efficacy of methods for lowering cholesterolemia
  1761. Optimization of Conditions for Production of Lovastatin, A cholesterol lowering Agent, from a Novel Endophytic Producer Meyerozyma guilliermondii
  1762. Optimization of cryoprotectant of I4 cholesterollowering plant Lactobacillus bacteria using response surface method
  1763. Optimization of Producing Enriched Yogurt With Phytosterols in Order To Reducing cholesterol Content
  1764. Optimization of producing enriched yogurt with phytosterols in order to reducing cholesterol content.
  1765. Osteopontin deficiency protects mice from cholesterol gallstone formation by reducing expression of intestinal NPC1L1
  1766. Other therapies for reducing low-density lipoprotein cholesterol: medications in development
  1767. Overview of 2013 American College of Cardiology/American Heart Association cholesterol guideline for reducing cardiovascular risk
  1768. Overview of clinical trials of cholesterol lowering in relationship to epidemiologie studies
  1769. Overview of therapeutic approaches for cholesterol lowering and attenuation of thrombosis for prevention of atherothrombosis
  1770. P02. 123. The anti-diabetic and cholesterollowering effects of common and cassia cinnamon (Cinnamomum verum and C. aromaticum): a randomized controlled trial
  1771. P173Low LDL-cholesterol goal attainment 4 months after ACS due to lack of adjustment in lipid lowering treatment: Results from DYSIS II
  1772. P5387 LDL cholesterol, apolipoprotein B, lipoprotein (a), apolipoprotein CIII and triglyceride lowering by MGL-3196, a thyroid hormone beta selective agonist, in a 12 …
  1773. P642 What is the most important residual risk after achievement of appropriate low-density lipoprotein cholesterol lowering therapy in secondary prevention of …
  1774. P698High cholesterol diet and angiotensin II induce spontaneous atherothrombotic occlusion of balloon-injured rabbit femoral arteries; effects of lipid-lowering
  1775. P828 Low-density lipoprotein cholesterol lowering therapy and target level attainment after a recent myocardial infarction-nationwide cohort study
  1776. Para-aminosalicylate 의 혈압및 혈청 cholesterol 저하작용 (Original Articles: Blood Pressure and Serum cholesterol Reducing Activity of Para-aminosalicylate)
  1777. Particle size reduction effectively enhances the cholesterollowering activities of carrot insoluble fiber and cellulose
  1778. Partners in lowering cholesterol: comparison of a multidisciplinary educational program, monetary incentives, or usual care in the treatment of dyslipidemia identified …
  1779. Pasta with cholesterollowering effect on human health
  1780. Patient booklet on lowering LDL cholesterol levels.
  1781. PCSK9 & lowering LDL cholesterol
  1782. PCSK9 and atherosclerosis: Beyond LDL-cholesterol lowering
  1783. PCSK9 genetic variants, life-long lowering of LDL-cholesterol and cognition: a large-scale Mendelian randomization study
  1784. PCSK9 inhibition and LDL cholesterol lowering: the biology of an attractive therapeutic target and critical review of the latest clinical trials
  1785. PCSK9 inhibition: a new player in cholesterollowering therapies?
  1786. PCSK9 inhibition: the dawn of a new age in cholesterol lowering?
  1787. PCSK9 inhibitors and their role in high-risk patients in reducing LDL cholesterol levels: alirocumab
  1788. PCSK9 inhibitors and their role in high-risk patients in reducing LDL cholesterol levels: evolocumab
  1789. PCSK9 inhibitors as LDL cholesterollowering agents: Rationale, concerns and preliminary outcomes
  1790. PCSK9 Inhibitors for lowering cholesterol: Ready for Prime Time?
  1791. PCSK9 inhibitors: novel therapeutic strategies for lowering LDL-cholesterol
  1792. PCSK9-A New and Potent Approach to lowering cholesterol
  1793. PCSK9—an exciting target for reducing LDL-cholesterol levels
  1794. PCSK9, a novel target for lowering LDL cholesterol: promise and progress
  1795. PCSK9: A Major New Advance in cholesterollowering Therapy
  1796. PCV2: THE COST-EFFECTIVENESS OF cholesterol lowering TREATMENT IN THE PRIMARY PREVENTION OF CORONARY HEART DISEASE: THE CASE …
  1797. PE-151: cholesterollowering Agents Decreased NAS Score without Intrahepatic Fat Improvement in Patients with Non-alcoholic Fatty Liver Disease: Systematic …
  1798. People with hyperlipidaemia who followed a dietary portfolio of cholesterollowering foods achieved a greater reduction in LDL cholesterol over 6 months than those …
  1799. Per os colchicine administration in cholesterol fed rabbits: Triglycerides lowering effects without affecting atherosclerosis progress
  1800. Per os colchicine administration in cholesterol fed rabbits: Triglycerides lowering effects without affecting atherosclerosis progress
  1801. Persistent inflammatory residual risk despite aggressive cholesterollowering therapy: further evidence fuelling the dual target concept
  1802. Perspectives in cholesterollowering therapy: the role of ezetimibe, a new selective inhibitor of intestinal cholesterol absorption
  1803. PERSPECTIVES IN LIPID lowering THERAPY. NEW THERAPIES TARGETING LDL–cholesterol
  1804. Perspectives on soy protein as a nonpharmacological approach for lowering cholesterol
  1805. Pharmacogenetics and pharmacogenomics of cholesterollowering therapy
  1806. Pharmacogenomics and pharmacogenetics of cholesterollowering therapy
  1807. Pharmacogenomics of cholesterollowering therapy
  1808. Pharmacokinetic/Pharmacodynamic Modelling to Describe the cholesterol lowering Effect of Rosuvastatin in People Living with HIV
  1809. Pharmacokinetics, Safety and cholesterol lowering in Healthy Volunteers Treated with Single and Multiple Doses of Madrigal’s 3196 Liver-directed Thyroid Hormone …
  1810. Pharmacologic options for aggressive low-density lipoprotein cholesterol lowering: benefits versus risks
  1811. Pharmacological cholesterol lowering reverses fibrotic NASH in obese, diabetic mice with metabolic syndrome
  1812. Pharmacological profile of tazasubrate, A new cholesterollowering agent
  1813. Pharmacological targeting of the atherogenic dyslipidemia complex: the next frontier in CVD prevention beyond lowering LDL cholesterol
  1814. Phenome-wide association analysis of LDL-cholesterol lowering genetic variants in PCSK9
  1815. Phenome-wide association analysis of LDL-cholesterol lowering genetic variants in PCSK9
  1816. Phenome-wide association analysis of LDL-cholesterol lowering genetic variants in PCSK9
  1817. Physiological and Biochemical Characters of the cholesterollowering Lactobacillus Plantarum LpT1 and LpT2
  1818. Phytochemical Analysis and cholesterol lowering Efficiency of Averrhoa Carambola Linn (star Fruit).: An Overview
  1819. Phytochemical analysis of fruit extracts of Baccaurea courtallensis and evaluation of cholesterol lowering property
  1820. Phytochemical characterization of Averrhoa bilimbi and in vitro analysis of cholesterol lowering effect on fatty food materials
  1821. Phytochemical profiling of Garcinia gummi-gutta (Malabar tamarind) and in vitro analysis of cholesterol lowering effect
  1822. Phytosterol compositions of enriched products influence their cholesterollowering efficacy: a meta-analysis of randomized controlled trials
  1823. Phytosterols dissolved in diacylglycerol oil reinforce the cholesterollowering effect of low-dose pravastatin treatment
  1824. Phytosterols: physiologic and metabolic aspects related to cholesterollowering properties
  1825. Pilot study examining the effect of cholesterol lowering on platelet nitric oxide responsiveness and arterial stiffness in subjects with isolated mild …
  1826. Plant stanol content remains stable during storage of cholesterollowering functional foods
  1827. Plant Stanol Ester Margarine as a Serum cholesterol lowering Agent in Healthy Children on a diet Low in Saturated Fat and cholesterol. The STRIP Project
  1828. Plant Stanol Ester: Review of cholesterollowering Efficacy and Implications for Coronary Heart Disease Risk Reduction
  1829. Plant sterol and stanols—comparison and contrasts. Sterols versus stanols in cholesterollowering: is there a difference?
  1830. Plant sterol-enriched spread enhances the cholesterollowering potential of a fat-reduced diet
  1831. Plant sterols and stanols as cholesterollowering ingredients in functional foods
  1832. Plant sterols and stanols as dietary factors reducing hypercholesterolemia by inhibiting intestinal cholesterol absorption
  1833. Plant sterols are efficacious in lowering plasma LDL and non-HDL cholesterol in hypercholesterolemic type 2 diabetic and nondiabetic persons
  1834. Plant sterols as cholesterollowering agents: clinical trials in patients with hypercholesterolemia and studies of sterol balance
  1835. Plant sterols: chemical and enzymatic structural modifications and effects on their cholesterollowering activity
  1836. Plant sterols/stanols as cholesterol lowering agents: a meta-analysis of randomized controlled trials
  1837. Plaque rupture and thrombosis are reduced by lowering cholesterol levels and crystallization with ezetimibe and are correlated with fluorodeoxyglucose positron …
  1838. Plaque stabilization by intensive LDL-cholesterol lowering therapy with atorvastatin is delayed in type 2 diabetic patients with coronary artery disease—Serial …
  1839. Plasma and hepatic cholesterollowering effects of tomato pomace, tomato seed oil and defatted tomato seed in hamsters fed with high-fat diets
  1840. Plasma and Liver cholesterol lowering Substances in Gyrophora Esculenta (Sogi) I. Effects of Gyrophora esculenta (Sogi) on the plasma and liver cholesterol in rats
  1841. Plasma cholesterol and lipoprotein lowering effect of Anna Pavala Sindhooram
  1842. Plasma cholesterol lowering action of bile acid binding polymers in experimental animals
  1843. Plasma cholesterol lowering in an AngII‑infused atherosclerotic mouse model with moderate hypercholesterolemia
  1844. Plasma cholesterol reducing effect of FR129169, a novel acyl-CoA: cholesterol acyltransferase inhibitor, in the rat
  1845. Plasma cholesterollowering activity of dietary dihydrocholesterol in hypercholesterolemia hamsters
  1846. Plasma cholesterollowering activity of gingerol-and shogaol-enriched extract is mediated by increasing sterol excretion
  1847. Plasma cholesterollowering activity of lard functionalized with mushroom extracts is independent of Niemann–Pick C1-like 1 Protein and ABC sterol transporter …
  1848. Plasma cholesterollowering activity of monocyte colony-stimulating factor (M-CSF).
  1849. Plasma cholesterollowering activity of piperine is mediated by inhibition on cholesterol absorption via down-regulation of intestinal ACAT2 and MTP
  1850. Plasma cholesterollowering Activity of Soybean Germ Phytosterols
  1851. Plasma cholesterollowering and transient liver dysfunction in mice lacking squalene synthase in the liver
  1852. Plasma cholesterollowering effect on rats of dietary fiber extracted from immature plants
  1853. Plasma cholesterollowering Effects of Alpiniae katsumadaii Extract as an Inhibiter of Pancreatic cholesterol Esterase Activity
  1854. Plasma cholesterollowering Effects of Alpiniae katsumadaii Extract as an Inhibiter of Pancreatic cholesterol Esterase Activity
  1855. Plasma cholesterollowering effects of soymilk and okara treated by lactic acid fermentation in rats
  1856. Plasma cholesterollowering potential of edible-oil blends suitable for commercial use
  1857. Plasma cholesterol, lipid lowering, and risk for cancer
  1858. Plasma LDL cholesterol lowering by plant phytosterols in a hamster model
  1859. Plasma lipoprotein composition in cholesterol fed rabbits treated with pirinixil (BR 931), a new lipid lowering agent
  1860. Plasmenylethanolamine: growth factor for cholesterol-reducing Eubacterium.
  1861. Platelet reactivity and arachidonic acid metabolism in type II hyperlipoproteinaemia and its modification by cholesterollowering agents.
  1862. Pleiotropic effects and cholesterollowering therapy
  1863. Policies for the prevention of coronary heart disease through cholesterollowering
  1864. Pollen as a cholesterollowering Agent
  1865. Polysorbates as novel lipid-modulating candidates for reducing serum total cholesterol and low-density lipoprotein levels in hyperlipidemic C57BL/6J mice and rats
  1866. Polyunsaturated fatty acids result in greater cholesterol lowering and less triacylglycerol elevation than do monounsaturated fatty acids in a dose-response …
  1867. Postprandial reverse cholesterol transport in type 2 diabetic patients: effect of a lipid lowering treatment
  1868. Postscripts from the Post Coronary Artery Bypass Graft Trial: the sustained benefit of more aggressive cholesterol lowering and the enigma of low-dose …
  1869. Potencies of vitamin D analogs, 1α‐hydroxyvitamin D3, 1α‐hydroxyvitamin D2 and 25‐hydroxyvitamin D3, in lowering cholesterol in hypercholesterolemic mice in vivo
  1870. POTENCY OMEGA-9 OLEIC ACID IN THE AVOCADO FRUIT MESOCARP cholesterol lowering BLOOD SERUM
  1871. Potent cholesterol lowering Effect by HM12525A, A Novel Long-acting GLP-1/Glucagon Dual Receptor Agonist
  1872. Potent cholesterollowering effect by human granulocyte-macrophage colony-stimulating factor in rabbits. Possible implications of enhancement of macrophage …
  1873. Potential effect on coronary-heart-disease morbidity of lowering the blood-cholesterol
  1874. Potential effects of antioxidant and serum cholesterollowering effects of Gynura bicolor water extracts in Syrian Hamster
  1875. Potential fat-lowering and prebiotic effects of enzymatically treated okara in high-cholesterol-fed Wistar rats
  1876. Potential for cholesterol lowering in secondary prevention of coronary heart disease in Europe: findings from EUROASPIRE study
  1877. Potential role of nonstatin cholesterol lowering agents
  1878. Practical Possibilities for lowering Serum cholesterol: Results of a Double-Blind Study
  1879. Pravastatin attenuates cardiovascular inflammatory and proliferative changes in a rat model of chronic inhibition of nitric oxide synthesis by its cholesterollowering
  1880. Pravastatin has cholesterollowering independent effects on the artery wall of atherosclerotic monkeys
  1881. Pravastatin in heterozygous familial hypercholesterolemia: low-density lipoprotein (LDL) cholesterollowering effect and LDL receptor activity on skin fibroblasts
  1882. Pravastatin reduces thrombogenicity by mechanisms beyond plasma cholesterol lowering
  1883. Pravastatin sodium activates endothelial nitric oxide synthase independent of its cholesterollowering actions
  1884. Pravastatin, a new cholesterol synthesis inhibitor for lowering increased serum cholesterol
  1885. Pravastatin: an antithrombotic effect independent of the cholesterollowering effect
  1886. Pre-freezing equilibration for 22 h improves post-thaw sperm functions in cryopreserved ram semen by reducing cholesterol efflux
  1887. Prediction of individualized lifetime benefit from cholesterol lowering, blood pressure lowering, antithrombotic therapy, and smoking cessation in apparently healthy …
  1888. Predictors of cholesterol lowering with Corn Oil Consumption: Results from a Pooled Analysis of Randomized, Free-living Feeding Trials (P08-112-19)
  1889. Preliminary evaluation of a non-dietary regimen for reducing cholesterol levels in the aged.
  1890. Preliminary probiotic and technological characterization of Pediococcus pentosaceus strain KID7 and in vivo assessment of its cholesterollowering activity
  1891. Preparation and characterization of immobilized phospholipase A2 on chitosan beads for lowering serum cholesterol concentration
  1892. Preparation of phytosteryl ornithine ester hydrochloride and improvement of its bioaccessibility and cholesterol-reducing activity in vitro
  1893. Preparation technology of mixed starter cultures about cholesterollowering effects
  1894. Prescription of lipid-lowering medications for patients with type 2 diabetes mellitus and risk-associated LDL cholesterol: a nationwide study of guideline …
  1895. Prevalence of cholelithiasis in men and women ingesting a serum-cholesterollowering diet.
  1896. Prevalence of depression in patients with coronary heart disease (CHD) on cholesterol lowering therapy with pravastatin
  1897. Preventing breast cancer recurrence through reducing dietary intake of oxidized cholesterol: An analytical tool.
  1898. Preventing cardiovascular disease in hypertension: effects of lowering blood pressure and cholesterol
  1899. Preventing coronary artery disease by lowering cholesterol levels: fifty years from bench to bedside
  1900. Prevention cholesterol of Stroke by lowering Blood Concentrations
  1901. Prevention of atherosclerosis with low-density lipoprotein cholesterol lowering—lipoprotein changes and interactions: the SANDS study
  1902. Prevention of myocardial infarction by reducing serum cholesterol levels. High-risk strategies should be limited
  1903. Prevention of stroke by cholesterollowering: a meta-analysis
  1904. Primary prevention and coronary heart disease: the economic benefits of lowering serum cholesterol.
  1905. Primary prevention of cardiovascular disease: The past, present, and future of blood pressure-and cholesterollowering treatments
  1906. Primary prevention remains expensive, notwithstanding the consensus on lowering serum cholesterol levels
  1907. Primary prevention using cholesterollowering medications in patients meeting new treatment guidelines: a retrospective cohort analysis
  1908. Primary Prevention Using cholesterollowering Medications in Patients Meeting New Treatment Guidelines: A Retrospective Cohort Analysis
  1909. Pro and con: low-density lipoprotein cholesterol lowering is and will be the key to the future of lipid management
  1910. Probiotic Characterization of cholesterollowering Lactobacillus fermentum MJM60397
  1911. Probiotic consumption does not enhance the cholesterollowering effect of soy in postmenopausal women
  1912. PROBIOTIC DEVELOPMENT OF ACID BACTERIA OF LUBRICATED POTENTIAL WASTE REDUCING CHICAGEN cholesterol BEHAVIOR BROILER STRAIN …
  1913. Probiotics and the BSH-related cholesterol lowering mechanism: a Jekyll and Hyde scenario
  1914. Probucol reduces plasma and aortic wall oxysterol levels in cholesterol fed rabbits independently of its plasma cholesterol lowering effect
  1915. Processing method modulates the effectiveness of black beans for lowering blood cholesterol in spontaneously hypertensive rats
  1916. Processing of oat: The impact on oat’s cholesterol lowering effect
  1917. Producing of bacterial concentrates with high cholesterol lowering activity
  1918. Production and quantification of eritadenine, a cholesterol reducing compound in shiitake (Lentinus edodes)
  1919. Production of apolipoprotein E-rich LDL by the liver. The effect of dietary cholesterol and some lipid lowering agents.
  1920. Progress and prospects of biological approaches targeting PCSK9 for cholesterollowering, from molecular mechanism to clinical efficacy
  1921. Progress in the Effect of Lactic Acid Bacteria on cholesterollowering and Its Mechanism [J]
  1922. Progress on cholesterollowering effect and mechanism of lactic acid bacteria
  1923. Progress on the Mechanism of Lactic Acid Bacteria in Reducing cholesterol
  1924. Progression of coronary artery calcium and risk of first myocardial infarction in patients receiving cholesterollowering therapy
  1925. Progression of coronary artery disease predicts clinical coronary events: long-term follow-up from the cholesterol lowering Atherosclerosis Study
  1926. Project ALBA-Creating a marketing strategy for a cholesterol lowering dairy product
  1927. Properties and cholesterol lowering effect of cholesterol-reduced milk supplemented with evening primrose oil
  1928. Properties of nanopowdered chitosan and its cholesterol lowering effect in rats
  1929. Property changes and cholesterollowering effects in evening primrose oil‐enriched and cholesterol‐reduced yogurt
  1930. Proposed mechanisms of cholesterollowering action of plant sterols
  1931. Proprotein convertase subtilisin/kexin type 9 inhibitor therapy—breakthrough in low-density lipoprotein cholesterol lowering, breakdown in value
  1932. Prospective meta-analysis of cholesterollowering studies: the Prospective Pravastatin Pooling (PPP) Project and the cholesterol Treatment Trialists (CTT) …
  1933. Protective role of soybean lecithin in reducing hypercholesterolemia and DNA fragmentation inducing by high cholesterol in adult male rats
  1934. Proucol (DH 581) 의고 cholesterol 혈증에 대한 임상적 효과 (Effect of a new cholesterol Reducing Agent-Probucol (DH-581) in Korean Patents with …
  1935. Prudent Reducing diet: Effect on Serum cholesterol: Study of 111 Obese Men 50-59 Years Old
  1936. Psychological and cognitive function: predictors of adherence with cholesterol lowering treatment
  1937. Psychological aspects of the measures for lowering the cholesterol level in a population study
  1938. Psychometric properties of the Perceived Therapeutic Efficacy Scale for adhering to a cholesterollowering diet
  1939. Psyllium augments the cholesterollowering action of cholestyramine in hamsters by enhancing sterol loss from the liver
  1940. Psyllium Feeding Increases the Rates of Hepatic and Intestinal Sterol Biosynthesis While lowering the Plasma and Hepatic cholesterol Levels in Rats
  1941. Psyllium is superior to wheat dextrin for lowering elevated serum cholesterol
  1942. Purification and characterization of a novel cholesterollowering protein from the seeds of Senna obtusifolia
  1943. Quantitative comparison of the efficacy of various compounds in lowering intracellular cholesterol levels in Niemann-Pick type C fibroblasts
  1944. Quercetin activates AMP‐activated protein kinase by reducing PP2C expression protecting old mouse brain against high cholesterol‐induced neurotoxicity
  1945. R230C but not− 565C/T variant of the ABCA1 gene is associated with type 2 diabetes in Mexicans through an effect on lowering HDL-cholesterol levels
  1946. Raising HDL-cholesterol and lowering CHD risk: does intervention work?
  1947. Raising high-density lipoprotein cholesterol and lowering low-density lipoprotein cholesterol as adjunctive therapy to coronary artery revascularization
  1948. Randomised placebo controlled trial of effect on mood of lowering cholesterol concentration
  1949. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S)
  1950. Randomized trial of the effects of cholesterollowering dietary treatment on psychological function
  1951. Randomized trial of the effects of cholesterollowering with simvastatin on peripheral vascular and other major vascular outcomes in 20,536 people with …
  1952. Rapid and substantial lowering of human serum cholesterol by mevinolin (MK-803), an inhibitor of hydroxymethylglutaryl-coenzyme A reductase
  1953. Rapid screening for potential cholesterollowering peptides using naturally derived micelle preparation
  1954. Ratio of lathosterol to campesterol in serum predicts the cholesterollowering effect of sitostanol-supplemented margarine.
  1955. Rationale and design features of a clinical trial examining the effects of cholesterol lowering and angiotensin-converting enzyme inhibition on coronary atherosclerosis …
  1956. Rationale and design of a secondary prevention trial of increasing serum high-density lipoprotein cholesterol and reducing triglycerides in patients with clinically …
  1957. Rationale and design of the Myocardial Ischemia Reduction with Aggressive cholesterol lowering (MIRACL) study that evaluates atorvastatin in unstable angina …
  1958. Rationale for cholesterol lowering
  1959. Rationale, design and baseline characteristics of a clinical trial comparing the effects of robust vs conventional cholesterol lowering and intima media thickness in …
  1960. Rationale, design, and baseline characteristics of a randomized trial to assess the effect of cholesterol lowering on the progression of aortic stenosis: the Aortic …
  1961. RE: The lowering of cholesterol due to the starch gelatinization of pectin, the soluble dietary fiber found in garbanzo beans
  1962. Reasons for the lack of salutary effects of cholesterollowering interventions in end-stage renal disease populations
  1963. Recent perspectives on the role of nutraceuticals as cholesterollowering agents
  1964. Reciprocal influence of fermentations and bile acid excretion on cholesterollowering effect of fermentable carbohydrate
  1965. Reconstituted high-density lipoprotein attenuates cholesterol crystal–induced inflammatory responses by reducing complement activation
  1966. Recovery and determination of cholesterollowering compounds from Olea europaea seeds employing pressurized liquid extraction and gas chromatography-mass …
  1967. Recovery and determination of cholesterollowering compounds from Olea europaea seeds employing pressurized liquid extraction and gas chromatography-mass …
  1968. Red yeast rice’as a cholesterollowering substance? Caution is warranted
  1969. Reducing Bad cholesterol with BAC
  1970. Reducing blood cholesterol by a healthy diet.
  1971. Reducing blood cholesterol levels in children: what have we learned from the DISC study?
  1972. Reducing blood cholesterol levels in patients with peripheral vascular disease: dietitian or diet fact sheet?
  1973. Reducing cardiovascular disease risk: cholesterol and diet
  1974. Reducing cardiovascular risk by targeting high-density lipoprotein cholesterol
  1975. Reducing cardiovascular risk: trends in risk, risk assessment, and cholesterol management.
  1976. Reducing cholesterol and atherosclerosis
  1977. Reducing cholesterol and atherosclerosis: the importance of cellular adhesion molecules?
  1978. Reducing cholesterol and fat intake improves glucose tolerance by enhancing β cell function in nondiabetic subjects
  1979. REDUCING cholesterol AND OXIDATIVE DETERIORATION OF IRAQI BEEF PASTIRMA INOCULATED BY LACTIC ACID BACTERIA
  1980. Reducing cholesterol does not reduce mortality
  1981. Reducing cholesterol Intake: Are the recommendations valid?
  1982. Reducing cholesterol levels
  1983. Reducing cholesterol levels in elderly persons
  1984. Reducing cholesterol Levels in Elderly Persons
  1985. Reducing cholesterol Levels in Elderly Persons-Reply
  1986. Reducing cholesterol levels to decrease cardiovascular events: the role of new proprotein convertase subtilisin/kexin type 9 inhibitors
  1987. Reducing cholesterol to prevent coronary heart disease
  1988. Reducing cholesterol with plant stanol esters
  1989. Reducing coronary risk by raising HDL-cholesterol: risk modelling the addition of nicotinic acid to existing therapy
  1990. Reducing dietary fat and cholesterol consumption: an evaluation of a behaviorally focused nutrition education program
  1991. Reducing dietary intake of fat and cholesterol in children
  1992. Reducing dietary Intake of Fat and cholesterol in Children-Reply
  1993. Reducing egg cholesterol through dietary addition of ginger and garlic in quails
  1994. Reducing elevated plasma LDL cholesterol: the central role of the LDL receptor
  1995. Reducing fat and cholesterol in foodservice
  1996. Reducing hepatic PKD activity lowers circulating VLDL cholesterol
  1997. Reducing Hepatic Very-Low-Density Lipoprotein Production by Knockdown of Microsomal Triglyceride Transfer Protein Decreases Transintestinal cholesterol
  1998. Reducing high blood cholesterol in children
  1999. Reducing high blood cholesterol levels: recommendations from the National cholesterol Education Program
  2000. Reducing LDL cholesterol with exon-skipping antisense oligonucleotides
  2001. Reducing low density lipoprotein-cholesterol levels by apheresis
  2002. Reducing low-density lipoprotein cholesterol levels in an ambulatory care system: results of a multidisciplinary collaborative practice lipid clinic compared with …
  2003. Reducing low-density lipoprotein cholesterol–treating to target and meeting new European goals
  2004. Reducing Low‐Density Lipoprotein cholesterol After Myocardial Infarction in Older Individuals, Levels Versus Change: Can Observational Studies Answer the …
  2005. Reducing residual cardiovascular risk: the relevance of raising high-density lipoprotein cholesterol in patients on cholesterollowering treatment
  2006. Reducing risk by raising HDL-cholesterol: the evidence
  2007. Reducing serum cholesterol
  2008. Reducing serum cholesterol levels in women
  2009. Reducing serum cholesterol. Confusion remains over whom to treat.
  2010. Reducing serum cholesterol. Lower cholesterol of doubtful benefit to anyone.
  2011. Reducing shell egg cholesterol content. I. Overview, genetic approaches, and nutritional strategies
  2012. Reducing shell egg cholesterol content. II. Review of approaches utilizing non-nutritive dietary factors or pharmacological agents and an examination of emerging …
  2013. Reducing stroke in women with risk factor management: blood pressure and cholesterol
  2014. Reducing the egg cholesterol level by including emulsified sitosterol in standard chicken diet
  2015. Reducing the risk for stroke in patients with myocardial infarction: a Myocardial Ischemia Reduction with Aggressive cholesterol lowering (MIRACL) substudy
  2016. Reducing the serum cholesterol level with a diet high in animal fat.
  2017. Reducing Total dietary Fat Without Reducing Saturated Fat Does Not Significantly Lower Total Plasma cholesterol Levels in Normal Males
  2018. Reducing total dietary fat without reducing saturated fatty acids does not significantly lower total plasma cholesterol concentrations in normal males
  2019. Reduction of high density lipoprotein cholesterol and apolipoprotein AI concentrations by a lipid-lowering diet
  2020. Reduction of ischemic events in Improved Reduction of Outcomes: Vytorin Efficacy International Trial: Intensive cholesterol lowering or ezetimibe antithrombotic effects …
  2021. Regional myocardial perfusion reserve during cholesterol lowering therapy compared with PTCA, assessed with PET
  2022. Regions of conformational flexibility in the proprotein convertase PCSK9 and design of antagonists for LDL cholesterol lowering
  2023. Regression of atherosclerosis in humans by lowering serum cholesterol
  2024. Regression of atherosclerosis: the clinical and metabolic response to cholesterollowering
  2025. REGRESSION OF CORONARY ARTERY DISEASE ACHIEVED BY lowering LDL-cholesterol LEVELS
  2026. Regulation of hepatic lanosterol 14α-demethylase gene expression by dietary cholesterol and cholesterollowering agents
  2027. Regulatory effect of Phikud Navakot extract on HMG-CoA reductase and LDL-R: potential and alternate agents for lowering blood cholesterol
  2028. Relapsing acute pancreatitis induced by re-exposure to the cholesterol lowering agent bezafibrate
  2029. Relationship between low-density lipoprotein cholesterol, lipid lowering agents and the risk of stroke: a meta-analysis of observational studies and randomized …
  2030. Relationship Between Low‐Density Lipoprotein cholesterol and Lipoprotein (a) lowering in Response to PCSK9 Inhibition With Evolocumab
  2031. Relationship between low‐density lipoprotein cholesterol, free proprotein convertase subtilisin/kexin type 9, and alirocumab levels after different lipid‐lowering
  2032. Relationship between plasma cholesterollowering effect of guar gum and its cecal fermentation products in rats
  2033. Relationship between the cholesterol ester transfer protein TaqIB polymorphism and the lipid-lowering effect of atorvastatin in patients with coronary …
  2034. Relationship between total mortality and cholesterol reduction as found by meta-regression analysis of randomized cholesterollowering trials
  2035. Relationship of self-efficacy to cholesterol lowering and dietary change in hyperlipidemia,
  2036. Renal safety of intensive cholesterollowering treatment with rosuvastatin: a retrospective analysis of renal adverse events among 40,600 participants in the …
  2037. Reply to:“Appropriate use of cholesterollowering therapy”
  2038. Research Advances on Nutritional Approaches for Reducing cholesterol Content in Eggs
  2039. Research advances with regards to clinical outcome and potential mechanisms of the cholesterollowering effects of probiotics
  2040. RESEARCH AND DEVELOPMENT FINAL PROJECT BROSO MUFFIN (lowering cholesterol muffin from brown rice flour and soy milk)
  2041. Research on screening of cholesterol-reducing lactobacillus.
  2042. Research on screening of cholesterol-reducing probiotics from pickle vegetable
  2043. Research on the Effect of cholesterol lowering in Vitro of Alpinia officinarum Hance Crude Polysaccharide
  2044. Research Progress in cholesterollowering Functional Bioactives and Mechanism
  2045. Research Progress in cholesterol-reducing Effect of Plant Saponins and Their Mechanism [J]
  2046. Research progress in the mechanisms of lowering cholesterol of several common kinds of microorganisms
  2047. Resolvin E1 attenuates atherosclerosis in absence of cholesterollowering effects and on top of atorvastatin
  2048. Response by Bonaca and Sabatine to Letters Regarding Article,“Low-Density Lipoprotein cholesterol lowering With Evolocumab and Outcomes in Patients With …
  2049. Response to a cholesterollowering diet: efficacy is greater in hypercholesterolemic subjects even after adjustment for regression to the mean
  2050. Response to a cholesterollowering diet: Efficacy Is Greater in Hypercholesterolemic Subjects Even After Adjustment for Regression to the Mean
  2051. Response to Comments from Ntanios et al. Regarding “The cholesterollowering Action of Plant Stanol Esters”
  2052. Restraint of cholesterol accumulation in tissue pools associated with drastic short-term lowering of serum cholesterol levels by clofibrate or cholestyramine in …
  2053. Results of recent large cholesterollowering trials and implications for clinical management
  2054. Resveratrol protects against diet-induced atherosclerosis by reducing low-density lipoprotein cholesterol and inhibiting inflammation in apolipoprotein E …
  2055. Reversibility of atherosclerosis–evolving perspectives from two arterial imaging clinical trials: the cholesterol lowering atherosclerosis regression study and the …
  2056. Reversibility of renal injury with cholesterol lowering in hyperlipidemic diabetic mice
  2057. Review of cholesterollowering therapy: coronary angiographic and events trials
  2058. Review of clinical studies on cholesterollowering response to soy protein.
  2059. Review of the major intervention trials of lowering coronary artery disease risk through cholesterol reduction
  2060. REVIEW OF THE STUDIES OF SOY PROTEINS FOR REDUCING SERUM cholesterol
  2061. Reviews: Fluvastatin: effects beyond cholesterol lowering
  2062. Revisiting the effectiveness of the National cholesterol Education Program’s Step I and Step II diets: cholesterollowering diets in a pharmaceutically driven world
  2063. RG 12561 (Dalvastatin): A novel synthetic inhibitor of HMG-CoA reductase and cholesterollowering agent
  2064. Riboflavin Deficiency Alters cholesterol Homeostasis Partly by Reducing Apolipoprotein B100 Synthesis in HepG2 Cells
  2065. Ro 48-8.071, a new 2, 3-oxidosqualene: lanosterol cyclase inhibitor lowering plasma cholesterol in hamsters, squirrel monkeys, and minipigs: comparison to …
  2066. Role and classification of cholesterollowering functional foods
  2067. Role of beef and beef tallow, an enriched source of stearic acid, in a cholesterollowering diet
  2068. Role of Berberis lycium in reducing serum cholesterol in broilers
  2069. Role of cholesterol 7α-hydroxylase (CYP7A1) in nutrigenetics and pharmacogenetics of cholesterol lowering
  2070. Role of dietary Supplements in lowering LDL-cholesterol
  2071. Role of dietary supplements in lowering low-density lipoprotein cholesterol: a review
  2072. Role of Lipid-lowering Therapy in Low-Density Lipoprotein cholesterol Goal Attainment: Focus on Patients With Acute Coronary Syndrome
  2073. Role of nonstatin therapies for low-density lipoprotein cholesterol lowering in management of atherosclerotic cardiovascular disease risk
  2074. Role of plant sterols in cholesterol lowering
  2075. Role of soy protein in cholesterollowering: How good is it?
  2076. Role of sweet orange (Citrus sinensis) waste in lowering the meat cholesterol and fat of Padjadjaran sheep
  2077. Role of the gut microbiota and their metabolites in modulating the cholesterollowering effects of citrus pectin oligosaccharides in C57BL/6 mice
  2078. Rosuvastatin could modulate insulin signaling and inhibit atheroclerosis beyond its plasma cholesterollowering effect in insulin-resistant mice
  2079. Rosuvastatin increased serum osteocalcin levels independent of its serum cholesterollowering effect in patients with type 2 diabetes and hypercholesterolemia
  2080. Rosuvastatin may modulate insulin signaling and inhibit atherogenesis beyond its plasma cholesterollowering effect in insulin-resistant mice
  2081. Rosuvastatin reduces atherosclerosis development beyond and independent of its plasma cholesterollowering effect in APOE* 3-Leiden transgenic mice: evidence …
  2082. Rosuvastatin: Beyond the cholesterollowering effect
  2083. RPR 101821, a new potent cholesterollowering agent: inhibition of squalene synthase and 7-dehydrocholesterol reductase
  2084. RPR 107393, a potent squalene synthase inhibitor and orally effective cholesterollowering agent: comparison with inhibitors of HMG-CoA reductase
  2085. Safety and effectiveness of combined antihypertensive and cholesterollowering therapy in high-/very high-risk patients
  2086. Safety and effectiveness of probucol as a cholesterol lowering agent.
  2087. Safety and efficacy of early aggressive versus cholesterol-driven lipid-lowering strategies in heart transplantation: a pilot, randomized, intravascular ultrasound study
  2088. Safety and efficacy of long-term diet and diet plus bile acid-binding resin cholesterollowering therapy in 73 children heterozygous for familial hypercholesterolemia
  2089. Safety and tolerability of cholesterol lowering with simvastatin during 5 years in the Scandinavian Simvastatin Survival Study
  2090. Safety aspects and cholesterollowering efficacy of chitosan tablets
  2091. Safety aspects and cholesterollowering efficacy of low fat dairy products containing plant sterols
  2092. Scandinavian simvastatin survival study (4S): Cost-effectiveness (CE) of cholesterol lowering treatment
  2093. Scientific Opinion on the substantiation of a health claim related to 3 g/day plant stanols as plant stanol esters and lowering blood LDL‐cholesterol and reduced risk of …
  2094. Scientific opinion on the substantiation of a health claim related to 3 g/day plant sterols/stanols and lowering blood LDL‐cholesterol and reduced risk of (coronary) …
  2095. Scientific Opinion on the substantiation of a health claim related to barley beta‐glucans and lowering of blood cholesterol and reduced risk of (coronary) heart disease …
  2096. Scientific Opinion on the substantiation of a health claim related to oat beta glucan and lowering blood cholesterol and reduced risk of (coronary) heart disease …
  2097. Screening and Identification of a Strain of Lactobacillus with cholesterol-reducing Ability and Its Application in Pickles
  2098. Screening and identification of cholesterollowering lactic acid bacteria from Dong minority traditional fermented sour fish and meat
  2099. Screening and identification of cholesterol-reducing KF5 strain
  2100. Screening and identification of cholesterol-reducing Lactic acid bacteria.
  2101. Screening and molecular characterization of cholesterollowering lactic acid bacteria isolated from African oil palm wine (Elaeis guineensis) and corn beer.
  2102. Screening for cholesterollowering probiotic based on deoxycholic acid removal pathway and studying its functional mechanisms in vitro
  2103. Screening for cholesterollowering probiotics from lactic acid bacteria isolated from corn silage based on three hypothesized pathways
  2104. Screening of bile salt hydrolase-active lactic acid bacteria for potential cholesterollowering probiotic use
  2105. Screening of Bile Salt Hydrolase-active Lactic Acid Bacteria from Philippine Cocowater Kefir as Potential cholesterollowering Probiotics
  2106. Screening of cholesterollowering Bifidobacterium from Guizhou Xiang pigs, and evaluation of its tolerance to oxygen, acid, and bile
  2107. Screening of cholesterollowering Lactic Acid Bacteria and Synergic Effect with Chinese Herbal Medicines
  2108. Screening of cholesterol-reducing bifidobacterium in vitro [J]
  2109. Screening of cholesterol-reducing lactic acid bacteria and its activity in cholesterol-reducing
  2110. Screening of cholesterol-reducing lactobacillus in vitro [J]
  2111. Screening of indigenous lactic acid bacteria for cholesterol lowering and additional probiotic attributes
  2112. Screening of isolated potential probiotic lactic acid bacteria for cholesterol lowering property and bile salt hydrolase activity
  2113. Screening of lactic acid bacteria with cholesterollowering and triglyceride-lowering activity in vitro and evaluation of probiotic function
  2114. Screening of Lactobacillus with cholesterollowering Activity and Its Application in Inner Mongolian Fermented Sausages
  2115. Secondary Prevention Using cholesterollowering Medications in Patients Meeting New Treatment Guidelines: A Retrospective Cohort Analysis
  2116. Secondary prevention with lipid lowering therapy in familial hypercholesterolemia: a correlation between new evolution of stenotic lesion and achieved cholesterol
  2117. Selecting and Identification cholesterollowering Ability and Acid Bile Tolerance of Lactic Acid Bacteria
  2118. Selection and physico-chemical characteristics of lactic acid bacteria which had cholesterol lowering activities
  2119. Selection of cholesterollowering lactic acid bacteria and its effects on rats fed with high-cholesterol diet
  2120. Selection of potential probiotic lactobacilli for cholesterollowering properties and their effect on cholesterol metabolism in rats fed a high-lipid diet
  2121. Selective cholesterol absorption inhibition: a novel strategy in lipid-lowering management.
  2122. Selective cholesterol lowering gene transfer attenuates the development of pressure overload-induced cardiomyopathy in mice
  2123. Selective inhibition of mammalian lanosterol 14. alpha.-demethylase: a possible strategy for cholesterol lowering
  2124. Selenium nanoparticles alleviate hyperlipidemia and vascular injury in ApoE-deficient mice by regulating cholesterol metabolism and reducing oxidative stress
  2125. Separation of high-class alkanols and high-class eicosanoic acids in sugar cane wax and activity of reducing blood cholesterol
  2126. Separation of immunomodulatory and cholesterollowering activities of heterocyclic azaspiranes.
  2127. Separation, Identification and Functional Analysis of cholesterollowering and Triglycerid-lowering Lactic Acid Bacteria
  2128. Sequence variation in NPC1L1 and association with improved LDL-cholesterol lowering in response to ezetimibe treatment
  2129. Serum cholesterol lowering effect of triterpene acetate obtained from Lactuca indica
  2130. Serum cholesterol lowering effects and triterpenoids of the herbs of Lactuca indica
  2131. Serum cholesterollowering Activity of β-Sitosterol Laurate Is Attributed to the Reduction of Both cholesterol Absorption and Bile Acids Reabsorption in Hamsters
  2132. Serum cholesterollowering effect of apple polyphenols in healthy subjects
  2133. Serum cholesterollowering Effect of Fermented Milk and Effect of Intestinal Microflora Composition on Function of Fermented Milk
  2134. Serum cholesterollowering Activity of Granulocyte-Macrophage Colony-Stimulating Factor
  2135. Serum lipoproteins of healthy persons fed a low-fat diet or a polyunsaturated fat diet for three months: a comparison of two cholesterollowering diets
  2136. Serum retinol levels throughout 2 years of cholesterollowering therapy
  2137. Serum-cholesterollowering effect of metronidazole and possible mechanisms of action
  2138. Shear stress activates mitochondrial oxidative phosphorylation by reducing plasma membrane cholesterol in vascular endothelial cells
  2139. Sheffield risk and treatment table for cholesterol lowering for primary prevention of coronary heart disease
  2140. Sheffield Risk and Treatment Table for cholesterol lowering for Primary Prevention of Coronary Heart Disease
  2141. Short term study of sucrose polyester a nonabsorbable fat-like material as a dietary agent for lowering plasma cholesterol
  2142. Short-term cholesterol lowering decreases size and severity of perfusion abnormalities by positron emission tomography after dipyridamole in patients with coronary …
  2143. Short-term effect of two cholesterollowering diets on sterol excretion in ileostomy patients
  2144. Short-term LDL cholesterollowering efficacy of plant stanol esters
  2145. Short-term treatment with a 2-carba analog of cyclic phosphatidic acid induces lowering of plasma cholesterol levels in ApoE-deficient mice
  2146. Should cholesterollowering medications be available in Canada without a prescription?
  2147. Should intensive cholesterol lowering play a role in the management of acute coronary syndromes?
  2148. Should we target HDL cholesterol level in lowering cardiovascular risk
  2149. Sibu olive inhibits artherosclerosis by cholesterol lowering effect in cholesterol fed-rabbit
  2150. Signal transduction via glycosyl phosphatidylinositol-anchored proteins in T cells is inhibited by lowering cellular cholesterol
  2151. Silicon Alleviates Nonalcoholic Steatohepatitis by Reducing Apoptosis in Aged Wistar Rats Fed a High–Saturated Fat, High-cholesterol diet
  2152. Similar cholesterollowering properties of rice bran oil, with varied γ–oryzanol, in mildly hypercholesterolemic men
  2153. Simultaneous lowering of serum phosphate and LDL-cholesterol by sevelamer hydrochloride (RenaGel) in dialysis patients.
  2154. Simultaneous treatment of blood pressure and cholesterol beats the’SILO’approach in lowering cardiovascular risk: results of the CRUCIAL study: opinions in …
  2155. Simvastatin alleviates myocardial contractile dysfunction and lethal ischemic injury in rat heart independent of cholesterollowering effects.
  2156. Simvastatin has anti-inflammatory and antiatherosclerotic activities independent of plasma cholesterol lowering
  2157. Simvastatin increases fibrinolytic activity in human peritoneal mesothelial cells independent of cholesterol lowering
  2158. Simvastatin reduces endotoxin-induced nuclear factor κB activation and mortality in guinea pigs despite lowering circulating low-density lipoprotein cholesterol
  2159. Simvastatin reduces human atrial myofibroblast proliferation independently of cholesterol lowering via inhibition of RhoA
  2160. Simvastatin was cost-effective in lowering cholesterol i coronary heart disease
  2161. Simvastatin, Pravastatin and Lovasting: Three Options for lowering cholesterol
  2162. SLCO1B1 polymorphisms affect atorvastatin pharmacokinetics and cholesterollowering effects in patients with hypercholesterolemia in a microdosing …
  2163. Small interfering RNA to proprotein convertase subtilisin/kexin type 9: transforming LDL-cholesterollowering strategies
  2164. Solubilization of phytosterols in diacylglycerol versus triacylglycerol improves the serum cholesterollowering effect
  2165. Soluble fibre oat and barley ß-glucan enriched products: can we predict cholesterollowering effects?
  2166. Some aspects of sensitivity and resistance to the cholesterol lowering effect of clofibrate
  2167. Sorghum extract exerts cholesterollowering effects through the regulation of hepatic cholesterol metabolism in hypercholesterolemic mice
  2168. Soy and cardiovascular disease: cholesterol lowering and beyond
  2169. Soy protein enhances the cholesterollowering effect of plant sterol esters in cholesterol-fed hamsters
  2170. Speaking of risk, managing uncertainty: decision-making about cholesterol-reducing treatment in general practice.
  2171. Species specificity in the blood cholesterollowering effect of YM‐16638
  2172. Spirulina Improves Antioxidant Status by Reducing Oxidative Stress in Rabbits Fed a High-cholesterol diet
  2173. Spirulina prevents atherosclerosis by reducing hypercholesterolemia in rabbits fed a high-cholesterol diet
  2174. Spreads enriched with three different levels of vegetable oil sterols and the degree of cholesterol lowering in normocholesterolaemic and mildly …
  2175. Stage-specific remodeling of atherosclerotic lesions upon cholesterol lowering in LDL receptor knockout mice
  2176. Stanol esters as a dietary adjunct to cholesterollowering therapies
  2177. Status analysis of certified auxiliary cholesterollowering health foods in China [J]
  2178. Steroid Hormones and cholesterol Metabolism The Mechanism of Serum cholesterollowering Action of an Anabolic Steroid (HMD)
  2179. Strategies for cholesterol lowering at the worksite
  2180. Structure and action of saikosaponins isolated from Bupleurum falcatum L. II. Metabolic actions of saikosaponins, especially a plasma cholesterollowering action.
  2181. Structure–activity studies of protease activating, lipase inhibiting, bile acid binding and cholesterollowering effects of pre-screened cumin seed bioactive peptides
  2182. Studies on a cholesterollowering Microcrystalline Phytosterol Suspension in Oil
  2183. Studies on cholesterollowering Effect and Mechanism of Aerobic Exercise Combined with Oat β-glucan on High-Fat diet Hamsters
  2184. Studies on screening for cholesterollowering agents using phenyl-and chromane substituted compounds (author’s transl)
  2185. Studies on the action mechanism for cholesterollowering of Lactobacillus which yields bile salt hydrolase from kefir grains
  2186. Studies on the Identification and Antagonistic Properties in the Imitative Gastroenteric Environment in a cholesterol Reducing Lactic Acid Bacteria
  2187. Studies on the mechanism of lowering of the cholesterol level by ethyl-alpha-p-chlorophenoxy-isobutyrate (clofibrate)(author’s transl)
  2188. Studies on the plasma cholesterollowering component in Coix
  2189. Studies on the reducing cholesterol ability of selected probiotic strains in vitro
  2190. Studies on the resistance of cholesterollowering of lactic acid bacteria to simulated gastrointestinal circumstance in vitro
  2191. Studies on the Substances Contained in Gyrophora Esculenta lowering Plasma and Liver cholesterol Levels (Part II)
  2192. Study bolsters case against cholesterol; a new study shows that aggressive cholesterollowering therapy can halt the growth of lesions and in some cases shrink them
  2193. Study of Chinese Herbal Medicine Additive on Reducing cholesterol and Serum Enzyme of Ecotype Rabbits
  2194. Study of cholesterollowering effect and safety of simvaglisin on rabbit model of hypercholesterolemia
  2195. Study of Five Alkaloids from Rhizoma Coptidis on loweringcholesterol
  2196. Study of Heart and Renal Protection (SHARP): randomized trial to assess the effects of lowering low-density lipoprotein cholesterol among 9,438 patients with chronic …
  2197. Study of lipid profile in obese individuals and the effect of cholesterol lowering agents on them
  2198. Study on Characteristic of Reducing cholesterol in Vitro by Lactococcus lactis Isolated from Sauerkraut Juice [J]
  2199. Study on characteristics of growth, screening and identification of cholesterol-reducing Lactic acid bacteria
  2200. Study on cholesterol lowering compounds in red yeast rice prepared from thai glutinous rice
  2201. Study on cholesterollowering and Antioxidative Function of Lactobacillus buchneri PG-7
  2202. Study on cholesterollowering effect of bile salt hydrolase-active Lactobacillus plantarum
  2203. Study on cholesterollowering mechanism of Lactobacillus acidophilus by adsorbing and assimilating cholesterol
  2204. Study on processing of cholesterol-reducing fermented coagulated whole egg beverage [J]
  2205. Study on Reducing cholesterol Content in Egg Yolk [J]
  2206. Study on Rosa juice anti-fatigue and cholesterol reducing in vitro [J]
  2207. Study on screening and identification of cholesterol-reducing lactic acid bacteria and its synergistic effect with traditional Chinese medicine
  2208. Study on the cholesterol-reducing activity of lactic acid bacteria from giant panda
  2209. Study on the cholesterol-reducing activity of Lactobacillus casei 21008 in vitro
  2210. Study on the cholesterol-reducing activity of Lactobacillus casei 21008 in vitro
  2211. Study on the cholesterol-reducing effects of complex bacteria leaven from kefir grain milk yoghurt in rats.
  2212. Study on the microencapsulation of cholesterol-reducing lactobacillus.
  2213. Study on tolerance characteristics of the gastrointestinal tract and cholesterollowering effects of Lactobacillus plantarum Zhang-LL
  2214. Study the Effect of Some Natural Substances on lowering Blood cholesterol in Rats
  2215. Subjects with familial hypercholesterolemia are characterized by an inflammatory phenotype despite long-term intensive cholesterol lowering treatment
  2216. Substituting non-HDL cholesterol with LDL as a guide for lipid-lowering therapy increases the number of patients with indication for therapy
  2217. Substrain‐specific cholesterollowering effects of oats in mice:‐Clues for mechanism of action?
  2218. Summary of Health Canada’s Assessment of a Health Claim about Soy Protein and cholesterol lowering
  2219. Superactivated Charcoal Versus Cholestyramine for cholesterol lowering: A Randomized Cross‐Over Trial
  2220. Superiority of dietary safflower oil over olive oil in lowering serum cholesterol and increasing hepatic mRNAs for the LDL receptor and cholesterol 7α-hydroxylase in …
  2221. Superiority of partial ileal bypass over cholestyramine in reducing cholesterol in familial hypercholesterolaemia
  2222. Supplementation of hydroxypropyl methylcellulose into yeast leavened all-whole grain barley bread potentiates cholesterollowering effect
  2223. Surface tension lowering and dissolution rate of hydrocortisone from solid solutions of selected n‐acyl esters of cholesterol
  2224. Surfactant Protein A Restores The Surface Tension Reducing Capability Of Human Pulmonary Surfactant With Elevated Levels Of cholesterol
  2225. Survival of probiotic strains in non-dairy indian spice condiment exhibiting cholesterol reducing properties
  2226. Sustained low-density lipoprotein cholesterol lowering with alirocumab in ODYSSEY OUTCOMES
  2227. Switching from High-Efficacy Lipid-lowering Therapies [Atorvastatin or Rosuvastatin] to Simvastatin and the Results on Low-Density Lipoprotein cholesterol
  2228. Switching from high-efficacy lipid-lowering therapies to simvastatin and low-density lipoprotein cholesterol goal attainment in coronary heart disease/coronary heart …
  2229. Synergetic cholesterollowering effects of main alkaloids from Rhizoma Coptidis in HepG2 cells and hypercholesterolemia hamsters
  2230. Synthesis and cholesterol lowering abilities of novel prebiotic galacto oligosaccharides produced using lactobacilli reverse enzyme synthesis
  2231. Synthesis and cholesterol-reducing potential of water-soluble phytosterol derivative
  2232. Synthesis and Evaluation of 2‐Azetidinone and 1H‐Pyrrole‐2,5‐dione Derivatives as cholesterol Absorption Inhibitors for Reducing Inflammation Response and …
  2233. Synthesis and serum cholesterollowering and uterotropic effects of 15, 16, 17-trisubstituted oestratriene 3-methyl ethers. Part 63: On steroids (author’s transl)
  2234. Synthesis of cholesterol-reducing sterol esters by enzymatic catalysis in bio-based solvents or solvent-free
  2235. Synthesis of multi-lactose-appended β-cyclodextrin and its cholesterollowering effects in Niemann–Pick type C disease-like HepG2 cells
  2236. Systematic review of green tea epigallocatechin gallate in reducing low-density lipoprotein cholesterol levels of humans
  2237. Systematic review on the risk and benefit of different cholesterollowering interventions
  2238. Systematic study of the effects of lowering low-density lipoprotein-cholesterol on regression of coronary atherosclerotic plaques using intravascular ultrasound
  2239. Systolic and pulse blood pressures (but not diastolic blood pressure and serum cholesterol) are associated with alterations in carotid intima–media thickness in the …
  2240. Targeted isolation and identification of bioactive compounds lowering cholesterol in the crude extracts of crabapples using UPLC-DAD-MS-SPE/NMR based on …
  2241. Targeting PCSK9 as a promising new mechanism for lowering low-density lipoprotein cholesterol
  2242. Taxonomic description and genome sequence of Christensenella intestinihominis sp. nov., a novel cholesterollowering bacterium isolated from human gut
  2243. Ten-year follow-up of familial hypercholesterolemia patients after intensive cholesterollowering therapy
  2244. Test on Emerita analoga as cholesterol Reducing Agent on Mus musculus BALB/C
  2245. Testing the Relationship between cholesterol lowering and Cardiovascular Disease—Past, Present, and Prospects
  2246. Th-P16: 306 Fenofibrate increases HDL-cholesterol by reducing the expression of the cholesteryl ester transfer protein
  2247. The adult patient with a congenital GH deficiency. cholesterollowering effects of therapy with biosynthetic GH
  2248. The awareness of the risk of elevated cholesterol levels and knowledge about cholesterollowering action in Australia
  2249. The benefit of cinnamon (Cinnamomum burmannii) in lowering total cholesterol levels after consumption of high-fat containing foods in white mice (Mus …
  2250. The benefits of lowering cholesterol in subjects with mild hyperglycemia
  2251. The benefits of lowering” average” cholesterol
  2252. The benefits of reducing cholesterol levels: the need to distinguish primary from secondary prevention 2. Implications for heart disease prevention in Australia
  2253. The benefits of reducing cholesterol levels: the need to distinguish primary from secondary prevention: 1. A meta‐analysis of cholesterollowering trials
  2254. The challenge of lowering blood cholesterol levels
  2255. The cholesterol derivative of a triantennary galactoside with high affinity for the hepatic asialoglycoprotein receptor: a potent cholesterol lowering agent
  2256. The cholesterol lowering Atherosclerosis Study (CLAS)
  2257. The cholesterol lowering Atherosclerosis Study (CLAS): design, methods, and baseline results
  2258. The cholesterol lowering effect of steroid sequestrants is modulated by large intestine fermentations
  2259. The cholesterol lowering Effects of Eurycoma longifolia Jack (Tongkat Ali) Root Extract in Male Rats
  2260. The cholesterol lowering Effects of Strawberry: A Randomized Controlled Trial Establishing Strawberry’s Role in Cardiovascular Health
  2261. The cholesterol lowering efficacy of plant stanol ester yoghurt in a Turkish population: a double-blind, placebo-controlled trial
  2262. The cholesterol lowering properties of the complex compound simvastatin with glycyrrhizic acid (simvaglyzin) in experimental models
  2263. The cholesterol lowering property of coriander seeds (Coriandrum sativum): mechanism of action
  2264. The cholesterollowering action of plant stanol esters
  2265. The cholesterollowering agent methyl-β-cyclodextrin promotes glucose uptake via GLUT4 in adult muscle fibers and reduces insulin resistance in obese mice
  2266. The cholesterollowering agent methyl-β-cyclodextrin promotes glucose uptake via GLUT4 in adult muscle fibers and reduces insulin resistance in obese mice
  2267. The cholesterollowering effect of alisol acetates based on HMG-CoA reductase and its molecular mechanism
  2268. The cholesterollowering effect of black beans (Phaseolus vulgaris, L.) without hulls in hypercholesterolemic rats
  2269. The cholesterollowering effect of black, carioquinha and red beans (Phaseolus vulgaris, L.) in hypercholesterolemic rats
  2270. The cholesterollowering Effect of Capsella Bursa-Pastoris Is Mediated via SREBP2 and HNF-1α-Regulated PCSK9 Inhibition in Obese Mice and HepG2 Cells
  2271. The cholesterollowering effect of coconut flakes in humans with moderately raised serum cholesterol
  2272. The cholesterollowering effect of commercial diet fed to germfree and conventional rats
  2273. The cholesterollowering effect of dextran-40
  2274. The cholesterollowering effect of guar gum in rats is not accompanied by an interruption of bile acid cycling
  2275. The cholesterollowering effect of indigestible proteins isolated from pulses
  2276. The cholesterollowering effect of oat bran cereals in rats: Influence of processing
  2277. The cholesterollowering effect of oats and oat beta glucan: Modes of action and potential role of bile acids and the microbiome
  2278. The cholesterollowering effect of plant sterol-containing beverage in hypercholesterolemic subjects with low cholesterol intake
  2279. The cholesterollowering effect of the unicellular green alga Scenedesmus acutus 276-3a. I. Effect of drum-dried algal material
  2280. The cholesterollowering effect of the unicellular green alga Scenedesmus acutus 276-3a. II. Effect of alga fractions
  2281. The cholesterollowering effect of unripe Rubus coreanus is associated with decreased oxidized LDL and apolipoprotein B levels in subjects with borderline …
  2282. The cholesterollowering Effects of Legumes Ii: Effects of Fibre, Sterols, Saponins and Isolavones
  2283. The cholesterollowering effects of legumes. I: Effects of the major nutrients
  2284. The cholesterollowering effects of oat varieties based on their difference in the composition of proteins and lipids
  2285. The cholesterollowering potential of whole grains
  2286. The cholesterollowering properties of a psyllium-based breakfast cereal in hamsters.
  2287. The cholesterollowering activity of miracle fruit (Synsepalum dulcificum)
  2288. The cholesterollowering effect of a breakfast cereal containing psyllium fibre
  2289. The cholesterollowering effect of guar gum is not the result of a simple diversion of bile acids toward fecal excretion
  2290. The cost-effectiveness of cholesterollowering therapy with simvastatin in the primary prevention of coronary heart disease in the Netherlands
  2291. The cost-effectiveness of intensive low-density lipoprotein cholesterol lowering in people with peripheral artery disease
  2292. The cost‐effectiveness of different blood‐cholesterollowering strategies in the prevention of coronary heart disease
  2293. The development of quantitative nutritional guidelines for a central kitchen: a tool for classifying menu items into diabetic, cholesterollowering and weight reduction …
  2294. The Development of Yogurt with cholesterollowering Effects
  2295. The effect of a dietary supplement spirulina and bifidobacterium adolescentis on the cholesterollowering in vitro and in vivo
  2296. The Effect of Age on cholesterollowering Therapy
  2297. The effect of aggressive and moderate lowering of LDL-cholesterol and low dose anticoagulation on plasma lipids, apolipoproteins and lipoprotein families in post …
  2298. The effect of aggressive lowering of low-density lipoprotein cholesterol levels and low-dose anticoagulation on obstructive changes in saphenous-vein …
  2299. The effect of amaranth flour on plasma cholesterol levels: Another option for cardiovascular risk lowering?
  2300. The effect of cholesterol lowering on carotid and femoral artery wall stiffness and thickness in patients with familial hypercholesterolaemia
  2301. The effect of cholesterol lowering therapy on endothelium-dependent vasodilation in hypercholesterolemia
  2302. The effect of cholesterollowering and antioxidant therapy on endothelium-dependent coronary vasomotion
  2303. The effect of cholesterollowering treatment on renal function
  2304. The effect of cholesterollowering agents on hepatic and plasma cholesterol in Niemann‐Pick disease type C
  2305. The Effect of Evening Primrose Oil on Chemical and Blood cholesterol lowering Properties of Cheddar Cheese Seoul 139-742, Korea.
  2306. THE EFFECT OF IRANIAN NATIVE FERMENTED MILK AS A PROBIOTIC ON cholesterol lowering IN MALE WISTAR RAT MODEL UNDER STRESS
  2307. THE EFFECT OF IRANIAN NATIVE FERMENTED MILKAS A PROBIOTICON cholesterol lowering INMALE WISTARRATMODEL
  2308. The effect of life and dead cell and cell free extract for same lactic acid bacteria in reducing cholesterol and microbial load for buffalo fatty tissue
  2309. The effect of lifestyle physical activity in reducing cardiovascular disease risk factors (blood pressure and cholesterol) in women: A systematic review
  2310. The effect of lowering cholesterol on mortality
  2311. The effect of lowering LDL cholesterol on vascular access patency: post hoc analysis of the Study of Heart and Renal Protection
  2312. The Effect of Olive Oil Addition into Oatmeal in lowering Total Blood cholesterol and LDL (Low Density Lipoprotein) in Wistar Rat
  2313. The effect of plasma-cholesterollowering diet in male survivors of myocardial infarction. A controlled clinical trial.
  2314. The effect of strawberries in a cholesterollowering dietary portfolio
  2315. The effect of the intensity of lipid‐lowering medications on the LDL cholesterol treatment goals of Asian patients with dyslipidaemia in primary care
  2316. THE EFFECT OF TWO cholesterollowering AGENTS ON PLATELETS IN PATIENTS WITH HYPERcholesterolEMIA
  2317. The effect of two novel cholesterollowering agents, disodium ascorbyl phytostanol phosphate (DAPP) and nanostructured aluminosilicate (NSAS) on the …
  2318. The Effectiveness of Garcinia Mangostana L. Rind extract in Reducing Total cholesterol Levels in Hypercholesterolemic Male White Mice
  2319. The effectiveness of probiotics, prebiotics, and dietary fiber on the lowering of cholesterol level and improvement of full lipid profile
  2320. The Effectiveness of Stew Carrot (Daucus Carota. L) On lowering Blood cholesterol Levels of White Rat (Rattus Norvegicus)
  2321. The effectiveness of the Mediterranean diet in reducing cholesterol
  2322. The Effectiveness of The Use of Pelawan Leaf Boiled Water (Tristaniopsis Merguensis (Griff.) as a Traditional Medicine for Reducing Blood cholesterol
  2323. The effects of cholesterol lowering with simvastatin on cause-specific mortality and on cancer incidence in 20,536 high-risk people: a randomised placebo …
  2324. The Effects of cholesterollowering diets with Lean Beef on Blood Pressure and Vascular Health: Results from the BOLD (Beef in an Optimal Lean diet) Study
  2325. The effects of dietary cholesterollowering on psychological symptoms: a randomised controlled study
  2326. The effects of lowering cholesterol on vasodilation.
  2327. The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a …
  2328. The effects of lowering serum cholesterol on coronary heart disease risk.
  2329. The efficacy of cholesterollowering action and side effects of garlic enteric coated tablets in man
  2330. The efficacy of corn oil in lowering the serum cholesterol of patients with coronary atherosclerosis.
  2331. The efficacy of evolocumab and other lipid-lowering therapies (LLT) for the management of low density lipoprotein cholesterol (LDL-C): a systematic review and …
  2332. The efficacy of lovastatin in lowering cholesterol in African Americans with primary hypercholesterolemia
  2333. The efficacy of vitamin C supplementation on reducing total serum cholesterol in human subjects: a review and analysis of 51 experimental trials
  2334. The emerging concept of “individualized cholesterollowering therapy”: A change in paradigm
  2335. The Evaluation of Red Clover (Trifolium Pretense L.) Active Compounds in Application for lowering Blood cholesterol Level:[elektroninis išteklius]
  2336. The evidence around safe and effective LDL cholesterollowering therapy in elderly individuals demands validity and clinical relevance
  2337. The Example of a cholesterol-Reducing Margarine
  2338. The expected cardiovascular benefit of plasma cholesterol lowering with or without LDL-C targets in healthy individuals at higher cardiovascular risk
  2339. THE EXPERIMENTAL STUDY 0N cholesterol-REDUCING EFFECTS AND TOLERANCE PROPERTY OF LACTOBACTERIA ISOLATED FROM KEFIR GRAIN
  2340. The fact and fiction of lowering cholesterol in the primary prevention of coronary heart disease
  2341. The fetal origins of atherosclerosis: maternal hypercholesterolemia, and cholesterollowering or antioxidant treatment during pregnancy influence in utero …
  2342. The final word about LDL-cholesterol lowering
  2343. The food matrix and sterol characteristics affect the plasma cholesterol lowering of phytosterol/phytostanol
  2344. The future direction of cholesterollowering therapy
  2345. The future of low-density lipoprotein cholesterol in an era of nonfasting lipid testing and potent low-density lipoprotein lowering
  2346. The great fat debate: reducing cholesterol
  2347. The ideal management of blood cholesterol: a review of the updated 2013 ACC/AHA cholesterol guideline for reducing cardiovascular risk
  2348. The impact of automatic prescriptions on reducing low-density lipoprotein cholesterol levels.
  2349. The impact of cholesterol lowering on patients’ mood
  2350. THE IMPACT OF DECREASED HIGH-DENSITY LIPOPROTEIN-cholesterol LEVEL AFTER LIPID-lowering THERAPY ON THE CLINICAL OUTCOMES IN …
  2351. The Impact of Obesity on the Efficacy of Simvastatin for lowering Low-Density Lipoprotein cholesterol in a Veteran Population
  2352. The importance of lowering cholesterol in patients with coronary heart disease
  2353. The Influence of Malting on Nutritional Value and cholesterol lowering Capacity of Chickpeas in Rats
  2354. The influence of physical parameters towards hyper cholesterol reducing agent production, lovastatin, under solid substrate fermentation (SSF) condition
  2355. The interpretation of cholesterol balance derived synthesis data and surrogate noncholesterol plasma markers for cholesterol synthesis under lipid lowering
  2356. The LDL-cholesterollowering effects of nano-particled Djulis Grains
  2357. The LDL-receptor and its molecular properties: From theory to novel biochemical and pharmacological approaches in reducing LDL-cholesterol
  2358. The lipid lowering effect of the aqueous root extract of Morinda lucida in albino rats fed on a high cholesterol diet
  2359. The local effects of proprotein convertase subtilisin/kexin type 9 (PCSK9) on the inflammatory atheroma: beyond LDL cholesterol lowering
  2360. The low‐density lipoprotein cholesterollowering effect of pravastatin and factors associated with achieving targeted low‐density lipoprotein levels in an African …
  2361. THE lowering EFFECT OF PANAXYDOL PURIFIED FROM KOREAN RED GINSENG ON BLOOD HIGH cholesterol LEVELS IN RATS
  2362. The lowering of plasma cholesterol by sucrose polyester in subjects consuming diets with 800, 300, or less than 50 mg of cholesterol per day
  2363. The Mechanism of Comparable Serum cholesterol lowering Effects of Pravastatin Sodium, a 3-Hydroxy-3-Methylglutaryl Coenzyme A Reductase Inhibitor, between …
  2364. The mechanism of improvement in endothelial function by pravastatin: direct effect or through cholesterol lowering
  2365. The mechanism of lowering cholesterol absorption by calcium studied by using an in vitro digestion model
  2366. The mechanism of the cholesterollowering effect of water-insoluble fish protein in ovariectomised rats
  2367. The molecular mechanism of the cholesterollowering effect of dill and kale: The influence of the food matrix components
  2368. The Myocardial Ischemia Reduction with Aggressive cholesterol lowering (MIRACL) trial: Effects of intensive atorvastatin treatment on early recurrent events after an …
  2369. The need for a new classification of cholesterol lowering therapies
  2370. The next generation of novel low-density lipoprotein cholesterollowering agents: proprotein convertase subtilisin/kexin 9 inhibitors
  2371. The nutrient repercussions of adopting an approved serum cholesterol lowering diet
  2372. The okra skin extract and its cholesterollowering activities-in vitro study
  2373. The perspective on cholesterollowering mechanisms of probiotics
  2374. The potential cholesterollowering and prebiotic effects of bamboo shoot dietary fibers and their structural characteristics
  2375. The predictive ability of lipoproteins and the value of lowering plasma cholesterol in the presence of coronary heart disease
  2376. The rationale for lowering serum cholesterol levels in American children
  2377. The Regulatory Mechanism and Measures of Reducing cholesterol in Eggs
  2378. The Relationship between Structure and Activity in a Novel Series of Serum cholesterollowering Agents1
  2379. The relationship between weight and response to cholesterollowering diets in women
  2380. The research and development progress of cholesterollowering Lactic acid bacteria
  2381. THE RESEARCH OF SECURITY ON cholesterol-REDUCING IN ANIMAL-ORIGIN FOOD WITH BIOLOGY MEASURES [J]
  2382. The Response to a cholesterollowering diet Instructed by Physicians and dieticians.
  2383. The revised NWLRC fat intake scale: A quick way to assess cholesterollowering diets
  2384. The role of dietary polyunsaturated fat in lowering blood cholesterol in man.
  2385. The role of gut microbiota in the low‐density lipoprotein (LDL) cholesterollowering effects of plant sterol esters
  2386. The role of linoleic acid and its metabolites in the lowering of plasma cholesterol and the prevention of cardiovascular disease
  2387. The role of nutrients in a dietary intervention in improving blood cholesterol profile and lowering cardiovascular risk
  2388. The serum cholesterol level lowering effect from the underground parts of Rosa rugosa
  2389. The serum LDL/HDL cholesterol ratio is influenced more favorably by exchanging saturated with unsaturated fat than by reducing saturated fat in the diet of women
  2390. The state of the art on the mechanisms of lactic acid bacteria in reducing cholesterol
  2391. The success story of LDL cholesterol lowering
  2392. The type of mutation in the low density lipoprotein receptor gene influences the cholesterollowering response of the HMG-CoA reductase inhibitor simvastatin in …
  2393. The use of cholesterol lowering medicine for postmenopausal women with estrogen receptor positive breast cancer
  2394. The use of cholesterollowering medications after coronary revascularization
  2395. The use of cholesterollowering medications and age-related macular degeneration
  2396. The use of DiazaCon™ to limit fertility by reducing serum cholesterol in female grey squirrels, Sciurus carolinensis
  2397. The value of lowering cholesterol after myocardial infarction
  2398. The value of surrogate markers to monitor cholesterol absorption, synthesis and bioconversion to bile acids under lipid lowering therapies
  2399. Therapies that target PCSK9 effective at reducing LDL cholesterol
  2400. Therapy and prevention of coronary heart diseases through lowering of the serum cholesterol levels; third consensus’ cholesterol‘. Consensus Working Group, CBO
  2401. This House believes that the UK healthcare system may be failing as many as 50% of patients with hyperlipidaemia by not reducing their cholesterol to effective levels …
  2402. This is a repository copy of Synthesis of cholesterol-reducing sterol esters by enzymatic catalysis in bio-based solvents or solvent-free.
  2403. Thyroid hormone β receptor activation has additive cholesterol lowering activity in combination with atorvastatin in rabbits, dogs and monkeys
  2404. Thyroid hormones: a potential ally to LDL-cholesterollowering agents
  2405. Time trends in the use of cholesterollowering agents in older adults: the Cardiovascular Health Study
  2406. Tissue selectivity of the cholesterollowering agents lovastatin, simvastatin and pravastatin in rats in vivo
  2407. Toward individualized cholesterollowering treatment in end-stage renal disease
  2408. Transcriptional analysis for cholesterollowering effects of marine Lactobacillus plantarum Lp10 isolated from kelp
  2409. Transcriptional Induction of cholesterol 7ä-Hydroxylase by Dexamethasone in L35 Hepatoma Cells Requires Sulfhydryl Reducing Agents
  2410. Transition from LDL apheresis to evolocumab in heterozygous FH is equally effective in lowering LDL-but without lowering HDL cholesterol
  2411. Transition from LDL apheresis to evolocumab in heterozygous FH is equally effective in lowering LDL, without lowering HDL cholesterol
  2412. Trattamento ipocolesterolemizzante con nutraceutici: dallo stato dell’arte alla pratica clinica sul territorio lowering cholesterol with nutraceuticals: from the state of the …
  2413. Treadmill exercise inhibits amyloid-β generation in the hippocampus of APP/PS1 transgenic mice by reducing cholesterol-mediated lipid raft formation
  2414. Treating to New Targets (TNT) Study: does lowering low-density lipoprotein cholesterol levels below currently recommended guidelines yield incremental clinical …
  2415. Treatment goals for low-density lipoprotein cholesterol in the secondary prevention of coronary heart disease: absolute levels or extent of lowering?
  2416. Treatment of myocardial infarction and angina. Advice on reducing cholesterol should be included.
  2417. Treatment of peptic ulcer with a cholesterollowering dietary supplement: preliminary report.
  2418. Treatment with ezetimibe plus low-dose atorvastatin compared with higher-dose atorvastatin alone: is sufficient cholesterollowering enough to inhibit platelets?
  2419. Trends in total and low-density lipoprotein cholesterol among US adults: contributions of changes in dietary fat intake and use of cholesterollowering
  2420. Trends in Utilization and Cost of Low-Density Lipoprotein cholesterollowering Therapies Among Medicare Beneficiaries: An Analysis From the Medicare Part D …
  2421. Trimethylamine N-oxide attenuates high-fat high-cholesterol diet-induced steatohepatitis by reducing hepatic cholesterol overload in rats
  2422. Two apolipoprotein E mimetic peptides with similar cholesterol reducing properties exhibit differential atheroprotective effects in LDL-R null mice
  2423. Two years after molecular diagnosis of familial hypercholesterolemia: majority on cholesterollowering treatment but a minority reaches treatment goal
  2424. Ultra heat treatment destroys cholesterollowering effect of soy protein
  2425. Understanding molecular mechanisms involved in the cholesterol-reducing action of dietary psyllium in rats.
  2426. Understanding new cholesterollowering agents
  2427. Underutilization of measurement of serum low‐density lipoprotein cholesterol levels and of lipid‐lowering therapy in older patients with manifest atherosclerotic …
  2428. United states cholesterol guidelines 2001: Expanded scope of intensive low-density lipoprotein–lowering therapy
  2429. Unresolved issues in early trials of cholesterol lowering
  2430. Update of planning tables of cholesterollowering therapy orientated to achieve LDL therapeutic targets
  2431. Update on lipid-lowering therapy and LDL-cholesterol targets
  2432. Use and outcomes of a cholesterollowering intervention for rural elderly subjects
  2433. Use of black cumin in layer diet as cholesterol lowering agents in egg yolk
  2434. Use of bread and rolls in a cholesterol reducing diet.-2. Part: Results of the controlled dietary study
  2435. Use of cholesterollowering medications in the United States from 1991 to 19971
  2436. Use of cholesterollowering Medications of Patients with Myocardial Infarction from 2007-2015 in Cardiology Clinic to “Mother Teresa” University Hospital in …
  2437. Use of cholesterollowering therapy and related beliefs among middle-aged adults after myocardial infarction
  2438. Use of cholesterollowering therapy by elderly adults after myocardial infarction
  2439. Use of lipid-lowering medications and the likelihood of achieving optimal LDL-cholesterol goals in coronary artery disease patients
  2440. Use of local isolate of Monascus purpureus for reducing blood cholesterol in Sprague Dawley rat
  2441. Use of starter cultures reducing the cholesterol content in meat products
  2442. Usefulness of lowering low-density lipoprotein cholesterol to< 70 mg/dl and usefulness of C-reactive protein in patient selection
  2443. Using genetic variants to evaluate the causal effect of cholesterol lowering on head and neck cancer risk: a Mendelian randomization study
  2444. Utility of fasting essential amino acid plasma levels in formulation of nutritionally adequate diets III: lowering of rat serum cholesterol levels by lysine supplementation
  2445. Utility of fasting essential amino acid plasma levels in formulation of nutritionally adequate diets IV: lowering of human plasma cholesterol and triglyceride levels by …
  2446. Utility of treatment with atorvastatin 40 mg plus ezetimibe 10 mg versus atorvastatin 80 mg in reducing the levels of LDL cholesterol in patients with ischaemic stroke or …
  2447. Utilization of cholesterollowering Therapies in Patients With Chronic Kidney Disease and Atherosclerotic Cardiovascular Disease (ASCVD). Results From a National …
  2448. Utilization of soybean residue to produce monacolin K-cholesterol lowering agent.
  2449. Utilization of Tropical Biomass Resources I. Effect of galactomannan from Leucaena leucocephala de WIT seed to cholesterollowering in rats
  2450. Utilization of Tropical Biomass Resources. I. Effect of galactomannan from Leucaena leucocephala de Wit seed to cholesterollowering in rats.
  2451. Utilization of Wheat Germ as Natural Antioxidant and Fat Mimetic to Increase Shelf-Life in Beef Sausage and as lowering cholesterol in Rats
  2452. Value of cholesterol lowering Medications
  2453. Variation in lipid-lowering therapy use in patients with low-density lipoprotein cholesterol≥ 190 mg/dL: insights from the National Cardiovascular Data Registry …
  2454. Varying pharmacy benefits with clinical status: the case of cholesterollowering therapy
  2455. Vascular effects of estrogen and cholesterollowering therapies in hypercholesterolemic postmenopausal women
  2456. Very low cholesterol and cholesterol lowering. A statement for healthcare professionals from the American Heart Association Task Force on cholesterol Issues.
  2457. Vicinal diaryl azole-based urea derivatives as potential cholesterol lowering agents acting through inhibition of SOAT enzymes
  2458. Vinegars but not acetic acid are effective in reducing plasma cholesterol in hamsters fed a high-cholesterol diet
  2459. Viscosity rather than quantity of dietary fibre predicts cholesterollowering effect in healthy individuals
  2460. Vitamin C and the cholesterollowering effect of clofibrate [proceedings]
  2461. What is the role of intensive cholesterol lowering in the treatment of acute coronary syndromes?
  2462. What Proportion of Patients Admitted with Stroke or Transient Ischemic Attack May Be Suitable for Newer cholesterollowering Treatment?
  2463. What should be the goal of LDL-cholesterol lowering in coronary patients; a fixed level or a percent reduction?
  2464. When to start cholesterollowering therapy in patients with coronary heart disease: a statement for healthcare professionals from the American Heart Association Task …
  2465. Whey dangke giving in drinking water lowering level of cholesterol, triglycerides and lipoproteins of broiler chickens blood.
  2466. Whole wheat flour exerts cholesterollowering in rats in its native form and after use in bread-making
  2467. Whole-body cryostimulation as an effective way of reducing exercise-induced inflammation and blood cholesterol in young men
  2468. Why cholesterollowering diets should still be encouraged in the face of effective pharmaceutical interventions
  2469. Will cholesterollowering Therapy Increase the Risk of Muscle Injury?
  2470. Will cholesteryl ester transfer protein inhibition succeed primarily by lowering low-density lipoprotein cholesterol? Insights from human genetics and clinical …
  2471. Will lowering population levels of serum cholesterol affect total mortality? Expectations from the Honolulu Heart Program
  2472. X-ray Crystallographic Studies of cholesterol lowering Target
  2473. Xanthohumol prevents atherosclerosis by reducing arterial cholesterol content via CETP and apolipoprotein E in CETP-transgenic mice
  2474. y is lowering LDL cholesterol levels reduced fatal coronary events in patients with acute Ml and average cholesterol levels
  2475. Yaobao Xuezhiqing Capsules on Reducing cholesterol in Serum
  2476. Zinc intake and plasma zinc level are maintained in men consuming cholesterollowering diets
  2477. α-tocopherol attenuates the triglyceride-and cholesterollowering effects of rice bran tocotrienol in rats fed a western diet
  2478. … -3 fatty acid has effect on improvement of peripheral artery disease in correlation with degree of lowering remnant-like lipoprotein cholesterol in hemodialysis patients …
  2479. … -like activity of Alzheimer’s disease β-amyloid: Cu-dependent catalytic conversion of dopamine, cholesterol, and biological reducing agents to neurotoxic …
  2480. … -term treatment with low-dose metoprolol CR/XL is associated with increased plaque echogenicity: the Beta-blocker cholesterollowering Asymptomatic Plaque Study …
  2481. … -world effectiveness of lipid-lowering therapy in male and female outpatients with coronary heart disease: relation to pre-treatment low-density lipoprotein-cholesterol
  2482. … ‐induced hyperhomocysteinemia impairs the antioxidant ability of high‐density lipoproteins without reducing in vivo macrophage‐specific reverse cholesterol
  2483. … ‐tailored atorvastatin therapy on ameliorating the levels of atherogenic lipids and inflammation beyond lowering low‐density lipoprotein cholesterol in patients with …
  2484. … : INSIGHTS FROM GETTING TO AN IMPROVED UNDERSTANDING OF LOW-DENSITY LIPOPROTEIN cholesterol AND DYSLIPIDEMIA MANAGEMENT …
  2485. … ” és a „cél%” hatásosságának összehasonlítása a hétköznapi gyakorlatban–Az ATTENTION-vizsgálat= Two LDL-cholesterol lowering strategy: comparison of …
  2486. … (a) lowering by alirocumab reduces the total burden of cardiovascular events independent of low-density lipoprotein cholesterol lowering: ODYSSEY OUTCOMES trial
  2487. … (a) particle production as a determinant of plasma lipoprotein (a) concentration across varying apolipoprotein (a) isoform sizes and background cholesterollowering
  2488. … (L-TAP): a multicenter survey to evaluate the percentages of dyslipidemic patients receiving lipid-lowering therapy and achieving low-density lipoprotein cholesterol
  2489. … (NDA) on the modification of the authorisation of a health claim related to plant sterol esters and lowering blood LDL‐cholesterol; high blood LDL‐cholesterol is a risk …
  2490. … ) SEBAGAI BAHAN PENURUN KOLESTEROL PADA MENCIT (Mus musculus BALB/C)(Test on Emerita analoga as cholesterol Reducing Agent on Mus …
  2491. … 17–Should tests such as C-reactive protein, carotid intima-media thickness, coronary artery calcification etc. be assessed while guiding cholesterollowering
  2492. … a major coronary event after myocardial infarction in the Scandinavian Simvastatin Survival Study (4S). Impact of predicted risk on the benefit of cholesterollowering
  2493. … Acid (EPA), but not other Triglyceride-lowering Agents, Inhibits Glucose-Induced Changes in Membrane Width and cholesterol Domain Formation through a …
  2494. … and Control: Reducing Out-of-Pocket Costs for Cardiovascular Disease Preventive Services for Patients with High Blood Pressure and High cholesterol
  2495. … and design of a secondary prevention trial of lowering normal plasma cholesterol levels after acute myocardial infarction: the cholesterol and Recurrent Events trial …
  2496. … and its analog, hydroxypropyl‐berberrubine, regulate LDLR and PCSK9 expression via the ERK signal pathway to exert cholesterollowering effects in human …
  2497. … and lower better and better? A re-evaluation of the evidence from the cholesterol Treatment Trialists’ Collaboration meta-analysis for low-density lipoprotein lowering
  2498. … and men with coronary heart disease to reach Adult Treatment Panel III low-density lipoprotein cholesterol goal without lowering high-density lipoprotein cholesterol
  2499. … and plasma lipid lowering effects of the novel calcium blocker with alpha 1-adrenoceptor antagonistic activity, monatepil, in high cholesterol diet-fed Japanese …
  2500. … and prevention of coronary heart disease by lowering serum cholesterol levels; from the pioneer work of CD de Langen to the third” Dutch Consensus on cholesterol” …
  2501. … and their haplotypes are associated with serum lipid levels, the risk of coronary artery disease and ischemic stroke and atorvastatin cholesterollowering
  2502. … AND VASCULAR RESPONSE TO LIPID-lowering THERAPY IN PATIENTS WITH HIGH VERSUS LOW HDL-cholesterol: SERIAL OPTICAL COHERENCE …
  2503. … APPROACH TO LIPID lowering (GOAL) MEDICAL PRACTICE ACTIVITY (MPA) TO ACHIEVE LOW DENSITY LIPOPROTEIN cholesterol (LDL-C) TARGETS
  2504. … Are Associated with Low-Density Lipoprotein cholesterol, non–High-Density Lipoprotein cholesterol, and ApoB Responses to Lipid-lowering Therapy in Patients …
  2505. … artery atherosclerosis in SR-B1 (Scavenger Receptor Class B Type 1)/ApoE (Apolipoprotein E) double knockout mice independently of plasma cholesterol lowering
  2506. … as unique sources of soluble and insoluble-bound phenolics: Reducing power, metal chelation and inhibition of oxidation of human LDL-cholesterol and DNA strand …
  2507. … assessed trial on the role of LDL‐apheresis in the secondary prevention of coronary heart disease: I. Evaluation of safety and cholesterollowering effects during the …
  2508. … breast cancer cell viability and alters membrane raft-localized EGFR expression by reducing lipogenesis and enhancing LXR-dependent cholesterol
  2509. … by Apolipoprotein B48 and cholesterol Absorption/Synthesis Markers Represents Residual Risks for Coronary Artery Disease during Intensive LDL-lowering
  2510. … C‐reactive protein lowering with atorvastatin in patients of South Asian compared with European origin: insights from the Achieve cholesterol Targets Fast with …
  2511. … cell model to compare the lipid-lowering effects of pomegranate peel polyphenols with several other plant polyphenols as well as its related cholesterol efflux …
  2512. … channel blockers with lipid-lowering therapy in retarding progression of coronary atherosclerosis in symptomatic patients with normal to moderately raised cholesterol
  2513. cholesterol is as tricky as lowering it; a federal panel has issued precise recommendations on how and when to treat elevated cholesterol levels, but determining …
  2514. cholesterol lowering for the Primary Prevention of Cardiovascular Disease Among Men With Primary Elevations of Low-Density Lipoprotein cholesterol Levels of 190 …
  2515. cholesterol lowering for the Primary Prevention of Cardiovascular Disease Among Men With Primary Elevations of Low-Density Lipoprotein cholesterol Levels of 190 …
  2516. cholesterol lowering for the Primary Prevention of Cardiovascular Disease Among Men With Primary Elevations of Low-Density Lipoprotein cholesterol Levels of 190 …
  2517. cholesterol lowering for the primary prevention of cardiovascular disease among men with primary elevations of low-density lipoprotein cholesterol levels of 190 mg …
  2518. cholesterol lowering, and calculated 10-year cardiovascular risk reduction of alirocumab and evolocumab in addition to maximal tolerated cholesterol
  2519. … College of Cardiology expert consensus decision pathway on nonstatin therapies for low-density lipoprotein-cholesterol lowering in the management of …
  2520. … comparative study of lipid-lowering effects of guggul and atorvastatin monotherapy in comparison to their combination in high cholesterol diet-induced hyperlipidemia …
  2521. … comparison of effectiveness of lowering apolipoprotein B versus low-density lipoprotein cholesterol and nonhigh-density lipoprotein cholesterol for cardiovascular risk …
  2522. … containing apoA-I but not apoA-II (LpA-I) by lipoprotein-deficient plasma and hepatic lipase: Its effect on the structure and cellular cholesterol-reducing capacity of LpA …
  2523. … CR/XL and fluvastatin slow progression of carotid intima-media thickness: main results from the β-Blocker cholesterollowering Asymptomatic Plaque Study (BCAPS)
  2524. … DARAH DIBANDINGKAN ISOFLAVON= SOY PROTEIN CONSUMPTION IS MORE EFFECTIVE THAN ISOFLAVONE IN lowering BLOOD cholesterol
  2525. … decreases heart disease; a clinical trial shows, at last, that reducing blood cholesterol reduces the risk of heart disease, providing the missing link in the cholesterol
  2526. … EFFECT OF MACRO ALGA Caulerpa sp. AND Gracilaria sp. EXTRACT lowering MALONDIALDEHYDE LEVEL OF WISTAR RATS FED HIGH cholesterol
  2527. … effects of ethanolic extract of Murraya Koenigii Linn. leaves in cognitive deficit aged mice involving possible anticholinesterase and cholesterol lowering
  2528. … Engineered E. Coli dhs Cells for In-Vitro lowering of Plasma Potassium, Phosphate, Magnesium, Sodium, Chloride, Uric Acid, cholesterol, And Creatinine: A …
  2529. … events after an acute coronary syndrome associated with high soluble CD40 ligand in the Myocardial Ischemia Reduction with Aggressive cholesterol lowering
  2530. … expect any pleiotropic effect of Proprotein Convertase Subtilisin/Kexin type 9 inhibition for reducing cardiovascular events beyond low-density lipoprotein cholesterol
  2531. … FAMILIAL HYPERcholesterolEMIA PATIENTS ACHIEVE LDL-cholesterol TARGET DESPITE BEING ON MAXIMAL CONVENTIONAL LIPID-lowering
  2532. … for lactic acid bacteria in traditional fermented Tibetan yak milk and evaluating their probiotic and cholesterollowering potentials in rats fed a high-cholesterol diet
  2533. … France in relation to the authorization procedure for health claims on plant stanols and plant sterols and lowering/reducing blood LDL‐cholesterol pursuant to Article …
  2534. … FRESH LEAF EXTRACT OF CHROMOLAENA ODORATA (LINN) IN ALBINO WISTAR RATS FED DIFFERENT CONCENTRATIONS OF cholesterol
  2535. … Functional Foods: What Have We Learned? An Examination of the Metamucil, Benefit, and Heartwise Introductions as cholesterol-Reducing Ready-to-Eat Cereals
  2536. … guidelines for diet and lifestyle changes for cholesterollowering: the Increasing Adherence of Consumers to diet & Lifestyle Changes to Lower (LDL) cholesterol
  2537. … health claim related to a low fat fermented milk product (Danacol®) enriched with plant sterols/stanols and lowering/reducing blood cholesterol and reduced risk …
  2538. … in healthy volunteers or hypercholesterolemic subjects using an indirect response model to predict low-density lipoprotein cholesterol lowering: support for a …
  2539. … in patients on lipid-lowering therapies outside Western Europe and North America: findings of the cross-sectional observational International cholesterol
  2540. … in the United States?: Primary, One-year Results of the Getting to an Improved Understanding of Low-density Lipoprotein cholesterol and Dyslipidemia Management …
  2541. … increases the efficacy of the American Heart Association (AHA) step I cholesterollowering diet without reducing high density lipoprotein cholesterol levels in non …
  2542. … increases the risk of chronic diseases. Thus, the high saturated fat consumption (foods high in saturated and trans fatty acids), cholesterol, salt, sugar, refined grains …
  2543. … last year. At my age, 78 years old, I find it hard to take it seriously when my doctor and my children tell me that I should be lowering my cholesterol and exercising. It …
  2544. … LDL cholesterol levels in patients with heterozygous familial hypercholesterolemia: A model that explores the efficacy of conventional and novel lipid-lowering therapy
  2545. … LDL cholesterol: questions from recent meta-analyses and subset analyses of clinical trial data issues from the Interdisciplinary Council on Reducing the Risk for …
  2546. … lecithin-cholesterol acyltransferase in nonhuman primates leads to an antiatherogenic lipoprotein phenotype by increasing high-density lipoprotein and lowering low …
  2547. … Lipid-lowering Therapy and the Guidelines? Results From a National Survey in the Getting to an Improved Understanding of Low-Density Lipoprotein cholesterol
  2548. … lipoprotein profile in morbidly obese patients by reducing LDL cholesterol, apoB, and SAA/PON1 ratio, increasing HDL cholesterol, but has no effect on cholesterol
  2549. … lovastatin on progression of non-dilated and dilated coronary segments and on restenosis in patients after PTCA. The cholesterol lowering atherosclerosis PTCA trial …
  2550. … low-carbohydrate diets more effective than standard carbohydrate diets in lowering cardiovascular risk factors such as blood pressure, cholesterol, and fasting glucose …
  2551. … Microsomal Triglyceride Transfer Protein Reverses Gallstone Susceptibility in Liver Fatty Acid Binding Protein Knockout Mice by Reducing Canalicular cholesterol
  2552. … no effects on cardiovascular outcome: a prospective analysis of the CETP TaqIB polymorphism on cardiovascular outcome and interaction with cholesterollowering
  2553. … of almonds in a cholesterollowering diet improves plasma HDL subspecies and cholesterol efflux to serum in normal-weight individuals with elevated LDL cholesterol
  2554. … of atorvastatin on stroke in patients with unstable angina or non-Q-wave myocardial infarction: a Myocardial Ischemia Reduction with Aggressive cholesterol lowering
  2555. … of cholesterol goal attainment for the primary and secondary prevention of atherosclerotic cardiovascular disease in dyslipidemia patients receiving lipid-lowering
  2556. … of high-dose atorvastatin in patients≥ 65 years of age with acute coronary syndrome (from the myocardial ischemia reduction with aggressive cholesterol lowering
  2557. … of Lactobacillus SP. Using Chitosan‐Alginate‐Xanthan Gum‐β‐Cyclodextrin and Characterization of its cholesterol Reducing Potential and Resistance Against pH …
  2558. … of Lactobacillus SP. Using Chitosanâ Alginateâ Xanthan Gumâ βâ Cyclodextrin and Characterization of its cholesterol Reducing Potential and Resistance Against …
  2559. … of Low-Density Lipoprotein cholesterol Treatment Target in Familial Hypercholesterolemia Patients: A Model Exploring Efficacy of Current and Novel Lipid lowering
  2560. … of multiple system atrophy using human bone marrow-derived mesenchymal stem cells by reducing polyamine and cholesterol-induced neural damages
  2561. … of Patients With Established ASCVD Participating in the Getting to an Improved Understanding of Low-Density Lipoprotein cholesterol and Dyslipidemia Management …
  2562. … OF PRIMARY PREVENTION AGAINST REDUCING HYPERTENSION FOCUS ON SUBJECTS WITH HIGH TOTAL cholesterol AND HIGH TRIGLYCERIDES IN …
  2563. … of results of a national cholesterol and blood pressure screening with the NHANES II Study: implications for further emphasis on reducing cardiovascular risk among …
  2564. … of the evidence considered by health Canada in the regulatory process to permit addition of plant sterols to selected foods accompanied by a cholesterollowering
  2565. … on mung bean (Vigna radiata) and white kidney bean (Phaseolus vulgaris) proteins: Enzymatic hydrolysis, cholesterol lowering activity and structural …
  2566. … on nitric oxide–dependent function in aorta and corpus cavernosum of diabetic mice: relationship to cholesterol biosynthesis pathway inhibition and lipid lowering
  2567. … on plasma lipid pattern in hypercholesterolemic subjects and its additive effect in patients with familial hypercholesterolemia on stable cholesterollowering
  2568. … on the modification of the authorisation of a health claim related to plant sterol esters and lowering blood LDL‐cholesterol; high blood LDL‐cholesterol is a risk factor …
  2569. … Pan-Asian survey: high low-density lipoprotein cholesterol goal attainment rate among hypercholesterolaemic patients undergoing lipid-lowering treatment in a …
  2570. … particle size of oat bran inhibits degradation and lowers extractability of β-glucan in sourdough bread–Potential implications for cholesterollowering properties in vivo
  2571. … Patients Referred to a Regional cholesterol Treatment Center with LDL cholesterol>= 70 mg/dl Despite Maximal Tolerated cholesterol lowering Therapy
  2572. … patients referred to a regional cholesterol treatment center with LDL cholesterol≥ 70 mg/dl despite maximal tolerated cholesterol lowering therapy
  2573. … patients referred to a regional cholesterol treatment center with LDL cholesterol≥ 70 mg/dL despite maximal-tolerated LDL-cholesterollowering therapy
  2574. … patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial—Lipid lowering Arm (ASCOT-LLA) …
  2575. … patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial—Lipid lowering Arm (ASCOT-LLA) …
  2576. … progression of atherosclerosis in coronary bypass grafts is similar in women compared to men following aggressive cholesterol lowering despite more frequent risk …
  2577. … Question About My cholesterol Levels. My Total cholesterol Level Is Normal (Just Over 200) but My HDL Is Low, Only 28. Should I Be Taking a cholesterollowering
  2578. … randomization analysis in three Japanese populations supports a causal role of alcohol consumption in lowering low-density lipid cholesterol levels and particle …
  2579. … Receptor δ Agonist, GW0742, and Ezetimibe Promote Reverse cholesterol Transport in Mice by Reducing Intestinal Reabsorption of HDL‐Derived cholesterol
  2580. … reduces liver injury by lowering cholesterol accumulation, improving dysregulated cholesterol synthesis and alleviating inflammation in high-fat, high-cholesterol and …
  2581. … Results: I. Reduction in Incidence of Coronary Heart Disease, and II. The Relationship of Reduction in Incidence of Coronary Heart Disease to cholesterol lowering
  2582. … SAFETY OF ALIROCUMAB AND EVOLOCUMAB, IN ADDITION TO MAXIMAL TOLERATED cholesterol lowering THERAPY: POST-COMMERCIALIZATION …
  2583. … salt hydrolase (Bsh) activity screening of Lactobacilli: in vitro selection of indigenous Lactobacillus strains with potential bile salt hydrolysing and cholesterollowering
  2584. … Savior™ Heart Savior-™ is a proprietary blend of several well known ingredients that have been known for their cholesterol reducing characteristics and for …
  2585. … severity influence the benefit of atorvastatin treatment in Alzheimer’s disease: results of the Alzheimer’s Disease cholesterollowering Treatment (ADCLT) trial
  2586. … simvastatin inhibits cell cycle progression at the G1/S checkpoint in immortalized lymphocytes from Alzheimer’s disease patients independently of cholesterollowering
  2587. … STONES USING TRANSFORMER STREPTO-COCCUS SALIVARIUS AND MEASURING OF RNA EXPRESSION TO cholesterol lowering GENES
  2588. … subtilisin/kexin type 9 (PCSK9) inhibition with evolocumab: powerful low-density lipoprotein cholesterol (LDL-C) lowering and improved cardiovascular …
  2589. … Supplementation Reduces Endothelin-1 Plasma Concentration in Moderately Hypercholesterolemic Individuals Independently of Their cholesterollowering
  2590. … suppresses progesterone production in primary cultured porcine granulosa cells by reducing gene expression of cytochrome P450 cholesterol side-chain cleavage …
  2591. … TEA AND MEAT FRUIT AVOCADO SIMVASTATIN COACH AS INTERVENTION IN lowering TOTAL cholesterol LEVELS TO HYPERcholesterolEMIA …
  2592. … the effects of ramipril versus telmisartan in reducing serum levels of high-sensitivity C-reactive protein and oxidized low-density lipoprotein cholesterol in patients with …
  2593. … the Intensity of Lipid lowering Therapy Vary by Sex in the United States? Insights From Getting to an Improved Understanding of Low-Density Lipoprotein cholesterol
  2594. … thrombin activity in elderly patients with atrial fibrillation on oral anticoagulation is decreased by anti-inflammatory therapy with intensive cholesterollowering
  2595. … TO A REGIONAL cholesterol TREATMENT CENTER WITH LDL cholesterol≥ 70 MG/DL DESPITE MAXIMAL TOLERATED cholesterol lowering
  2596. … UTLISATION IN PATIENTS ON LIPID-lowering THERAPIES OUTSIDE OF WESTERN EUROPE: FINDINGS OF THE INTERNATIONAL cholesterol
  2597. … who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial–Lipid lowering Arm (ASCOT-LLA): a …
  2598. … With LDL cholesterol> 100 Mg/dl and/or Atherosclerotic Cardiovascular Disease With LDL cholesterol> 70 Mg/dl Despite Maximal Tolerated cholesterol lowering
  2599. [Use of bread and rolls in a cholesterol reducing diet.-2. Part: Results of the controlled dietary study].[German]
  2600. P. 144 Coronary heart disease prevention; How much can we expect from cholesterollowering therapy?
  2601. P. 211 Patterns of non compliance to cholesterollowering therapy assessed by electronic monitoring
  2602. 1) Acupuncture Goes Mainstream 2) American Study Fails to Observe Lipid-lowering Effects of Garlic? 3) Artichoke for Serum cholesterol Reduction? 4) Novel …
  2603. 1084-179 Ezetimibe/Simvastatin therapy is more effective than simvastatin alone at reducing remnant-like particle cholesterol
  2604. 12 The economics of cholesterol lowering
  2605. 12-Week Effectiveness and Safety of Low-Density Lipoprotein cholesterollowering Therapy by Proprotein Convertase Subtilisin/Kexin Type 9 Inhibition in Patients …
  2606. Targeting HMGCoA Reductase and Reducing Blood cholesterol Using Interfering RNA Delivered to the Liver by SV40-Derived Vectors
  2607. 16 cholesterol lowering Vegetable Oil Spreads: Results of a Post Launch Monitoring Programme
  2608. 16, 16-Difluoroestrone derivatives. A new series of cholesterol lowering agents
  2609. 2013 ACC/AHA cholesterol guideline for reducing cardiovascular risk: what is so controversial?
  2610. 22-Hydroxycholesterol derivatives as HMG CoA reductase suppressors and serum cholesterol lowering agents
  2611. 3 Probiotic characterization and in vitro cholesterol lowering effects of lactic acid bacteria 4 isolated from Thai healthy infants
  2612. 3-Hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors: a new class of cholesterollowering agents
  2613. 333-OR: DMHCA Reduces the Development of Diabetic Retinopathy (DR) in db/db Mice by lowering cholesterol Levels and Altering the Transcriptomic Profile of …
  2614. 54 Role of the gut microbiome for the cholesterol lowering effect of atorvastatin
  2615. 769-4 lowering of cholesterol With Simvastatin may Prevent Development of Heart Failure in Patients With Coronary Heart Disease
  2616. 7S protein is more effective than total soybean protein isolate in reducing plasma cholesterol
Shopping Cart
Scroll to Top